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1 Introduction 
1.1 Inflammatory bowel diseases   
Since the beginning of the 20th century and especially over its second half, there has been a 
significant increase in the incidences of chronic inflammatory disease, which seems to follow 
a geographical pattern of industrialization and urban living (Bach et al., 2002, Eder et al., 2006). 
These inflammatory phenotypes include allergic conditions such as asthma, food allergies and 
eczema as well as autoimmune disorders such as type 1 diabetes, chronic inflammatory bowel 
disease and neurodegenerative disease (figure1.1). Inflammatory bowel diseases (IBD; OMIM 
601458), as one of such phenotypes, are chronic, relapsing inflammatory disorders of the 
gastrointestinal tract (see figure 1.2), with a peak age of onset in the second to fourth decades 
of life (Podolsky et al., 2002). Among the chronic inflammatory diseases, however, the unique 
feature of IBD is the close apposition of the intestinal immune system to high concentrations 
of bacteria in the lumen of the gut. The gut contributes essentially to absorb nutrients from 
digested food and process waste for elimination. 
 
 
 
Figure 1.1 Inverse relation between the Incidence of Prototypical Infectious Diseases (A) and the Incidence of 
Immune Disorders (B) from 1950 to 2000. Reprinted from Bach et al. (2002). 
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These activities are performed at the inner mucosal surface, which consists of a thin, 
permeable epithelium (see figure 1.2). In the small intestine, this surface is greatly expanded 
by the presence of fingerlike villi, making the mucosal lining of the gut the largest surface in 
the body. The lumen is a nutrient-rich microenvironment with a complex microbial population 
that has coevolved with the host. These commensal microbes perform essential functions, 
such as digestion of complex carbohydrates and production of vitamins and other small 
molecules (Bäckhed et al., 2005). Microbial density in the colon has been estimated to reach 
1011–1012 cells per gram of luminal contents (Whitman et al., 1998).  
 
 
 
      
   1: Mucosa: Epithelium 
    2: Mucosa: Lamina propria 
    3: Mucosa: Muscularis mucosae 
    4: Lumen 
    5: Lymphatic tissue 
    6: Duct of gland outside tract 
    7: Gland in mucosa 
    8: Submucosa 
    9: Glands in submucosa 
    10: Meissner's submucosal plexus 
    11: Vein 
    12: Muscularis: Circular muscle 
    13: Muscularis: Longitudinal muscle 
    14: Serosa: Areolar connective tissue 
    15: Serosa: Epithelium 
    16: Auerbach's myenteric plexus 
    17: Nerve 
    18: Artery 
    19: Mesentery 
 
Figure 1.2 Upper and Lower human gastrointestinal tract (right) and General structure of the gut wall 
(Left). Illustration from https://en.wikipedia.org/wiki/Human_gastrointestinal_tract 
(Small intestine) 
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More recently modern high throuput metagenomic analysis have shown that the normal gut 
comprises 100 trillion diverse microbes, mostly bacteria, encompassing over 1100 prevalent 
species, with at least 160 species in each individual (Qin et al., 2010). This creates a key 
challenge for the intestinal immune system to prevent commensal and pathogenic microbes 
from crossing the gut epithelial barrier. There is strong evidence to support that dysregulated 
interaction of the host immune system with the commensal microflora and other luminal 
antigens leads to IBD (Xavier et al., 2007; Kamada et al., 2013; Belkaid et al., 2014).  
IBD patients typically suffer from frequent and chronically relapsing flares, resulting in 
diarrhea, abdominal pain, rectal bleeding and malnutrition. (Podolsky et al, 2002). IBD is 
divided in two main sub-phenotypes of Crohn’s disease (OMIM 266600) and ulcerative colitis 
(OMIM 191390). Crohn’s disase (CD) was first recognized by German surgeon Wilhelm 
Fabry (aka Guilhelmus Fabricius Hildanus) in 1623 and was later described by and named 
after the US physician Burril B Crohn (Crohn, et al., 1984). Ulcerative colitis (UC) was first 
described by the British physician Sir Samuel Wilks in 1859. CD can be distinguished from 
UC, in that it is characterized by inflammation that can extend into all layers of the bowel wall 
(transmural). Areas of deep ulceration can form localized regions of nodular inflammation 
(granulomas) (see also figure 1.3) or tube-like connections between loops of the intestines or 
nearby organs (fistulas).  
 
Table 1.1. Comparison of CD and UC.  
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However, the most commonly affected segment is the terminal ileum. Another distinguishing 
feature of CD is its segmental distribution, so that regions of inflammation can be separated 
by tissue with normal appearance. By contrast, the inflammation seen in UC is restricted to 
the mucosa and, as the disease progresses, the submucosa. Intestinal fistulas, granulomas and 
deep fissures are not found in UC, and the inflammation usually involves the rectum and 
extends proximally to include part of or the entire colon. The region of inflammation in UC is 
continuous without any skipped segments (Podolsky et al, 2002). In ∼5% of IBD cases, it is not 
possible to assign a definitive diagnosis of CD or UC, because of the overlap in their 
pathologies (Friedman, et al., 2008). Patients with IBD often have various extra-intestinal 
symptoms such as arthalgias (inflammatory paints in the joints) and are more likely to have 
other chronic inflammatory diseases, particularly primary sclerosing cholangitis (Saich et al., 
2008), ankylosing spondylitis and psoriasis (Lees et al., 2011, parkes et al., 2013). 
 
  
Figure 1.3 Histologic hallmarks of IBD.  
Left panel, CD-biopsy from a terminal ileum with active disease. The figure illustrates a discrete granuloma 
composed of compact macrophages, giant cells and epithelioid cells. Surrounding the nodule there is marked 
infiltration of lymphoid cells, plasma cells and other inflammatory cells, but there is no necrosis. Right panel, UC-
colonic mucosal biopsy taken from a patient with active disease. The crypt abscess is composed of transmigrated 
neutrophils and the surrounding epithelium exhibits features of acute mucosal injury. Illustration from Xavier et al. 
(2007). 
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1.1.1 Epidemiology of IBD 
The highest prevalence of UC and CD has been reported from northern Europe, the UK, and 
North America, with the average number of cases ranging from 100 to 200 cases per 100,000 
persons (Loftus et al., 2000; Bernstein et al., 1999). Most reports show CD to be more common in 
European Americans (~ 43 per 100,000) compared with African Americans (~30 per 
100,000), with the lowest rates reported in Hispanics and Asians (~ 5 per 100,000) (Binder et 
al., 1998). Despite this fact, however rates continue to rise in low-incidence areas such as 
southern Europe, Asia and most developing countries. Within population of European 
ancestry, CD is more prevalent in persons of Jewish descent than in any other ethnic group 
(Sandler et al, 1994). The phenomenon of genetic anticipation, which means earlier onset in 
offspring of people with the disease, has been reported for North American Ashkenazi Jews 
(Lowe et al, 2009). Different incidence rates, especially the lower incidence of IBD in Asia and 
Africa compared with North America and Europe could have resulted from different genetic 
backgrounds. Despite this, epidemiological studies have shown that prevalence of IBD in 
North America and northern Europe increased rapidly during the early- and mid-20th century 
and then stabilized at higher levels (Molodecky et al., 2012). Additionally incidence rates of 
IBD continue to rise in low-incidence areas such as southern Europe, Asia and the majority of 
the developing world (Loftus  et al., 2004). These evidences have indicated that there is a 
substantial environmental or lifestyle component to disease risk. Factors such as diet, 
breastfeeding, oral contraceptives and childhood infections have been proposed to contribute 
to the etiology of IBD (Podolsky et al, 2002; Freidman et al., 2008). However, it has been argued 
that those with the strongest association are cigarette smoking and appendectomy (Loftus  et al., 
2004). Beside these factors, etiology of autoimmune and inflammatory diseases like IBD has 
been also attributed to the ‘hygiene hypothesis’, which proposes that lack of exposure to 
certain infectious agents in childhood results in an overactive immune response in later life 
(Gent et al., 1994). On the other hand, there exist evidences for the hereditary contribution to 
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IBD. A positive family history is the largest independent risk factor for the disease, as 
population-based studies have found that 5–10% of patients, have a first-degree family 
member with IBD (Orholm et al., 1991). Further, the relative risk to siblings of affected 
individuals has been estimated to increase 15–35 fold for CD and 6–9-fold for UC (Binder et 
al., 1998, Bengtson et al., 2009). Twin studies provide additional evidence for a genetic 
contribution in IBD. The concordance rate is significantly greater in MZ twins than DZ ones 
(Brant, 2011) for both CD (30.3% versus 3.6%) and UC (15.4% versus 3.9%). Although the 
genetic contribution to risk is stronger in CD, multiple studies show that relatives with either 
CD or UC are at increased risk of developing either form of IBD, indicating the existence of 
both phenotype-specific and shared susceptibility mechanisms for UC and CD (Budarf  et al., 
2009). These observations have implicated that IBD, like most other common diseases, have a 
complex etiology involving multiple genetic and environmental factors. 
 
1.1.2 Genetic architecture of IBD 
1.1.2.1 Gene discovery approaches 
As discussed in previous section, familial aggregation, significant increased sibling relative 
risk and twin studies have demonstrated the genetic contribution to IBD. Despite this, the 
underlying genetic loci were mostly unknown until 2000. In 1996 the first attempts at 
identifying the CD genetic risk factors used linkage mapping, which identified the peri-
centromeric region on chromosome 16 called IBD1 (Hugot et al., 1996) and chromosome 12q 
called IBD2 (Satsangi et al. 1996). Family-based linkage studies identify large segments of 
human genomes (mostly megabases in size and therefore containing multiple genes), which 
are shared among affected relatives more frequently than expected by chance. In 2001, the 
first IBD gene, NOD2 (nucleotide-binding oligomerization domain containing 2; also known as 
caspase recruitment domain protein 15, CARD15) was identified through association mapping 
of the linkage region on chromosome 16 (Hugot et al., 2001). Genome-wide linkage scans 
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analyzed a relatively small number (300–5,000) of genetic markers and have been highly 
successful at finding genetic loci with high penetrances in rare single-gene (Mendelian) 
disease phenotypes (Risch, et al., 2000; Rioux et al., 2005). After few early findings of genetic 
linkage studies for IBD, two main developments i.e. the International HapMap Project 
(http://www.hapmap.org/) and the development of microarray genotyping platforms allowed 
the design of powerful population-based genome-wide association (GWAs) studies for 
common complex diseases like IBD. The sequencing of the human genome (International 
Human Genome Sequencing Consortium, 2004) and the generation of public resources of 
single nucleotide polymorphisms (SNPs), especially dbSNP (Smigielski et al., 2000) have 
contributed essentially to these developments. SNPs are inter-individual differences in a 
nucleotide base at a given site in the genomic DNA sequence. It has been estimated that in the 
world's human population, about 10 million sites (that is, one variant per 300 bases on 
average) vary such that both alleles are observed at a frequency of 1% (Kruglyak et al., 2001). 
The specific set of the alleles, who are located on the same chromosome and segregate 
together, is called a haplotype. Sequence variants in a haplotype are said to be in Linkage 
disequilibrium (LD), which refers to the phenomenon that two or more alleles in a 
chromosomal region occur together more often than accounted for by chance. This mostly 
indicates that the alleles are in close proximity on the DNA strand and are most likely to be 
passed on together within a population (The international HapMap project, 2003). Based on 
the haplotype pattern map in human genome, a genome wide subset (several thousands up to a 
million) of SNPs, known as tagSNPs, are selected and genotyped simultaneously for 
unrelated disease cases and healthy controls on microarray platforms (Xavier et al., 2008). 
GWAS are largely hypothesis-free approaches that identify common risk alleles, which are 
significantly more frequent in patients compared to healthy individuals. Since 2006, the year 
of the first published GWAS study on IBD using > 100,000 SNPs (Duerr et al, 2006), there has 
been an exponential growth in the set of validated genetic risk factors for IBD. This has been 
Introduction                                                                                                                                               8 
 
 
     IL23R 
Predictive 
    effect 
 
 
 
 
 
mainly achieved through Meta-analyses of SNP-GWAS data, which provided increased power 
towards indentifying associated variants with small effect sizes for both CD (Franke at al., 
2010) and UC (Anderson, C. A. et al. 2011). In 2012, the largest genetic association study for 
IBD employed GWAs data set of over 75,000 patients and controls and established the 
association of 163 susceptibility loci (Jostins et al., 2012). Despite this large number of 
identified associated loci, two main issues still need to be addressed; First, SNPs identified 
through GWA studies do not mostly constitute the actual causal variants, instead point to 
genomic regions that vary in size, depending on the extent of the local LD pattern (Kohr et al., 
2011). Some of these identified regions contain only one gene, some contain several genes 
and others do not contain any known coding sequence (gene deserts). An example in  
 
 
Figure 1.4 Features of disease-associated genetic variation. Most cases of IBD are multifactorial in etiology, 
reflecting the effects of multiple genetic risk alleles and developmental and environmental factors. Rare cases of early-onset 
IBD, with extreme phenotypes, might be single-gene, Mendelian disorders (e.g., autosomal recessive mutations in IL10RA or 
ILRB or X-linked inhibitor of apoptosis protein (XIAP)) - extremely rare mutations with strong effects. In contrast, most of the 
alleles identified by GWAS are relatively common (allele frequencies > 5%), with modest or low effects (odds ratios < 1.5). 
Greater effects (intermediate to high) include the relatively low-frequency risk alleles in NOD2 and the variant that encodes 
Arg381Gln in IL23R. Among complex diseases, it is unusual to have common alleles that have strong effects; an exception is 
that some alleles of the gene that encodes complement factor H confer high-risk for age-related macular degeneration 
(AMD). Adopted from Cho et al., 2011. 
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this context is the association of CD with a region of chromosome 5p13 (Libioulle et al., 2007), 
which contains no known genes. Further investigation implicated that the identified variants in 
the region correlated with differential expression of the nearby prostaglandin E receptor 4 
(PTGER4) gene (Libioulle et al., 2007), indicating that functional studies are needed to 
characterize the actual effect of the associated variants and the underlying biological 
mechanism. The second challenge is that nearly all the identified associated variants have low 
to modest effect sizes (odds ratio (OR) <1.3) and therefore explain only 13.6% and 7.5% of 
disease variance for CD and UC respectively (Jostins et al., 2012). Odds ratio is a measure of 
effect size, defined as the ratio of the odds (the probability of disease divided by 1 minus the 
probability) of a disease being observed in one group of genotypes and the odds of a disease 
being observed in another group (Nurminen et al., 1995).   
It has been assumed that all risk loci with a minor allele frequency > 5% in the general 
population and an OR > 1.2 have already been identified in IBD patients with European 
ancestry by means of GWAS (Liu, J.Z. et al, 2014). Genetic factors such as rare variants, 
private mutations, structural variants and interactions between genes have, however, not been 
captured by GWAS studies (Eichler, et al., 2010). 
 
1.2.1.1 Identified genes and implicated pathways  
Of the 163 genetic risk loci identified for IBD till now, 110 loci are associated with both 
disease phenotypes of CD and UC (Jostins et al., 2012), indicating that despite distinct clinical 
characteristics, both phenotypes have common pathways involved in their pathogenesis. 
Analyses of the genes and genetic loci identified in IBD show several pathways that are 
significant for intestinal homeostasis. These include barrier function, epithelial restitution, 
microbial defense, innate immune regulation, reactive oxygen species (ROS) generation, 
autophagy, regulation of adaptive immunity, endoplasmic reticulum (ER) stress and metabolic 
pathways associated with cellular homeostasis (see also Figure 1.6). (Khor et al., 2011; Cho et al., 
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2011). Intestinal homeostasis involves the coordinated actions of epithelial, innate and 
adaptive immune cells. Barrier permeability might permit microbial incursion, which is then 
often detected by the innate immune system and leads to appropriate tolerogenic, 
inflammatory and restitutive reactions. These responses are mainly activated by releasing 
extracellular mediators known as cytokines, which instead could recruit other cellular 
components related to adaptive immune system (Kaser et al., 2009). Here some of the most 
relevant pathways and essential genes contributing to IBD pathogenesis are described. More 
comprehensive and detailed review of the pathobiological mechanisms and cellular pathways 
involved in IBD can be seen in Khor et al., 2011 and Parkes et al., 2013. 
Epithelial barrier integrity 
In addition to nutrient absorption, intestinal epithelial cells perform both barrier and signal 
transduction functions, so that they recognize luminal contents through surface receptors and 
in return secret regulatory products that can mediate appropriate responses in the underlying 
lamina propria (see figure 1.2). Abnormal intestinal permeability has been observed in IBD 
patients and in some of their first degree relatives (Kaser et al., 2009). Several IBD loci contain 
genes such as CDH1, GNA12 and PTPN2, which contribute to epithelial integrity. CDH1 encodes 
adherent junction protein E-cadherin and variations leading to truncated form of the protein 
have been associated with CD (Muise et al., 2009). GNA12 encodes the G protein Gα12 and its 
activation leads to phosphorylation of the tight junction proteins ZO-1 and ZO-2, resulting in 
destabilization of cell junctions in epithelial cell lines (Sabath et al., 2008). In vitro studies show 
that the protein tyrosine phosphatase family member PTPN2 protects against interferon-γ 
(IFN-γ)-induced epithelial permeability (Scharl et al, 2009). Concordantly, Ptpn2-deficient mice 
show increased susceptibility to experimental colitis (Hassan, et al., 2010). 
Innate immune responses  
Mucosal innate immune system defends against pathogenic factors and simultaneously 
regulates inflammatory responses to maintain a state of controlled responsiveness to 
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commensal bacteria. Dendritic cells, macrophages, innate lymphoid cells (ILCs) and 
neutrophils are essential cellular components of the innate immune system during infection or 
inflammation (Nochi et al., 2006). Patients with innate immunodeficiencies such as chronic 
granulomatous disease and Hermansky–Pudlak syndrome (a syndrome associated with 
defective responses to bacterial DNA motifs (CpG oligonucleotides) specifically in 
plasmacytoid dendritic cells) tend to develop IBD (Blasius et al., 2010). Some major 
components of the innate immunity implicated in IBD are introduced here.  
Microbe Recognition 
 Cells of the innate immune system have pattern-recognition receptors that recognize microbe-
specific macromolecules, enabling them to target the pathogens. NOD2 was the first gene to be 
associated with CD (Hugot et al., 2001) and after that several genes interacting with NOD2 
signaling were also identified as associated with IBD. NOD2 is expressed by many leukocytes, 
including antigen presenting cells, macrophages and lymphocytes as well as ileal Paneth cells 
and is an essential component for microbial sensing (Shaw et al., 2011). Activation of NOD2 by 
microbial ligands activates the transcription factor nuclear factor−κB (NF-κB) and mitogen-
activated protein kinas signaling and thereby functions as a positive regulator of immune 
defense (Abraham et al., 2006). The most common mutations in NOD2 that are associated with 
CD (Arg702Trp [rs2066844], Gly908Arg [rs2066845], and Leu1007fsinsC [rs41450053]) lie 
either within or near the C-terminal, leucine-rich repeat domain, which is required for 
microbial sensing (Ogura et al., 2001). NOD2 mutations are consistently associated with ileal 
and stricturing (transmural) CD (Economou et al., 2004).  
CARD9 is an adaptor protein that integrates signals from many innate immune receptors that 
recognize viral, bacterial and fungal motifs. Depending on the stimulus, CARD9 interacts with 
distinct signaling complexes and activates different pathways to modulate cytokine 
environments appropriately (Hsu et al., 2007). Defective CARD9 function leads to the immune 
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deficiency, at least in part owing to failure to promote an adequate TH17 immune response 
(Poeck, H. et al., 2010).  
Autophagy 
Autophagy degrades damaged organelles and proteins and is important for the clearance of 
pathogens (xenophagy), which is required for immunity to multiple different types of bacteria. 
Genetic analyses have implicated an essential role for autophagy in innate immunity and IBD, 
indicating two component genes of ATG16L1 and IRGM in IBD pathogenesis (Rioux, et al. 2007; 
McCarroll et al., 2008). ATG16L1 (Autophagy 16-like 1) is widely expressed, including in small 
intestinal Paneth cells, where it mediates exocytosis (secretion) of secretory granules that 
contain antimicrobial peptides (Cadwell et al., 2008). A single Thr300Ala (Threonine to Alanine) 
substitution in ATG16L1 results in decreased capability to capture bacteria and has been shown 
to be associated with CD risk (Kuballa et al., 2008). 
Additionally leucine-rich repeat kinase 2 (LRRK2) also regulate autophagy and is located in the 
CD-associated region on chromosome 12q12, (Barrett et al., 2008) along with MUC19. 
Alterations in autophagy have important roles in pathogenesis of CD, possibly because of the 
close apposition of microbial components with high cellular turnover of the intestinal 
environment. 
Oxidative stress 
The equilibrium between oxidant factors, such as free radicals, reactive oxygen species (ROS) 
or reactive nitrogen species, and antioxidant components, such as glutathione peroxidase 
(GPX) and glutathione S-transferase enzymes is important in gut homeostasis, as the 
reduction-oxidation-state affects many signal transduction pathways (Schroeder et al., 2011). 
Genes within several IBD loci may either regulate ROS production or protect against 
oxidative stress. In particular, NOD2, CARD9 and IFN-γ-regulated leucine-rich repeat kinase 2 
(LRRK2) contribute to ROS production (Wu et al., 2009). In addition to pro-inflammatory 
pathways, ROS are also involved in Treg-cell polarization and function (Efimova et al., 2011). 
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 Adaptive immune responses  
If a microbial invasion cannot be controlled by the innate immune system, inflammatory 
signals that activate the adaptive immune response are released. This response is mediated by 
lymphocytes (B and T cells) and has functional specificity, but might require several days to 
reach an effective immune response. Here some of the essential cellular processes and 
mechanisms of adaptive immunity implicated in IBD are described. 
Lymphocyte Activation 
In the healthy gut, naïve T cells receive cytokine signals, such as transforming growth factor β 
(TGF-β) and interleukin-10 (IL-10), which stimulate them to differentiate along a tolerogenic 
pathway to become regulatory T cells. During infection or chronic inflammation, naïve T cells 
receive a different set of signals from antigen-presenting cells, which lead them to be 
differentiated into TH1, TH2 or TH17 helper cells and thereby inflammatory pathways are 
activated.   
Human leukocyte antigens HLA class II genes are a major player in T cell activation and have 
been significantly associated with UC and several other autoimmune diseases (Gregersen et al., 
2009). These genes are a member of the major histocompatibility complex (MHC), which 
comprises a contiguous 4 Mb region on the short arm of chromosome 6. The extended MHC 
(xMHC), as its name suggests, spans an even larger 7.6 Mb region and comprises more than 
400 annotated genes and pseudogenes (Horton et al., 2004). HLA genes are frequently 
associated with chronic inflammatory genetic disorders, probably because of the enormous 
genetic and functional diversity contained within this region as well as its essential role in 
regulating interactions between host cells and pathogens. 
IL-23 signaling pathway 
One of the strongest associations observed in GWAs of CD is in the gene region encoding 
interleukin-23 receptor (IL-23R). Disease-associated IL23R polymorphisms have also been 
reported in UC patients (Duerr et al., 2007). It has been recognized that IL-23 drives a 
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pathogenic T cell population with a distinct inflammatory transcription profile, which includes 
putative cytokines specially IL17 and contributes essentially to autoimmune inflammation 
(Langrish et al., 2005). Based on this distinct gene transcription profile, harboring unique Janus- 
kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, a novel subset 
of T helper (TH) cells i.e. ThIL-17 or Th17
 was discovered (Harrington et al., 2005). It has been 
proposed that an important component in association of IL23 signalling with IBD is mediated 
by its roll in inducing IL-17 expression in TH17 cells (Gaffen et al., 2014). In addition to the 
receptor, other components of the IL-23R signaling pathway i.e. IL12B, STAT3 and JAK2 have  
 
 
Figure 1.5 key features of the intestinal immune system 
 The epithelial-cell layer is comprised of absorptive and secretory cells, goblet cells and Paneth cells. Goblet cells 
contribute to the formation of the protective mucus layer. Microfold cells (M cells) and dendritic cells (DCs) sample 
intestinal luminal contents. The presence of either pathogenic bacteria or disruption of the epithelial-cell barrier 
results in activation and migration of DCs to the mesenteric lymph nodes, where they activate naive T cells, which 
then undergo differentiation under the influence of factors released by DCs and other stromal elements. SED, 
subepithelial dome; TGFβ, transforming growth factor-β; TH, T helper; TReg, T regulatory.  Illustration from Cho et al., 
2008. 
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also shown strong association with both CD and UC (Barrett et al., 2008; Franke et al., 2008). 
The leading hypothesis is that the IL-23R signaling pathway contributes to 
immunopathogenesis of IBD by promoting the pro-inflammatory state. An analysis of the IBD 
loci list (with 300 prioritized genes) for enrichment in Gene Ontology terms, showed that after 
excluding high level categories like “immune system processes”, the most significant enriched 
category comprised regulation of cytokine production, specifically interferon-γ, IL-12, tumor-
necrosis factor-α and IL-10 signalling (Jostins et al., 2012). Lymphocyte activation was the next 
most significant, with activation of T cells, B cells and natural killer cells being the strongest 
contributors to this signal. Strong enrichment was also seen for “response to molecules of 
bacterial origin” (P = 2.4 × 10−20) and for JAK-STAT signalling pathway (Jostins et al., 2012). 
 
 
 
Figure 1.6  Biological processes implicated by IBD loci.  
Font sizes are proportional to the number of genes associated with each respective process. Breg cells, B 
regulatory cells; ER, endoplasmic reticulum; GPCR, G-protein-coupled receptor; IL, interleukin; lincRNA, large 
intervening non-coding RNA; miRNA, microRNA; ncRNA, non-coding RNA; NF-κB, nuclear factor-κB; ROS, 
reactive oxygen species; TH17 cells, T helper 17 cells; Treg cells, T regulatory cells. Illustration from Khor et al., 2011. 
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1.2 Copy number variations (CNVs) 
The landscape of genetic variations in humans includes single nucleotide substitutions, 
structural variations, ranging in size from 50 base pairs (bp) to more than one mega-base-pair 
(Mb), and large chromosomal aberrations (> 1-3 Mb) (see figure 1.7). Variations at either 
extreme of this spectrum, i.e. single-nucleotide polymorphisms (SNPs) and cytogenetically 
recognizable chromosomal changes (Jacobs et al., 1992) have long been known. About 10 years 
ago, scientists began to recognize abundant variation of the intermediate-size class known as 
structural variations (Iafrate et al., 2004. Sebat et al., 2004.Redon et al., 2006. Tuzun et al. 2005). 
Within this class, CNVs include insertions, deletions and duplications of genome sequences, 
typically defined to be 50 bp or larger. Smaller genomic segments (< 50 bp) with variable 
copy number are referred to as small insertion/deletions (indels) (Conrad et al., 2010; 
MacDonald et al., 2014). 
 
  
Figure 1.7 Major categories of genetic variants. Copy number variants are imbalanced structural variants within the 
size range of ~50 bp to 1-3 Mb. Insertions and deletions smaller that 50 bp are usually called small indels. Large 
chromosomal aberrations (>3 Mb, microscopically visible after G-banding) are rare and often associated with major 
congenital disorders. Chromosomal monosomies and trisomies represent extreme instances of chromosomal abnormalities 
(e.g., trisomy 21 associated with Down syndrome). Mb (mega base pair), kb (kilo base pair), bp (base pair).  
Small 
 indels 
 
 
50 bp  ~3 Mb 
  
Large  
chromosomal 
     aberrations 
 
> 3 Mb 
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Other types of structural variations include copy-number-balanced rearrangements such as 
inversions, which change the orientation of a DNA segment, and translocations, in which a 
DNA segment is reciprocally exchanged between two chromosomes (see figure 1.8). These 
rearrangements change the spatial organization of DNA, but unlike CNVs do not result in any 
net gain or loss of sequence. 
The widespread occurrence and high prevalence of CNVs in human genome was first 
recognized through large-scale population studies, carried out by Sebat et al. and Iafrate et al. in 
2004. Afterwards a survey of 270 individuals from the human HapMap samples estimated that 
up to 12% of the human genome is subjected to CNVs (Redon et al., 2006).  
 
 
 
Figure 1.8 Different classes of structural variations. The schematic depicts deletions, novel sequence 
insertions, tandem and interspersed segmental duplications, inversions and translocations in a test genome 
(lower line) when compared with the reference genome. Adopted from Alkan et al. 2011. 
 
Introduction                                                                                                                                               18 
 
 
These studies implicated that CNVs are at least as important as SNPs in contributing to inter-
individual genome differences and they are actually a major driving force in evolution. Indeed 
between any two individuals, the number of base pair differences derived by CNVs is >100-
fold higher, compared with that by SNPs (Lupski, 2007). 
Routinely for nearly all genes in the human genome, each individual inherits one copy from 
each parent, so that two copies of each gene exist in the nucleus of every diploid cell. 
However, various studies have indicated that the copy number per genome varies for some 
genes. The set of the genes that were found to vary in copy number is enriched for those 
involved in olfaction, immunity and secretion, i.e. genes relevant to the immediate 
environmental responses (Cooper et al., 2007; Conrad et al., 2010). For example, a cluster of 
several β-defensin genes shows common CNVs of between two and seven copies per diploid 
genome, and occasionally copy numbers are as high as 10 or 11(Hollox et al., 2003). Similarly, 
the salivary amylase gene, AMY1, varies in copy number from two to 15 with a mean of seven 
in the European–American population (Perry et al., 2007). The amount of salivary amylase is 
directly correlated with the copy number of AMY1. The average number of copies of AMY1 
is higher in cultures that consume a high level of starch than in cultures that consume little 
starch (Perry et al., 2007), suggesting that a high copy number of AMY1 is advantageous in 
cultures with a high starch intake and neutral in cultures with low starch intake. 
Those CNVs that are present at a greater than 5% frequency in the population and mostly 
occur in multiple copy number states (0 to 30 copies per diploid genome) are called copy 
number polymorphisms (CNPs). In contrast, large CNVs (>100 kb) are mostly individually 
rare (<1% frequency) and exist in fewer copy number states (single copy gain / loss). These 
rare CNVs are under strong selection pressure, so that their frequency in the population is 
largely contributed to by de novo events and they persist only for a few generations (Turner et 
al., 2008). 
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1.2.1 Discovery and mapping of CNVs 
 The systematic discovery and genotyping of CNVs at the genome-wide level has become 
possible due to advances in whole genome technologies, which have enabled characterization 
of CNVs that are intermediate between large chromosomal aberrations (>1 Mb) and smaller 
indels (1–50 bp). The two main approaches to systematically characterize CNVs are 
microarray-based and sequencing-based methodologies.  
 
Microarray-based approaches 
These include two main platforms, namely array comparative genomic hybridization (array 
CGH) and single nucleotide polymorphism (SNP) microarrays. 
Array CGH platforms are based on the principle of comparative hybridization of two labeled 
samples (test and reference) of genomic DNA to a set of hybridization targets, typically long 
oligonucleotides or primarily large-insert clones known as bacterial artificial chromosomes 
(BACs) (Pinkel et al., 1998). The signal ratio between test and sample is normalized and 
converted to a log2 ratio, which acts as a proxy for copy number. An increased log2 ratio 
represents a gain in copy number in the test compared with the reference; conversely, a 
decrease indicates a loss in copy number. Early large scale surveys of CNVs have mainly used 
array CGH. Initially in 2004, two studies reported that CNVs of many large DNA genomic 
segments exist between normal human individuals. Sebat and colleagues employed an array 
CGH analysis through 85,000 interrogating probes with an average spacing of 35 kb and 
identified large-scale (>100-kb) copy number differences between 20 normal individuals 
(Sebat et al.. 2004). In total, 221 copy number changes at 76 CNV loci were detected by them. 
Similarly Using a BAC-CGH array with resolution of 1 Mb, Iafrate  and colleagues 
investigated large-scale CNVs in 55 unrelated individuals and identified 255 clones with copy 
number gain or loss (Iafrate et al. 2004)  
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SNP microarray platforms are also based on hybridization, in which signal intensities for the 
sample being analyzed are compared to a collection of reference hybridizations or the rest of 
the population being analyzed. However two key differences distinguish SNP microarrays 
from CGH technologies. First, hybridization in SNP platforms is performed on a single 
sample per microarray, and log-transformed ratios are generated by clustering the intensities 
measured at each probe across many samples (McCarroll et al., 2008 Perry et al., 2008). Second, 
SNP platforms take advantage of probe designs that are specific to single-nucleotide 
differences between DNA sequences, either by single-base-extension methods (Illumina) or 
differential hybridization (Affymetrix) (Cooper  et al., 2008  Peiffer et al.2006). Early SNP arrays 
demonstrated poor coverage of CNV regions but recent arrays (such as the Affymetrix 6.0 
SNP and Illumina 1M platforms) incorporate better SNP selection criteria for complex regions 
of the genome and non-polymorphic copy-number probes (Winchester et al., 2009). 
In 2006 Redon et al. constructed the first-generation CNV map of the human genome through 
the study of 270 HapMap individuals from four populations with ancestries in Europe, Africa 
or Asia. They employed both SNP genotyping arrays (Affymetrix 500K, 474642 SNPs) and 
Whole Genome BAC arrays (26574 large insert BAC clones) and found a total of 1,447 CNV 
regions, covering 360 megabases and consisting 12% of the human genome (Redon et al., 
2006).  
The Database of Genomic Variants (DGV) (www.projects.tcag.ca/variation), primarily 
developed by Lafrate and colleagues, is the most up-to-date catalogue for the results of 
comprehensive genome-wide CNV screenings in peer-reviewed studies (Iafrate et al., 2004, 
MacDonald et al., 2014). In this database duplications, insertions and deletions of more than 1 
kb of genomic DNA sequences are integrated as CNVs and those of 100–1000 bp as small 
indels. However, further high resolution CNV surveys showed that CNV sizes were often 
overestimated in initial studies, mainly due to the low resolution of the primary platforms 
(e.g., BAC arrays) used in CNV screening. With the aid of higher resolution (1 kb) array 
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CGH, Perry et al studied 2191 known CNV regions in 30 individuals from 4 HapMap 
populations. They detected copy number changes in 1153 loci and narrowed the boundaries of 
1020 (88%) CNV regions (Perry et al., 2008). Reduced CNV sizes were also reported in another 
survey of HapMap samples via Affymetrix 6.0 array, as a hybrid SNP-CNV genotyping 
platform (McCarroll et al., 2008). Upon these studies, it was argued that the large-scale CNVs 
may affect the genome less extensive than initially proposed, encompassing about 5% of the 
total human genome (McCarroll 2008). 
More recent technologies of whole-genome array CGH platforms routinely produce arrays 
with up to 2.1 million (2.1M) (Roche NimbleGen) and 1M oligonucleotides (Agilent 
Technologies) per microarray. Detection of a CNV typically requires a signal from at least 3 
to 10 consecutive probes. 
 
Sequencing-based approaches 
In addition to the array-based platforms, CNVs can also be investigated by DNA sequencing 
at whole genome levels, either by Sanger-based sequencing approaches (Sanger et al., 1977) or 
through next generation sequencing (NGS) platforms (McKernan et al., 2009; Metzker, 2010). 
One of the first efforts of using Sanger-based technology for CNV characterization was done 
in 2006, in which split capillary reads of DNA resequencing traces, generated by shotgun 
sequencing, were used for identification of insertion and deletion polymorphisms from the 
genomic DNA of 36 individuals (Mills et al., 2006). This survey discovered 415,436 indels and 
CNVs ranging from 1 to 9989 bp in size. 
Balanced SVs such as inversions cannot be identified by array platforms but are detectable 
through NGS- based paired-end sequencing technique, in which both ends of the test DNA 
segment is sequenced and is compared to the reference genome (Korbel et al., 2007). Eichler 
and colleagues compared fosmid (a phage cloning vector with DNA packaging limited to 40 
kb) DNA sequences from a library constructed from the genomic DNA of the HapMap 
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individual NA15510 and identified 297 potential SVs, varying in size from 8 kb to 1.9 Mb 
(Tuzun et al., 2005). In a related study, they constructed new fosmid libraries from eight 
HapMap samples (four Yoruba Africans and four non-African individuals) and sequenced 
both ends of approximately one million clones per genome (Kid et al., 2008). Combined with 
the previous analysis of the NA15510 fosmid library, they validated 1695 SVs across 9 
diploid human genomes, including 747 deletions, 724 insertions, and 224 inversions. 50% of 
these were found in multiple libraries.  
NGS-based platforms typically generate shorter reads than Sanger sequencing-based methods 
and they can sequence billions of bases in parallel. The first study of structural variation 
discovery using NGS technology was done by Korbel and colleagues that sequenced paired 
ends of 3-kb DNA fragments and mapped DNA reads onto the reference genome (Korbel et al., 
2007). By this strategy they identified deletions, inversions and insertions of ~3 kb or larger.  
In total, 1297 SVs, including 853 deletions, 322 insertions and 122 inversions, were identified 
in two female individuals, one African (NA18505) and one European (NA15510). 
So far the most high throughput and large scale use of NGS technologies towards a 
comprehensive map of human genomic variation has been done in the 1000 Genome Project 
(www.1000genomes.org), which has provided an integrated catalogue of variations from 1092 
individuals (1000 Genomes Project Consortium et al., 2010 and 2012). Different NGS-based 
discovery approaches and algorithms for CNV mapping, including read-pair, read-depth and 
split-read methods, used in the 1000 genome project are explained elsewhere (Medvedev et al., 
2009  Mills et al., 2011) and are beyond the scope of this thesis to be described here. The most 
important point to be mentioned is that different platforms and technologies have distinct 
power profiles in CNV genotyping, with regard to size, distribution and type of CNVs and 
therefore no single discovery strategy can capture the entire spectrum of structural variations 
in the genome. Table 1.2 shows the numbers of events detected for various categories of 
genomic structural variations including deletions, novel insertions, inversions and 
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duplications, as reported in the database of dbVar (Church et al., 2010) for the associated 
publications. Compared with array-based platforms, NGS-based methods for CNV discovery 
are biased towards the detection of deletions (Pang et al., 2014). The 1000 Genomes Project 
studies analyzed a large number of samples (1092) from a wider range of populations but used 
low-coverage sequencing, which instead limited CNV detection efficiency. Therefore the 
majority of the CNVs discovered by them were smaller than 400 bp, and duplications as well 
as larger variations were under-represented (1000 Genomes Project Consortium et al., 2010 and 
2012). However, whereas array-based approaches have a limited resolution capacity, 
sequencing-based approaches provide more accurate sequence-level breakpoint resolutions. 
The highest-resolution genome-wide array platform was used by Conrad and colleagues, in 
which the minimum size threshold for CNV detection was 450 bp (Conrad et al., 2010). 
 
 
Method 
Samp 
les 
Deletions 
Novel 
Insertions 
Inversions Duplication 
References 
Calls 
 
Median  
length 
Calls 
 
Median  
length 
Calls 
 
Median  
length 
Calls 
 
Median  
length 
SNP 
microarray* 
270 1,122 6,216   _        _        _        _ 442 14,122 McCarroll et al. ,2008 
SNP 
microarray‡ 
2,493 9,963 50,265    _        _        _        _ 3,880 108,336 Itsara et al.,2009 
Fosmid ESP 8 1,843 8,657 560 7,594 1,146 77,119 1,768 8,429 Kid et al., 2008 
Array CGH§ 40 7,909 2,284     _        _        _        _ 4,740 5,265 Conrad et al., 2010 
Array CGH|| 30 14,597 2,439     _        _        _        _ 5,502 3,835 Park et al., 2010 
NGS 185 22,025 742 128 98        _        _ 501¶ 138 1000 Genome proj 
Con.,2010 
 
Table 1.2 Comparison of different methodologies in identifying CNVs of different types and sizes. Ascertainment 
depends largely on the platforms and algorithms used. The significant bias of array platforms to deletion events, as well as 
the use of fosmid and sequencing-based platforms in detecting inversions and novel insertions which are missed by array 
technologies is highlighted. *Affymetrix 6.0 SNP (CNP calls only). ‡Illumina 300K, 550K and 650K. §Custom 42M probe, 
NimbleGen (unique CNV loci). ||Custom 24M probe, Agilent.  ¶ Tandem duplications only. ESP: end-sequence pair 
(Adopted form Alkan et al., 2011).  
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At present DGV has collected and curated 2,791,408 CNVs (comprising 202,431 CNVRs) 
that were discovered from 75 peer reviewed studies (www.projects.tcag.ca/variation). On the 
basis of the approach used for CNV discovery and characterization, these studies could be 
split into three main categories (i) studies which have used sequencing (NGS and Sanger 
approaches), (ii) surveys based on oligonucleotide array CGH or SNP arrays and (iii) studies 
using other methods, for example, fluorescence in situ hybridization (FISH), polymerase 
chain reaction (PCR), multiplex ligation-dependent probe amplification (MLPA) and optical 
mapping. 
 
1.2.2 Mechanisms of evolving CNVs  
Any change in copy number requires a change in chromosome structure, resulting in joining 
two formerly separated DNA sequences. Structural variants result from different mutational 
mechanisms, comprising DNA recombination-, replication- and repair-associated processes 
(Carvalho et al., 2016). Four major mechanisms, namely, nonallelic homologous recombination; 
non-homologous end-joining; replication fork stalling and template switching; and L1-
mediated retrotransposition generate rearrangements in the human genome and account for the 
majority of CNVs (reviewed in Gu et al., 2008 and Hasting et al., 2009, Carvalho et al., 2016). 
These mechanisms are introduced and described here briefly. 
Nonallelic Homologous Recombination (NAHR) 
NAHR occurs by the alignment and subsequent crossover between two nonallelic (i.e., 
paralogous) DNA sequence repeats with high similarity to each other (Figure 1.9) 
(Stankiewicz et al., 2002). NAHR has been argued to be the underlying mechanism for the 
majority of CNVs (Lee et al., 2007; Hasting et al., 2009). Repeats on the same chromosome and 
in direct orientation mediate duplication and/or deletion, whereas inverted repeats mediate 
inversion of the genomic interval flanked by the repeats. These recombinations require 
extensive DNA sequence homology (approximately 50 bp in E. coli (Lovett et al., 2002) and at 
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least 300 bp in mammalian cells and humans (Reiter et al., 1998). Junctions of the recurrent 
CNVs have been often found to be located in low copy repeats (LCRs), which provide this 
extensive homology (Stankiewicz 2002). LCRs, also called segmental duplications (SD), are 
large blocks (>10 kb) of interspersed duplicated sequences with >95% sequence identity and 
constitute five to six percent of the human genome (Bailey et al. 2002; Bailey and Eichler 2006) 
(See figure 1.9. a). CNPs are not distributed uniformly in the genome, but are enriched four to 
ten folds in SD regions (Redon et al., 2006 Cooper  et al., 2008.  Conrad et al., 2009). Due to their 
high degree of sequence identity, non-allelic copies of LCRs can be aligned in meiosis or 
mitosis. This leads to subsequent crossover between them, which instead results in genomic 
 
 
 
.  
Figure 1.9  a) Low Copy Repeats (LCR).  b) Non-allelic homologous recombination (NAHR) will occur by 
unequal crossing over if a recombination event uses a direct repeat (x) as homology. In this situation, a crossover 
outcome leads to products that are reciprocally duplicated and deleted for the sequence between the repeats (y). 
Adopted form Hastings et al. 2009 
a 
b 
Low copy repeat (LCR) 
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rearrangements in the form of CNVs in progeny cells (see figure 1.9. b). In addition to LCR, 
repetitive sequences such as the retrotransposable L1 elements (Han et al., 2008) and Alu 
repeats (Sen et al., 2006) can act as NAHR substrates if they are derived from similar families or 
have enough sequence identity to facilitate homologous recombination. 
Non-Homologous End-Joining (NHEJ) 
There are evidences that not all CNVs are associated with large block of repeats such as SDs. 
At least two main studies proposed that a significant fraction of CNVs are formed by NHEJ, 
which is associated with microhomology rather than with long stretches of sequence identity 
at CNV breakpoints (Korbel et al., 2007; Perry et al.,2008). NHEJ is utilized by human cells to 
repair DNA double-strand breaks (DSBs). DSBs are usually caused by ionizing radiation or 
reactive oxygen species as pathologic lesions, but are also induced as mediators for some 
cellular physiological processes such as V(D)J recombination (Lieber et al., 2003; Schwarz et al., 
2003). In NHEJ mechanism, however, double strand breakage of DNA is followed by end 
joining in the absence of extensive sequence homology and is associated with small insertions 
or loss at the junction sites (Lieber et al., 2003) (see also figure 1.10). NHEJ was first proposed, 
when sequencing the breakpoints of non-recurrent deletions in introns 47 and 48 of the human 
dystrophin gene (DMD) in patients with muscular dystrophy (Nobile et al., 2002; Toffolatti et al. 
2002). These deletions were not flanked by LCRs and the junctions showed only 
microhomology. Paradoxically, it was later found that the breakpoints of NHEJ-mediated 
rearrangements sometimes overlap with repetitive elements such as Non-long terminal repeats 
(LTRs), long interspersed nuclear elements (LINEs), Alu repeats and mammalian interspersed 
repetitive (MIR) elements. These observations suggested that although CNVs, arising due to 
NHEJ mechanism, do not obligatory require LCRs but are still stimulated by certain genomic 
homology architectures (Stankiewicz et al, 2003). 
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Replication Fork Stalling and Template Switching (FoSTeS) 
As it was difficult to explain the complexity of some CNV rearrangements by either NAHR or 
NHEJ recombination mechanisms, Lee and Lupski proposed the FoSTeS Model (Lee et al., 
2007) (see figure 1.10). According to this model, during DNA replication, the DNA 
replication fork stalls at one position, so that the lagging strand (i) disengages from the 
original template; (ii) transfers and (iii) then anneals, by virtue of microhomology at the 3' 
end, to another replication fork in physical proximity (not necessarily adjacent in primary 
sequence); (iv) 'primes' and restarts the DNA synthesis. Switching to another fork located 
downstream (forward invasion) would result in a deletion, whereas switching to a fork located 
upstream (backward invasion) results in duplication. The most distinguished hallmark of this 
model for CNV formation is that FoSTeS is a replication-based mechanism and rearrangement 
is induced by errors in the replication procedure. FoSTeS model has been argued to be the 
underlying mechanism for gene duplication/triplication and even rearrangements of single 
exons (Zhang et al., 2009). These notions propose FoSTeS to be a significant mediator in gene 
duplication and exon shuffling; two predominant processes in driving new genes and genome 
evolution.  
L1 Retrotransposition 
Long interspersed elements-1 (L1) comprise 16.89% of genomic DNA sequence and currently 
are the only active autonomous transposons in the human genome (Kazazian et al., 1998; 
Goodier et al., 2008). Of the 516,000 copies of L1 in our genome, only about 80–100 copies are 
full length (about 6 kb in size) and have two intact open reading frames (ORF): ORF1 coding 
for a RNA-binding protein and ORF2 encoding a protein with both endonuclease  and reverse 
transcriptase activity (Babushok et al., 2007). L1 transposition occurs via an RNA intermediate 
that is probably transcribed by RNA polymerase II (Babushok et al., 2007). The reverse 
transcription and integration are thought to occur in a coupled process called target primed 
Introduction                                                                                                                                               28 
 
 
reverse transcription (TPRT) (Ostertag et al., 2001). The resultant insertion is flanked by 
duplicated target sites (TSD) that is a characteristic of TPRT (Ostertag et al., 2001).  
The predominant mechanisms mediating the majority of CNVs have been reported 
controversially in different studies. 30% of the SVs, identified through paired-end mapping in 
HapMap individual NA15510 were attributed to retrotransposition, of which 90% due to L1 
elements (Korbel et al., 2007). Kidd et al. however reported 15% of their detected SV events in 9 
HapMap individuals to be due to retrotransposition (Kid et al. 2008). Some initial whole 
genome CNV detection studies have estimated that only 9% (Korbel et al., 2007) or 14% (Perry  
 
 
Figure 1.10  Genomic rearrangement mechanisms underlying CNV formation.  
a) Non-homologous end-joining (NHEJ). Double-stranded DNA break (DSB) occurs and is repaired via NHEJ mechanism. 
The two thick lines depict two DNA strands with DSB, the thin segments in the middle represent the modifications which the 
ends have gone through before the final ligation. The enzyme machineries catalyzing each step are briefly mentioned. Note 
at step 3 that in order to repair ends, some addition or deletion of bases may be required, leaving behind a 'signature' of 
NHEJ. b) Replication Fork Stalling and Template Switching (FoSTeS) After the original stalling of the replication fork 
(dark blue and red, solid lines), the lagging strand (red, dotted line) disengages and anneals to a second fork (purple and 
green, solid lines) via microhomology (1), followed by (2) extension of the now 'primed' second fork and DNA synthesis 
(green, dotted line). After the fork disengages (3), the tethered original fork (dark blue and red, solid lines) with its lagging 
strand (red and green, dotted lines) could invade a third fork (gray and black, solid lines). Dotted lines represent newly 
synthesized DNA. Serial replication fork disengaging and lagging strand invasion could occur several times (e.g. FoSTeS x 2, 
FoSTeS x 3, ... etc.) before (4) resumption of replication on the original template. Illustration from Gu et al., 2008 
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et al., 2008) of CNV breakpoints fall within repetitive sequences, suggesting that nonrecurrent 
mechanisms predominate, whereas others have argued that 47% of breakpoints follow NAHR 
rules (Kidd et al., 2010). Rate of formation of new CNVs is mostly dependent on the underlying 
mechanism, which instead correlate with local and regional genome architecture. Estimations 
of locus-specific CNV mutation rates rang from 1.6 × 10−6  to 1.2 × 10−4  per locus per 
generation, which are 100 to 10,000 times greater than that for SNPs (van Ommen, 2005; 
Lupski, 2007). Of note, mutation rate of single base substitutions is estimated to be 1.8 – 2.5 × 
10−8 per base pair per generation (Nachman et al., 2000; Kondrashov, 2003). 
1.2.3 Functional consequences of CNVs 
Predicting the phenotypic consequences of structural variations has been shown to be 
complex. In this context the location of CNVs in relation to genes is particularly important. 
CNVs may occur anywhere, but are more common in regions devoid of genes known as gene 
deserts (Buchanan et al., 2008). Some CNVs encompass entire genes, the expression of which is 
assumed to vary according to gene dosage effects. CNVs may also have their breakpoints 
intersected with coding regions, resulting in gene fusions or truncations. Yet others are in 
nongenic regions but can have measurable effects on expression of the genes that are 
hundreds of kilobases away from the rearranged site (see Figure 1.11). When genes are 
involved, impact of the variant will be dependent on the function(s) of these genes. Essential 
or housekeeping genes are less likely to be tolerant of any disruption, and de novo variants that 
affect them encounter strong selection (Goh et al., 2007). Studies on human transformed cell 
lines have shown that globally there is a significant correlation between mRNA levels and 
gene copy number (Ait Yahya-Graison et al., 2007; Schlattl et al., 2011). Notably, however, for 
individual genes mRNA levels often deviated from the expected levels; that is, they were not 
halved when one gene copy was deleted, nor increased by a 3:2 ratio in a trisomic (one copy 
gain) state. Further to this, not all genes with altered copy number displayed altered 
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expression, and a small proportion even showed expression changes that were inverse to the 
copy-number alteration (Schlattl et al., 2011; Vazquez-Mena et al., 2012). It has been argued that 
part of these aberrant observations might be due to dosage compensation mechanisms, acting 
on larger regions of the genome (Straub et al., 2007). In addition, structural variants that overlap 
    
 
Figure 1.11  Functional consequences of structural variants. a) Genes (boxes) are regulated by the collective 
and combinatorial input of regulatory elements, including tissue-specific enhancers (hexagons, with different colours 
indicating tissue-specificity, and arrows pointing to the target gene) and insulators (black rectangles), which block the activity 
of regulatory elements. b–d) Structural variants (shown by square brackets) can have phenotypic consequences by altering 
coding regions. For example, they can remove part of a coding region or fuse different coding regions after a duplication, 
resulting in aberrant transcripts (b). Alternatively, deletions or duplications can lead to altered doses of otherwise functionally 
intact elements (c), resulting in altered regulatory input (left) or altered gene copy number (right). Structural variants can also 
affect the expression of genes outside of the variants, which is a positional effect (d), thus resulting in a gain or loss of 
regulatory inputs. (Illustration from Weischenfeldt et al., 2013) 
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cis-regulatory elements may be inversely correlated with the expected directional change of 
mRNA abundance. Cis-regulatory elements are genomic regions (e.g. enhancers) that regulate 
the expression of genes on the same chromosome. It has been shown that deletions can lead to 
increased gene expression, where the deletion affects a silencer or insulator element (Merla et 
al., 2006).  
An expression quantitative trait locus (eQTL; a genomic locus that regulates the mRNA 
expression level of a gene) survey, carried out in inbred mouse strains found that structural 
variants contribute on average to larger effect sizes on gene expression than single nucleotide 
variants (SNVs) (Keaneet al., 2011). The transcriptional effect of CNVs might be distinct in 
different cell types and tissues. For example a 20 kb deletion, locating immediately upstream 
the IRGM gene, is associated with a reduced expression of the gene in Hela (immortalized 
cervical cancer) and hepatocellular carcinoma cells, but leads to increased expression in colon 
carcinoma cells as well as bronchus smooth muscle cells. (McCarroll et al, 2008). This 
differentiated effect could be due to the fact that eQTLs are cell-type-, tissue- and 
developmental-stage-specific, so that gene expression programs could operate in a highly 
context-dependent manner (Chaignat, et al., 2011) 
1.2.4 CNVs and diseases  
So far based on the reports of involvement of CNVs in various disease phenotypes, two 
general types or models of CNV-disease associations have emerged. The first type involves 
CNVs that are individually rare (<1% frequency), typically involve larger chromosomal 
segments (>100 kb) and exist in fewer copy number states (single copy gain or loss). These 
CNVs are under strong selection pressure; their frequency in the population is largely 
contributed by de novo events and they can only persist for a few generations (Girirajan et al., 
2010). The second model involves CNPs that occur at a population frequency of >1% and 
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often exist in multicopy number states, ranging from 0 to 30 copies per diploid genome 
(Sudmant et al., 2010). 
Large rare CNVs in neuro-developmental and neuropsychiatric diseases 
Extreme representations of deleterious pathogenic CNVs comprise whole or partial 
chromosomal duplications and deletions as well as sub-chromosomal structural changes of 
megabases of DNA, detectable by conventional microscopy such as molecular karyotyping or 
fluorescent in situ hybridization (FISH). A well-known instance in this context is Down 
syndrome (MIM 190685) caused by duplication of the whole human chromosome 21 
(Lejeune et al.,1959; Antonarakis et al., 2004). Duplication (trisomy) or deletion (monosomy) of a 
whole chromosome is called chromosomal aneuploidy and is mostly lethal (Hassold et al., 
2001). Trisomies of chromosomes 21, 18, 13 and X are viable (although harboring major 
congenital abnormalities), whereas except for monosomy X, all chromosomal monosomies 
are embryonically lethal (O'Connor, 2008). Aside from these extreme chromosomal 
imbalances, a lot of microdeletions and microduplicatios (megabase-sized variations yet 
submicroscopic) have been recognized, which lead to sporadic or Mendelian 
neurodevelopmental syndromes, generally known as genomic disorders (Lupski, 1998; 
Stankiewicz et al., 2002; Sharp et al., 2006). These large scale CNVs are frequently flanked by 
large segmental duplications that make these genomic regions prone to recurrent DNA 
rearrangements (Itsara et al., 2009). This instead leads these CNV events to occur recurrently in 
multiple unrelated individuals in a relatively short period of time, although they are under 
strong negative selection in the population (Lupski et al., 2005; Itsara et al., 2010). Some 
prototypic examples of genomic CNV disorders are Smith–Magenis syndrome (SMS), 
Williams–Beuren syndrome (WBS) and Potocki–Lupski syndrome (PLS). Clinical 
phenotypes associated with submicroscopic chromosomal imbalances (including deletions, 
duplications, insertions, translocations, and inversions) have been archived in DECIPHER 
(DatabasE of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources; 
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http://www.sanger.ac.uk/PostGenomics/decipher/) (Firth et al., 2009). Only 20% of the 
disorders annotated in this database are caused by duplications, whereas 80% are caused by 
deletions, and duplications in the database are on average associated with less-severe 
phenotypes. These observations reconfirm the fact that loss of genomic regions is less 
tolerated than the gain (Firth et al., 2009). Large CNV rearrangements are not only associated 
with sever in-born or early-onset intellectual disabilities and neurodevelopmental 
malformations with patterns of sporadic or Mendelian inheritance; they have also been 
implicated in more common complex neuropsychiatric diseases such as autism (MIM 209850) 
(Sebat et al, 2007; Weiss et al., 2008), schizophrenia (MIM 181500) (Walsh et al., 2008; Xu et al., 
2008), bipolar disorder and attention deficit hyperactivity disorder (ADHD) (Girirajan et al., 
2011). 
Some studies have reported recurrent large pathogenic CNVs with variable penetrance and 
expressivity. For example, the 1.5 Mb deletion at 15q13.3 was initially identified in 
individuals with developmental delay (Sharp et al., 2008). Further studies showed that the same 
deletion was enriched in cases with autism (Pagnamenta et al., 2009) and schizophrenia 
(Stefansson et al., 2008) and, in fact accounts for approximately one percent of cases with 
idiopathic generalized epilepsy (Helbig et al., 2009). Similarly, the 1.6 Mbp microdeletion on 
1q21.1 was found to be enriched in individuals with developmental delay (Mefford et al., 2008), 
autism (Szatmari et al., 2007) Schizophrenia (Stefansson et al., 2008), and cardiac defects 
(Greenway et al., 2009).  
CNPs in common complex diseases 
CNPs are CNVs that have high frequencies (>=5%) in human population (see also 1.2 page 
18).  Two types of CNPs may be distinguished; those that simply represent a gain or loss of a 
particular segment of DNA, referred to as bi-allelic CNPs, and those where the underlying 
sequence can exist as a series of whole integers, termed multicopy CNPs (Bailey et al 2002; 
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Conrad et al., 2006). CNPs have been associated with some complex human diseases (see table 
1.3), nevertheless findings of their contribution to the genetic variance of most common 
diseases have been far less than that for SNPs (Wellcome Trust Case Control Consortium., 
2010). In 2010, Conrad et al. generated a map of over 10,000 common copy-number variants in 
the human population through high resolution array CGH. Most of common CNPs, 
characterized in their study were in strong LD with common SNPs (Conrad et al., 2010). They 
therefore argued that the associations of the Common CNVs with complex diseases have 
already been analyzed in GWAs studies for common SNPs. In contrast to this argument, it has 
been emphasized that most of multi-allelic CNPs occur in segmental duplication rich regions 
and therefore are difficult to be assayed either by array-based or NGS-based methodologies. 
These CNVs even tend to show less LD to SNPs (Alkan et al., 2011) and their disease 
associations have therefore not been dissected comprehensively.  
CNPs in the human leukocyte antigen (HLA) region have been associated with multiple 
diseases, including Crohn's disease, rheumatoid arthritis, and type 1 diabetes (Wellcome Trust 
Case Control Consortium., 2010). Indeed SNPs in the HLA region have also been strongly 
associated with many immune-mediated diseases (Shiina et al., 2004) and considering the 
strong extended LD across this locus, it is not surprising that CNPs in this region contribute to 
risk of these diseases. It has been shown that large number of common CNVs associated with 
diseases lie in segmental duplications highlighting the role of these regions in genomic 
pathogenesis (Girirajan et al., 2011). Examples of these include association of CNVs of the β-
defensin locus on chromosome 8 with psoriasis (Hollox et al., 2008) and Crohn's disease 
(Fellermann et al, 2006) as well as association of low copy number of FCGR3B with lupus 
(Fanciulli et al., 2007). However follow-up analysis has failed to replicate the association of β-
defensin copy number with Crohn's disease using different copy number genotyping methods 
(Aldhous et al., 2010). Therefore, although CNPs in segmental duplications are important for 
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human genetic diversity, accurate genotyping methods are required to test these variants for 
association to disease.  
SNPs around IRGM (immunity-related GTPase family, M) have been associated with CD 
(Parkes et al., 2007). McCarroll and colleagues showed that a previously known 20-kb deletion 
polymorphism upstream of IRGM is in perfect LD with a CD-associated SNP in this region 
(McCarroll et al., 2008). The deletion haplotype of IRGM was shown to have a distinct 
expression pattern compared to the reference haplotype. It has been proposed that IRGM-
upstream deletion may cause CD through the altered level of IRGM expression, which instead 
affects the efficacy of autophagy (McCarroll et al., 2008). 
 
Gene Disease/trait Variant type Associated allele 
DEFB4, DEFB103, DEFB104 Psoriasis Amplification High copy number 
DEFB4, DEFB103, DEFB104 Crohn's disease Amplification Low copy number 
CCL3L1 HIV/AIDS Amplification Low copy number 
C4 Lupus Amplification Low copy number 
FCGR3B Glomerulonephritis in Lupus patients Amplification Low copy number 
FCGR3B Lupus Amplification Low copy number 
IRGM Crohn's disease Upstream deletion Deletion 
CFHR1, CFHR3 Age-related macular degeneration Deletion No deletion 
CYP2D6 Reduced drug metabolism Deletion Deletion 
RHD Rh-negative blood group Deletion Deletion 
OPN1LW, OPN1MW Color blindness Deletion Deletion 
LPA Coronary heart disease Amplification Low copy number 
SMN2 Severity of spinal muscular atrophy Amplification Low copy number 
AZFc region Spermatogenetic failure Deletion Deletion 
CYP21A2 Congenital adrenal hyperplasia Amplification 
Two copies 
 per chromosome 
UGT2B17 Osteoporosis Deletion No deletion 
UGT2B17 Graft-versus-host disease Deletion Deletion 
LCE3B, LCE3C Psoriasis Deletion Deletion 
NEGR1 Obesity Upstream deletion Deletion 
NBPF23 Neuroblastoma Deletion Deletion 
TSPAN8 Type 2 diabetes Amplification Low copy number 
HLA Crohn's disease, rheumatoid arthritis,  
 type 1 diabetes 
Multiple CNVs Various 
GPRC5B Obesity Upstream deletion Deletion 
Table 1.3  Selected copy number polymorphisms associated with complex diseases. (According to Girirajan et al., 2011) 
 
Introduction                                                                                                                                               36 
 
 
1.3 Monozygotic (MZ) twins 
In the 19th century, the Scottish obstetrician J Matthews Duncan distinguished two types of 
twins as identical versus non-identical. However, the Britain Francis Galton is usually cited as 
the first scientist that proposed the possibility of using twins to compare the contributions of 
nature (heredity) versus nurture (environment) (Galton, 1875; Boomsma et al, 2002). MZ twins 
- also called identical twins - arise from a single ovum (egg), fertilized by one sperm (and 
therefore from a single zygote), whereas dizygotic (DZ) twins result from two different eggs, 
fertilized by two different sperms. Generally MZ twins have been assumed to be genetically 
identical and phenotypic differences between individuals of a MZ pair (discordance) have 
been classically attributed to non-genetic factors, mainly differential environmental exposures 
(Schinzel et al., 1979). On the other hand, DZ twins share on average only half of their genetic 
variations (like any non-twin siblings) and therefore phenotypic discordances between them 
are the result of both genetic and non-genetic factors (see also table 1.4).  
The spontaneous rate of monozygotic twinning is about 4 in 1000 human live births around 
the world (Hall, 2003), although there exists evidence for a familial susceptibility with  
autosomal dominant inheritance in some cases (Machin, 2009). The rates of twinning have  
increased in the past decades, in part due to assisted reproductive technologies as well as 
increases in maternal age (Chang et al., 2009). The etiology of monozygotic twinning in 
humans is mostly unknown. Earlier assumptions considered this as a random process and 
proposed that stochastic damage to the inner cell mass of the blastomer (see figure 1.12) and 
subsequent generation of two points of regrowth leads to twinning in humans (Hall et al., 1996). 
More recently it has been proposed that cells within the blastocyst may develop in such a way 
as to become discordant, recognizing each other as foreign cells and use cell-recognition 
mechanisms to set up two separate cell masses (Zwijnenburg, 2010). Further it has been 
argued that post-zygotic epigenetic changes such as differentiated DNA methylation very 
early in embryonic development (within two weeks after fertilization) could establish two 
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separate cell masses, which eventually develop to MZ twins (Shur 2009; Machin, 2009). Such 
a model could be an explanation for increased prevalence of certain (epi-) genetic syndromes 
among MZ twins compared to singletons, such as Beckwith–Wiedemann syndrome (BWS) 
(Shur, 2009; Bliek et al., 2009). In this model, it is not however clear whether unequal splitting 
of the inner cell mass results in differential methylation between the two cell masses or 
alternatively a lack of methylation maintenance in the early zygote results in splitting of the 
zygote. In both cases, however, a difference in genomic methylation between MZ twins may 
also account for their phenotypic discordance ( Zwijnenburg, 2010). 
 
 
Figure 1.12  Three types of monozygotic placenta and membranes 
 A) If the zygote splits within 3 days, the twins are dichorionic and diamniotic (18 to 36% of all MZ births). B) If 
splitting occurs after the third but before the seventh day, the twins are monochorionic but diamniotic (60 to 80% 
of cases). C) If division occurs between days 7 and 14, the twins are monochorionic and monoamniotic (2 to 4% 
of all MZ twins). Conjoined twins arise when splitting happens after the days 13 or 14. A=dichorionic diamniotic 
pregnancy. B=monochorionic pregnancy. C=monochorionic monoamniotic pregnancy. (Adopted from Hall, 2003) 
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In addition to post-zygotic genetic and epigenetic events, prenatal intra-uterine exposures 
could also contribute to phenotypic divergence of MZ twins, despite deriving from a single 
zygote. The majority of MZ twins (about two-thirds) are monochorionic (MC), that is, twins 
who are both connected to a truly single (not fused) placenta (Machin, 2009). The remaining 
one-third of MZ twins are dichorionic (DC), developing in separate sacs (see figure 1.12). 
Parents of same-sexed DC MZ twins are sometimes informed mistakenly that their twins are 
dizygotic. In the past, zygosity in same-sex twin pairs was mainly determined by blood group 
and HLA typing and comparison of physical characteristics ( Keith, et al, 1997). However, 
DNA polymorphisms such as microsatellite markers and SNPs are more reliable and used 
more routinely in zygosity testing (Hall 2003). The most common approach has been 
analyzing eight variable microsatellite loci by PCR of the genomic DNA from buccal 
samples. In large-scale epidemiological projects, zygosity is still often determined on a series 
of questionnaire items (Rietveld et al., 2000). 
1.3.1 Discordant MZ twins in disease studies 
In classical twin studies, comparing the resemblance (concordance) rate of a complex trait or 
disorder in MZ twins with that in DZ ones is used to estimate the heritability (extent to which 
genetic variations determines phenotypic variation) of that trait (Boomsma et al, 2002). It is 
expected that any heritable disease will show more concordant rates in MZ twins that in non-
identical (DZ) ones. MZ twins are in general expected to be similar; nonetheless an increasing 
number of reports have been published on MZ twins discordant for congenital malformations, 
chromosomal abnormalities and Mendelian and complex disorders (Machin 2009; 
Zwijnenburg et al., 2010; Czyz et al., 2012). Primary assumptions proposed that discordances in 
Z twins are generally due to differentiated environmental exposures; although responsible 
factors have not been well delineated. To date there exist evidences that beside environmental 
and stochastic effects, genetic and epigenetic differences could also account for discordance in 
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MZ twins (Czyz et al., 2012, Castillo-Fernandez., 2014). It is however appreciated that 
epigenetic modifications, especially those that occur postnatal in twins are driven by 
environmental exposures. 
1.3.2 Genetic differences in MZ twins: Somatic mosaicism 
Genetic differences might arise during prenatal cell divisions and differentiations (during 
embryonic development) or post-natally during the life time of MZ twins and could 
potentially contribute to their phenotypic discordance. The presence of cells within an 
organism that have differences in genetic composition, despite deriving from a single zygote 
is described as somatic mosaicism, which plays a key role in carcinogenesis, ageing and 
possibly autoimmunity (Youssoufian et al., 2002). Any variations in genomic sequences 
between MZ twins can also be viewed as extreme examples of somatic mosaicism. Mosaicism 
for de novo genome alterations including point mutations, indels, CNVs and chromosomal  
 
 
Table 1.4 Original twin model proposed that discordance especially in MZ is due to post-natal environmental 
factors (upper). More recent data proposes that genetic and epigenetic factors largely account for discordance in 
both MZ and DZ twin pairs (lower). MC: monochorionic (see also figure 1.12). According to Zwijnenburg et al., 2010 
Environmental effects
Phenotype Concordance Discordance
MZ twin pair identical genome; similar
    pre- and post-natal
       "environment"
different post-natal
     "environment"
DZ twin pair similar pre- and post-natal
       "environment"
different genomes; different
post-natal "environment"
Genetic/epigenetic effects
Phenotype Concordance Discordance
MZ twin pair common (initial) genome post-zygotic divergence of
genome/epigenome;
prenatal environment of MC placenta
DZ twin pair concordant for approximately
              50% of allels
discordant for approximately
              50% of allels
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rearrangements have been observed in MZ twins (Bruder et al., 2008; Machin 2009; 
Zwijnenburg et al., 2010; Czyz et al., 2012). MZ twins discordant for chromosomal abnormality 
(aneuploidy) have been recognized for a longer time; discordant MZ twins have been reported 
for monosomy X, trisomy 1, trisomy 13, and trisomy 21 (Zwijnenburg et al., 2010). The rate of 
de novo single nucleotide variation (SNV) has been estimated at about 1.18 x 10-8 per base pair 
per generation, which account for ~74 novel SNVs per genome per generation (Veltman et al, 
2012). Although this estimation primarily explains germline mutations, it has been assumed 
that most cells in the body carry at least one de novo point mutation (Veltman et al, 2012), an 
assumption that can rationally be applied to MZ twins as well. Accordingly, post-zygotic 
point mutations in MZ twins have been described to be the source of discordance for some 
disease phenotype. For example, in a pair of MZ twins discordant for Darier's disease  
 
 
 
Figure 1.13 Somatic mosaicism. Mosaic populations arise if new mutations that occur early in development (blue circles) 
do not inhibit cell growth and division or, alternatively, new mutations that occur relatively late in development (green circles) 
confer a proliferative advantage. Mutations that compromise cell growth early on most likely will not contribute to the mosaic 
phenotype (red circle). Illustration from Youssoufian  et al., 2002. 
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(an autosomal-dominant skin disorder characterized by loss of adhesion between epidermal 
cells and abnormal keratinization), discrepancy was attributed to a point mutation in the 
ATP2A2 gene, which encodes the sarco/endoplasmic reticulum Ca2(+)-ATPase type 2 
isoform and is highly expressed in keratinocytes (Sakuntabhai et al., 1999) Furthermore, a 
mutation in IRF6 was found in the affected twin from a MZ twin pair discordant for Van der 
Woude syndrome, an autosomal dominant form of cleft lip and palate with lip pits (Kondo et 
al., 2002). Likewise discordance for a point mutation in FLNA has explained the development 
of otopalatodigital syndrome in one sibling of a MZ twin pair (Robertson et al., 2006) and 
mosaicism within a MZ twin pair for a mutation in the COL4A5 gene was suggested to cause 
discordance of Alport syndrome (Matsukura et al., 2004). It has been hypothesized that the 
inheritance of a single recessive mutated allele of a gene coupled with a somatic mutation in 
the normal allele during critical periods of development in the affected twin may result in 
discordance for Schizophrenia in MZ twins (Singh et al., 2009). These reports highlight the 
potential value of discordant MZ twins in identifying new genes (Mansilla et al., 2005).  
The presence of CNVs has been demonstrated both within concordant and discordant MZ 
twin pairs. Bruder et al. studied a total of 19 pairs of MZ twins, of which 9 were discordant for 
Parkinson disease or Lewy body dementia, whereas 10 were phenotypically unselected. 
Comparisons within the twin pairs revealed a considerable number of loci suggestive of 
putative CNVs in both groups (Bruder et al.,2008). It has been even estimated that de novo 
CNVs may occur at a rate of 10% per twinning event (Czyz et al., 2012). NAHR as a mechanism 
underlying CNV formation (see 1.2.3) may also occur in mitosis and thereby result in mosaic 
populations of somatic cells carrying genomic rearrangements (Lupski, 2007). 
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1.3.3 MZ twins in IBD 
Until 2012, six population-based studies in cohorts of both MZ and DZ twin pairs, in which at 
least one individual was affected by IBD have been reported (table 1.5). In 1988, the Swedish 
twin registry identified 34 MZ and 43 same-sex DZ twins with at least one diagnosis of CD or 
UC (Tysk C 1988). Among 18 MZ twins, each with a CD proband, eight were concordant for 
CD, whereas in 26 DZ twin pairs only one was CD-concordant. In contrast, the observed MZ 
and DZ concordance for UC was 6.3% and 0%, respectively. This significantly higher 
concordance rate for CD (44.4%) versus UC (6.3%) in MZ twins proposed that genetic risk 
factors play a greater role in CD, whereas UC is influenced more by environmental triggers. 
Later cohort studies, however, showed that the rate of concordance within MZ twins is more 
modest for CD and is somewhat greater for UC than that primarily observed in Swedish 
registry. For example results of a nationwide study of a total of 189 IBD twin pairs (68 MZ 
and 121 DZ pairs) in Germany revealed MZ-twin-concordance rate to be 35% for CD and 
16% for UC (Spehlmann et al., 2008). Indeed German cohort reconfirmed the stronger genetic 
influence in CD than UC, but simultaneously estimated a greater genetic component for UC in 
comparison to Swedish study. The question, whether Swedish twin study actually 
overestimated heritability of CD and underestimated that of UC, or CD is really more genetic 
in the Scandinavian population, was addressed by a long term follow-up of the Swedish IBD 
cohort by Halfvarson and colleagues. They recognized that primary study had not been age-
standardized and only included a relatively small window of time to ascertain IBD cases and 
therefore they included IBD cases missed during the original study period and extended the 
time of observation for an additional 15 years (Halfvarson et al., 2011). The MZ concordance 
rate for UC revealed to be higher (15%) in their updated study, which is also very consistent 
with MZ concordance rate for UC (16%) in German twin cohort (Spehlmann et al., 2008). 
These studies clearly implicated that twins provide a valuable resource to estimate the 
contribution of genetic versus environmental factors in susceptibility to common complex 
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disorders like IBD. There are however challenges such as correct zygosity determination, 
standardization for age and onset of disease as well as variability in disease manifestations 
that could potentially lead to biased estimations of heritability in twin cohort studies (Brant, 
2011). 
 
 
         MZ Twins         DZ Twins   
  
 
(No. Concordant:         Pair (No. Concordant:        Pair 
Year Population    No. Discordant) Concordance   No. Discordant) Concordance 
1988 
Sweden 
Tysk et al. 
CD  8 : 10  44.4% CD 1 : 25 3.8% 
UC  1 : 15  6.3% UC 0 : 17 0.0% 
1996 
British 
Thompson et al. 
CD  5 : 20 20.0% CD 3 : 43 6.5% 
UC 6 : 32 15.8% UC 1 : 33 2.9% 
2000 
Denmark 
Orholm et al. 
CD  5 : 4 55.5% CD 1: 27 3.6% 
UC 3 : 18 14.3% UC 2: 42 4.5% 
2008 
Germany 
Spehlmann et al. 
CD  11 : 20 35.5% CD 2 : 56 3.4% 
UC 6 : 31 16.2% UC 1 : 62 1.6% 
2010 
Sweden a 
Halfvarson et al. 
CD  9 : 24 27.3% CD 1 : 49 2.0% 
UC  6 : 35 14.6% UC 3: 46 6.1% 
2010 
Sweden b 
Halfvarson et al. 
CD  4: 10 28.6% CD 0 : 14 0.0% 
UC  1 : 5 16.7% UC 1 : 15 6.3% 
1988-
2010 
All combined 
non-overlapping 
cohorts 
CD 34 : 78 30.3% CD 7 : 189 3.6% 
UC 22 : 121 15.4% UC 8 : 198 3.9% 
 
Table 1.5  IBD Reported in Published Studies of Unselected Twin Cohorts (Adopted from Brant et al., 2011) 
Swedena twins born 1886–1958; Swedenb twins born 1959–1980.  
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1.4  Aims of this study 
As mentioned earlier, IBD risk loci identified so far confer only a modest effect on disease 
susceptibility and therefore the majority of the genetic contribution to disease risk remains to 
be explained. CNVs, as one major form of genomic variations have been shown to be 
involved in the pathogenesis of some common disease phenotypes. However the limited 
findings in case-control association studies for CNVs might suggest the need to pursue 
alternative approaches for dissecting genetic copy number variability and their probable 
involvement in susceptibility to common diseases. In this thesis we conducted two related 
studies to examine whether CNVs contribute to IBD risk;  
In one, 6 IBD-discordant monozygotic twin pairs were compared genome-wide to explore 
somatic CNVs. This was conducted to ascertain if twin individuals harbor any genomic copy 
number differences in comparison to their co-twins and whether the probable CNV regions 
potentially implicate further susceptibility loci in IBD.  
In parallel, we recruited an existing SNP-GWAS data set of UC as well as four other 
independent UC cohorts and performed a multi-step genome-wide case-control analysis to 
interrogate the presence of disease-relevant rare CNVs.  
We hypothesized that the probable findings of these two studies could provide insights on 
pathogenic genomic CNVs, which are shared or complementary in germline and somatic 
tissues. 
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2 Methods 
2.1 Twin sample recruitment 
6 pairs of German MZ twins, where in each pair only one sibling was diagnosed as IBD patient, 
were recruited for this study. Of these 3 pairs were discordant for UC and 3 pairs discordant for 
CD. These twin individuals were part of a cohort consisting of a total of 189 twin pairs 
previously gathered by several calls for twin pairs using advertisements and the nationwide 
newsletter of the German Cohn’s and Colitis Association (patient association with more than 
20,000 members; DCCV e.V.) and the Competence Network Inflammatory 
Bowel Disease (medical expert network; Kompetenznetz Darmerkrankungen e.V.) (Spehlmann et 
al., 2008). In these calls individuals had been asked to participate and complete a questionnaire if 
they had IBD and were born as one of a twin pair. Among others, questions were related to 
zygosity, medical history, social status, lifestyle (e.g., former and present smoking status), if they 
grew up together, and birth order. Diagnosis of CD and UC was confirmed in the previous 
epidemiological survey conducted on this twin cohort (Spehlmann et al., 2008). In that study 
diagnosis of IBD has been confirmed by review of the patients’ original medical records 
including ileocolonoscopies. Diagnosis of CD had been confirmed when at least 2 of the criteria 
published by Landers and colleagues (Landers et al., 2002) were fulfilled. Diagnosis of UC was 
based on endoscopic appearance and continuity of inflammation, histology, and proven exclusive 
involvement of the colon. Patients had been also profiled with regard to age of onset of 
symptoms, age at time of diagnosis, location of disease (ileal or colonic by CD) or behavior of 
disease (e.g., mucosal-confined inflammatory, structuring or penetrating by CD), disease extent 
(in UC), current treatment, and treatment since diagnosis. The non-diseased member of the twins 
had been evaluated for signs and symptoms of IBD and records of previous ileocolonoscopies 
(Spehlmann et al., 2008).  
Table 2.1 describes the characteristics of the 12 twin individuals used in this study.  
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In addition to twin individuals, the genomic DNA of the anonymous HapMap sample NA15510 
and 3 healthy Lithuanian MZ twins were recruited as controls in the way that will be described 
later. 
ID 
Clinical  
status Gender 
 
Age  
(y) 
 
Smoking  
Status CAI 
Duration 
  of the  
disease Location Treatment Surgery 
Hu1 H M 57 NS na         
UC1 UC M 57 NS 4 15 Pancolitis 5-ASA/Steroids 0 
Hc2 H F 36 NS na         
CD2 CD F 36 NS na 5 Ileum 5-ASA 0 
Hu3 H M 42 S na         
UC3 UC M 42 NS 3 14 Left-sided 5-ASA/Steroids 1 
Hc4 H F 28 NS na         
CD4 CD F 28 NS na 3 Ileum na 0 
Hu5 H F 41 NS na         
UC5 UC F 41 NS 7 4 Pancolitis 5-ASA/Azathioprin 0 
Hc6 H M 33 S na         
CD6 CD M 33 S na 4 Colon na 0 
 
Table 2.1. Clinical Data for 6 IBD-Discordant MZ Twin Pairs 
UC, ulcerative colitis patient; CD, Crohn’s disease patient; Hu Healthy co-twin of UC patient: Hc Healthy co-twin 
of CD patient; CAI, Colitis Activity Index; na, non applicable; NS, Never smoked; S, Smoker; ASA, mesalamine. 
 
2.2 Twin sample preparation 
After recruitment of twin individuals, genomic DNA was isolated from peripheral  
blood cells as well as biopsy specimens sampled from the sigmoid colon or rather ileum and 
were checked for quality on agarose gel. 
2.2.1  DNA extraction from blood and biopsy samples 
Genomic DNA (gDNA) was extracted from EDTA whole blood samples, using the Invisorb® 
Blood Giga Kit for DNA isolation. Lysis of erythrocytes, while leukocytes stayed intact, was 
performed by incubating 9 ml of blood for 10 min with 30 ml of cold buffer 1 at room 
temperature. Afterwards, the suspension was centrifuged for 3 min at 3,000 rpm and the 
supernatant was carefully discarded. This step was repeated with 20 ml buffer 1 until the 
leucocyte containing pellet was free of haem. The pellet was resuspended in 3 ml of buffer 2 
and50 μl of Proteinase K and incubated for 2 hours in a 60°C water bath under continuous 
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shaking(95 turns/min) to increase the lysis efficiency. This step leads to the lysis of the 
leukocytesand their nuclei and therefore to a release of DNA into the suspension. To seperate the 
DNA from cell and protein fragments, 1.8 ml of buffer 3 were added. Vigorous mixing and a 5 
min incubation on ice were subsequently carried out. Then, the mix was centrifuged for 15 min 
at 5,000 rpm. Afterwards, the cleared supernatant was transferred into a 15 ml centrifuge tube. 
For the precipitation of the DNA, 10 ml of 96% ethanol were added and the tube carefully 
inverted several times. If precipitation did not take place, the tube was incubated for 2 h at -20°C. 
The precipitated DNA was obtained by centrifugation for 3 min at 5,000 rpm and was then 
collected with a pipette tip and transferred into 2 ml reaction tubes containing 1 ml of 70% 
ethanol. The DNA pellet was rinsed by vortexing and subsequently centrifuged for 2 min 
at13,000 rpm. Finally, the ethanol was removed with a pipette and samples were dried for 10min 
at room temperature. All samples were quantified by measuring the concentration with 
PicoGreen®. The purified gDNA was resuspended in 500 μl of 1x TE buffer and stored at+4°C 
for short periods or at -20°C for long periods. Average yields were 200 ng/μl, which corresponds 
to an amount of 100 μg DNA.  
 
Figure 2.1  Preparation of Agarose Gel Electrophoresis for gDNA from twin individuals  It was ensured that 
gDNA appeared as a single prominent band greater than 12 kb. If the sample appears as more than one band or as a smear, the 
DNA may be degraded or have a contaminant that could affect the labeling procedure. RNA contamination results in a smear 
that is less than 200 bp. 
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To determine the quality of the DNA samples, 250 ng of genomic DNA (gDNA) were run on a 
1% agarose gel to ensure that they show no signs of RNA contamination or degradation (see 
figure 2.1). 
All biopsies used in this study were primary tissues from the intestinal mucosa. Biopsies were 
taken endoscopically from a defined area of the colon, and immediately snap-frozen in liquid 
nitrogen. DNA was extracted from biopsies using the QIAamp Tissue DNA preparation kit 
(Qiagen, Hilden, Germany).  
2.2.2 Twin Sample combinations  
In each twin pair, 4 different combinations were designed and used for the following array 
experiments. The rationale behind these combinations will be discussed in results and discussion 
later. Here only the design of four combinations is mentioned as following; 
1. Blood DNA from diseased twin individual as test versus blood DNA from healthy co-twin as 
reference. 
2. Biopsy DNA from diseased twin individual as test versus blood DNA form healthy co-twin 
as reference. 
3. Biopsy DNA from diseased twin individual as test versus Blood DNA form the same 
individual 
4. Blood DNA from the HapMap sample individual as test versus blood DNA from healthy 
twin individual as reference. 
Concentrations of the genomic DNA were measured using the PicoGreen® method (Rengarajan 
et al., 2002). The PicoGreen® reagent is a proprietary, unsymmetrical cyanine dye. Free dye is 
essentially nonfluorescent and exhibits >1000-fold fluorescence enhancement upon binding to 
double stranded DNA (dsDNA) with excitation and emission maxima of  ~500 nm and ~520 nm, 
respectively. The assay displays a linear correlation between dsDNA concentration and 
fluorescence and has a detection range extending from 25 pg/mL to 1 μg/mL dsDNA using a 
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single dye concentration. The assay is highly selective for dsDNA over RNA, single-stranded 
DNA (ssDNA) and oligonucleotides. 
 
 
Figure 2.2  Sample combinations with ids on 96-well plate design (upper) and corresponding concentrations (ng/ul) of 
the samples used as test and reference samples in the array-CGH experiments (lower)   
 
 
2.3  Array-CGH experiments 
 Human CGH 2.1 M Whole-Genome Tiling v2.0 array from Roche NimbleGen 
(www.nimblegen.com) was used for genome-wide discovery of CNVs in this study. This array 
platform spans the entire human genome with 2.1 million 60 nucleotide-long probes at a median 
distance of 1,169 bp, enabling detection of CNVs down to ~5 kb. 
 
Table 2.2  NimbleGen Human CGH 2.1M Whole-Genome Tiling v2.0D Design Specifications 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A ZS 015 ZS 001 ZS 007 LT008 ZS 013 LT013 LT024 ZS 020 ZS 024
B HapMap HapMap HapMap HapMap HapMap HapMap HapMap HapMap HapMap
C ZS 015 ZS 001 ZS 007 LT008 ZS 013 LT013 LT024 ZS 020 ZS 024
D R68 R374 R74 MIIN R96 FEAU AZVL R421 R81
E ZS 015 ZS 001 ZS 007 LT008 ZS 013 LT013 LT024 ZS 020 ZS 024
F ZS 019 ZS 009 ZS 025 LT007 ZS 004 LT014 LT023 ZS 012 ZS 017
G ZS 015 ZS 001 ZS 007 LT008 ZS 013 LT013 LT024 ZS 020 ZS 024
H R70 R72 R300 MIZI R307 KYRA AZSE R426 R79
1 2 3 4 5 6 7 8 9 10 11 12
A 211.4 250 250 250 250 250 94.1 200.5 221.6
B 250 250 250 250 250 250 250 250 250
C 211.4 250 250 250 250 250 94.1 200.5 221.6
D 74.2 122.4 52.4 68.2 74.7 90.6 102 59.5 67.9
E 211.4 250 250 250 250 250 94.1 200.5 221.6
F 185.4 250 60.8 154.5 250 197.7 53.6 250 250
G 211.4 250 250 250 250 250 94.1 200.5 221.6
H 57.2 47.1 73.1 63.7 51.4 117.9 126 87.5 222
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2.3.1  Array-CGH workflow 
DNA labeling and hybridization 
Differential labeling of gDNA samples from twin individuals followed by co-hybridization to 
arrays slides and scanning with a 5um scanner was performed at the Nimblegen center. Pairs of 
samples intended for hybridization to the same array should be labeled in parallel using Cy3-
random and Cy5-random Nonamers. Roche NimbleGen applied CY3 fluorescent dye for test 
samples and CY5 fluorescent dye for  reference samples and used a high concentration of exo¯ 
Klenow fragment, lacking both proofreading (3' -> 5') and nick translation (5' -> 3') nuclease 
activities, to incorporate dNTPs while replicating the DNA. As these steps have been provided us 
by Nimbelgen, I would pass on theme here. A detailed description of these protocols can be 
found in http://chromatin.bio.fsu.edu/docs/CGH_userguide. 
Segmentation and primary CNV prediction 
NimbleScan v2.5 was used for the primary analysis of the signal intensity raw data taken from 
Nimbelgen in the form of “.pair files” and “.tif files” from the arrays. Segmentation algorithm 
CGH-segMNT implemented in NimbleScan was used for primary segmentation. For calling 
segments we used the default value of 0.1 for “Min segment difference”.  This value represents 
the minimum difference in the log2 ratio that two segments must exhibit, to be 
identified as separate segments. Nevertheless we increased the “Min segment length” from 
Nimbelscan default value of 2 to 5. This value represents the minimum number of consecutive 
probes that must exhibit a change in log2 ratio in order to call a segment. Prior to segmentation 
analysis, spatial correction and qspline fit normalization (Workman, et al. 2002) were applied to 
the raw data. This normalization compensates for inherent difference of signals between the 2 
dyes. Finally we chose to generate GFF (General Feature Format, .gff) files which contain the 
log2 ratio of Cy3 and Cy5 for each probe plotted versus genomic position. Additionally 
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segmentation PDF plots as well as Data summary files which contains a summary of predicted 
segments were used to review the array data.  
Visualizing through SignalMap software 
 SignalMap v1.9 software was used to review and visualize GFF files, generated by the CGH 
data analysis. Additionally human genome (hg)18 annotation files from 
www.nimblegen.com/human-annotation were  imported into SignalMap. This also gave us the 
opportunity to see peak correlations between our data and annotation tracks or link to a web site 
with detailed information for a selected gene (see table 2.3) 
 
 
Figure 2.3 GFF file tracks from array-CGH Data visualized through SignalMap. Upper track shows the log2 ratio of signal 
intensities plotted versus genomic coordinates in base pairs. Predicted CNV segments (red horizontal lines) are pointed by 
vertical blue arrow lines. Lower track shows known structural variants (in green) from imported hg18 annotation files. 
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Annotation files 
In order to prioritize predicted CNVs for further validation, a suite of human hg18 annotation 
files was used. Table 2.3 describes the annotation tracks that was recruited. We imported and 
viewed these files alongside our microarray data using Roche NimbleGen SignalMap software. 
 
Annotation Files Description 
hg18: Genes. Indicates all genes for build hg18 as 
reported in the UCSC Genome browser 
(http://genome.ucsc.edu). Genes annotated above 
the baseline in each track represent features 
identified on the sense strand, while entries below 
the baseline represent features identified on the 
antisense strand. 
hg18: Genes_Exon-Intron Indicates the exon-intron boundaries of all genes in 
build hg18 as reported in the UCSC 
Genome browser. Exons are denoted as dark blue 
bars, and introns are denoted as light blue bars 
hg18: Transcription_Start_Sites Indicates all transcription initiation sites for build 
hg18 as reported in the UCSC Genome browser 
hg18: Structural_Variants Displays all copy number variants as reported in 
the Database of Genomic Variants 
(http://projects.tcag.ca/variation) 
hg18: 42M_CNV_Regions Displays validated CNVs identified by the Genome 
Structural Variation Consortium in a high-resolution 
CNV discovery project 
(http://www.sanger.ac.uk/humgen/cnv/42mio). In 
this study, common CNVs > 500 bp were identified 
from 20 CEU and 20 YRI HapMap research samples 
using a set of NimbleGen CGH arrays that contains 
approximately 42 million probes tiled across the 
genome 
hg18: Segmental_Duplications Displays regions of genomic duplication > 1 kb in size 
and with > 90% sequence identity after masking high-
copy repeat regions (Bailey, et al. 2001; 11:1005-17) 
and reported in the UCSC Genome browser. The level 
of similarity is indicated as follows: light to dark gray 
bars = 90 - 98% similarity, light to dark yellow bars = 
98 - 99% similarity, light to dark orange bars ≥ 99% 
similarity; red = duplications of > 98% that lack 
sufficient evidence in the Segmental Duplication 
database 
hg18: Cytogenetic_Ideogram Displays the cytogenetic bands, in grayscale format, 
for each chromosome as reported in the UCSC 
Genome browser 
hg18: miRNA Indicates all miRNAs as reported in the miRBase 
database (http://microrna.sanger.ac.uk/).  
 
Table 2.3  Description of annotation files imported and visualized alongside the array-CGH data.  
 
 
2.4 UC case-control-study cohorts 
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We recruited 5 case control sample sets, one as screening (discovery) panel for CNVs and 4 
others for follow-up. Here we describe them upon the platform used for CNV genotyping and 
origin of the samples; 
Array-sample sets 
Initial screening cohort consisted of 1121 German UC patients and 1770 healthy controls, 
previously used in a SNP-GWAS experiment using the Affymetrix® Genome-wide Human SNP 
array 6.0 (Affy6.0) and has been described previously (Franke et al., 2010). Additionally the 
Affy6.0 data sets of two independent cohorts, one Norwegian and one from UK were recruited. 
The Norwegian study population consisted of 274 clinically well-characterized UC patients and 
an ethnically and sex-matched group of Norwegian healthy controls (n=282), also studied and 
described previously (Franke et al., 2010). The UK study population was part of the “Welcome 
Trust case-control consortium 2” (WTCCC2) used for UC GWAS (UK IBD Genetics 
Consortium, 2009) and contained data sets of 2396 UC cases and 4886 controls after processing 
and filtrations described later. 
 
TaqMan-sample sets  
These samples included two disease cohorts originated from Germany and Lithuania which were 
genotyped for initially selected CNVs through real-time PCR automated by TaqMan CNV assays 
(see section 2.5.x). The German UC patients consisted of 245 males and 315 females. The 
German controls consisted of 779 females of age 18 to 81 (average age: 51) and 637 males of 
age 27 to 75 (average age: 50). The Lithuanian study population consisted of 443 UC patients 
and a control group of 1147 ethnically, age and sex-matched healthy blood donors (see also table 
2.4). 
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  Discovery Replication Replication Replication 
  Germany Germany Norway Lithuania 
                     case/control -> (1121/1770 (553/1420) (274/282) (443/1147) 
Sex distribution; % Female  
controls 45.9 59.3 40.6 51.0 
cases 56.9 59.7 47.8 50.6 
Age distribution; median age (years) 
at sampling 
controls 
56 ±12.9 38 ±12.4 31.8 ±6.9 40.2 ±12.8 
at sampling 
cases 
41 ±13.8 42 ±13.8 39.0 ±15.0 44.3 ±16.6 
at onset 27 ±11.7 27 ±11.4 37.7 ±14.9 38.4 ±15.9 
Disease extent         
Left sided colitis, % 51.2  56.7 69.4 75.8 
Extensive colitis, % 46.8 39.1 30.6 24.2 
Colectomy 5.7 11.7 6.0 1.1 
Smoking habit at diagnosis, % cases 
current 23.8 36.4 13.1 12.2 
previous 24.2 18.1 31.3 28.0 
never 51.9 45.5 55.6 59.8 
 
Table 2.4  Characteristics  of  UC case/control  sets  used  for  discovery  and replication of CNVs 
 UC cohort of WTCCC2(UK) is not included in the table 
 
In silico control sample sets  
These samples comprised altogether 6724 individuals recruited in previous genotyping studies 
as; 60 unrelated HapMap CEU samples genotyped with the Illumina 1M Dua SNP array 
(Costello et al., 2005), 445 CEU controls genotyped with the Illumina 500k v3 (Cooper et al., 2008), 
283 Caucasian controls genotyped with the Illumina Human Hap 300 and 231 Caucasian 
controls genotyped with the Illumina Human 610-Quad BeadChip (Simon-Sanchez, et al., 2007), 
653 Caucasian controls genotyped with the Illumina Human Hap 300 and 551 Caucasian 
controls genotyped with the Illumina Human 610-Quad BeadChip Simon, et al., 2006; Albert et al., 
2001), 3181 European controls genotyped with the Affymetrix® Human SNP array 6.0 (Stone et 
al., 2008). 
2.4.1 Patient Recruitment and Ethics 
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Diagnosis of UC has been based on the review of the patients’ original medical records including 
colonoscopies at the recruiting university hospitals. The currently accepted pathophysiological 
characteristics of UC include exclusive inflammation of the colon, continuity of inflammation, 
histological evidence for an inflammation limited to the mucosa, absence of granuloma, 
intestinal tract architectural changes including crypt abscesses, leukocyte aggregates, distortion 
of crypt architecture and cryptitis, mucosal edema, and infiltration of neutrophils (Podolsky, 
2002). German patients of the discovery and replication panels were recruited either at the 
Department of General Internal Medicine of the Christian-Albrechts-University Kiel, the Charité 
University Hospital Berlin, through local outpatient services, or nationwide with the support of 
the German Crohn and Colitis Foundation. Clinical, radiological, histological, and endoscopic 
(i.e. type and distribution of lesions) examinations has been required to unequivocally confirm 
the diagnosis of ulcerative colitis (UC) (Lennard-Jones, 1989). 1214 German healthy control 
individuals of discovery panel (1703 total) were obtained from the biobankPopGen 
(http://www.popgen.de).  
Popgen targets the population of northern Schleswig-Holstein (1.1 million people) which is 
surrounded by the Danish border (North), the North Sea and Elbe river (West), the Baltic Sea 
(East), and the Kiel Canal (South). The remaining 489 German healthy controls in discovery 
panel were selected from the KORA F4 survey, an independent population-based sample from 
the general population living in the region of Augsburg, Southern Germany (Wichmann et al, 
2005). Written, informed consent had been obtained from all study participants and all protocols 
were approved either by the ethical committee of the University-Hospital Schleswig-Holstein, 
Center Kiel or through the institutional committee of the “Kompetenznetz Darmerkrankungen” 
(http://www.kompetenznetz-ced.de/)  in Germany. The 274 clinically well-characterized 
Norwegian UC patients of replication panel were recruited through a population-based incidence 
study, the Inflammatory Bowel disease in South-Eastern Norway (IBSEN) study (Moum et al, 
1996). An ethnically and sex-matched group of Norwegian healthy controls (n=282) was 
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randomly selected from the Norwegian Bone Marrow Donor Registry (NBMDR). The strict 
criteria (including absence of any autoimmune disease) on inclusion in the NBMDR ensured 
correct classification of these controls as healthy. Norwegian sample recruitment was approved 
by the ethics committee of Oslo University Hospital, Rikshospitalet, Norway. 
The Lithuanian study population consisted of 443 UC patients recruited at 6 hospitals in 
Lithuania: Kaunas Medical University Hospital (Kaunas), Vilnius University Hospital 
Santariskiu Clinic(Vilnius), M. Marcinkevicius Hospital (Vilnius), Klaipeda Seamen’s Hospital 
(Klaipeda),Panevezys Regional Hospital (Panevezys), Siauliai Regional Hospital (Siauliai) and 
2hospitals in Latvia: P. Stradin Clinical University Hospital (Riga) andRiga Eastern 
ClinicalUniversity Hospital,Clinic Linezers (Riga). The diagnosis of UC was based on standard 
clinical, endoscopic, radiological and histological criteria. The control group consisted of 
1157ethnically, age and sex-matched healthy blood donors. Written, informed consent was 
obtained from all study participants and all protocols were approved by the institutional ethical 
review committee of the Lithuanian University of Health Sciences, Kaunas, Lithuania.   
 
2.5 CNV calling of Affy6.0 datasets 
Affy6.0 platform consists of two main types of probe sets; SNP probes which include 936,000 
SNPs (chosen from HapMap and dbSNP ) and copy number probes (CN probes) consisting of 
940,000 oligo-nucleotide probes which provides a uniform coverage across the genome to 
directly interrogate CNVs. In this platform a metric called log 2 Ratio (LRR) compares the 
observed normalized intensity (R observed) of the subject sample to the expected intensity (R expected) 
calculated from the collection of reference hybridizations, or the rest of the population being 
analysed (Peiffer, et al., 2006). Additionally a second metric, termed B allele frequency (BAF) is 
calculated as the proportion of the total allele signal (A + B) explained by a single allele (A). The 
BAF has a significantly higher per-probe signal-to-noise ratio than the log ratio data and can be 
interpreted as follows: a BAF of 0 represents the genotype (A/A or A/–), whereas 0.5 represents 
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(A/B) and 1 represents (B/B or B/–). Different BAF values occur for AAB and ABB genotypes 
or more complex genotypes (for example, AAAB, AABB and BBBA). Homozygous deletions 
result in a failure of the BAF to cluster (Cooper et al., 2008). These two parameters, LRR and BAF 
are then plotted along the entire genome for all probes on the array (see figures 2.4 and 2.5). For 
CNV calling from array data, raw image files were converted into CEL-files by Affymetrix® 
genotyping console. CEL files were processed with the Affymetrix Power Tools (APT) apt-
copynumber-workflow version1.67. The values for contrastQC (based on Affymetrix®GTC 3.0.1 
User Manual) and MAPD were extracted and samples that failed default QC values were 
discarded (MAPD > 0.4 and/or contrastQC < 0.4).    
 
 
 
 
Figure 2.4  Raw data visualization of intensities as LRR and BAF for a predicted duplication on Affy6.0. In the 
LRR panel (upper) SNP probe sets are in black and copy number probe sets in blue whereas only SNP probes are used for BAF 
metric (lower panel). Duplication (blue horizontal bar) has spread the SNP probe distribution at frequencies about 0.5 (in BAF 
panel).  
 
 
For the remaining samples an identity by state (IBS) and principal component analysis (PCA) 
was performed as described previously (Franke et al., 2010). The output of apt-copynumber-
  LRR = log 2 (R observed /R expected) 
 BAF = R allele B (R allele A /R allele B) 
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workflow was used as the input file for CNV data mining tool “CNVineta” (Wittig et al., 2010). 
CNVineta is an R package for rapid data mining and visualization of CNVs in large case-control 
datasets genotyped with SNP arrays. A preliminary batch-wise filtering was performed based on 
the number of called CNVs per samples. This was performed batch-wise, as one batch consists 
of a sample collection which was prepared in the same process. Outliers were defined as samples 
which had more CNVs than the 75% quantile plus 1.5 fold of the interquantile range.  
 
 
Figure 2.5  Raw data visualization of intensities as LRR and BAF for a predicted deletion in one individual on 
Affy6.0. In the LRR (upper) panel SNP probe sets are in black and copy number probe sets in blue. Only SNP probes are used 
for BAF metric (lower panel). Deletion (red horizontal bar) has resulted to loss of SNP probe distribution at frequency 0.5. (lower 
panel). RefSeq genes are annotated with purple lines.  
The screening was followed by a rigorous manual raw data inspection for identifying false-
negative and -positive CNVs. This approach especially reduces false-positive CNVs and can also 
uncover false-negatives at candidate positions. For the whole data mining process, the predicted 
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CNVs with less than 5 supporting probes per CNV and mean probe set distance less than one 
kilobase, were ignored. 
 
2.6 Screening for rare CNVs in Affy6.0 datasets 
 To screen for rare CNVs, we used CNVineta (http://www.ikmb.uni-kiel.de/resources/download-
tools/software/cnvineta). In this package a function called “dox0” is implemented which screens 
for rare deletions, duplications and CNVs without respect to the copy number state (deletion or 
duplication). In order to identify rare CNVs by this method, three parameters namely “min.diff”, 
“max.one.side” and “cases.more.affected” should be specified. Trigger “min.diff” (default = 5) 
sets the parameter for the required absolute difference in CNVs within particular regions 
between cases and controls; “max.one.side” (default = 1) defines the maximum number of 
individuals with a CNV in a particular region for the group with the lower CNV load (usually 
controls); “cases.more.affected” (default = TRUE) defines the direction of the scan, i.e. whether 
cases (TRUE) or controls (FALSE) are screened for rare CNVs. 
 
2.7 Association analysis for common CNVs 
Screening of common CNVs and Association testing with UC was done through CNVineta using 
a logistic regression model (Dobson, 1990) with disease status as the outcome variable and total 
copy number as the dependent variable. This was undertaken by assigning integer copy number 
to each individual based on SNP allele hybridization (BAF) and intensity data (LRR) (see figure 
2.5), followed by comparing obtained copy number states between cases and controls. To screen  
for common CNVs, CNVineta provides the do.log.regression method, which instead implements 
the so called “glm” function. 
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Figure 2.6 Example of rare CNVs, found in our UC German discovery panel screened by CNVineta. Three duplications 
predicted in cases and no in controls (A). Three deletions predicted in cases and no in controls (B). In each part the predicted 
CNVs are shown for cases (upper track) and controls (lower track). Duplications are seen in blue and deletions in red. Involved 
RefSeq genes are annotated. SNP probe sets are seen in black and copy number probe sets in blue.  
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Figure 2.7 SNP-chip CNV analysis pipeline. 
 
2.8 Technical validation and replication of predicted CNVs 
For technical verification of the CNVs predicted from array-CGH data in twin analysis, we used 
TaqMan® CNV genotyping (Mayo et al., 2010). This was also the main independent platform that 
we used for verification and replication of rare CNVs identified in the discovery panel from 
Affy6.0 dataset. 
 
2.8.1 TaqMan® copy number analysis 
Principles and Chemistry (Adopted from TaqMan® Copy Number Assay Protocol (PN 4397425D)) 
 TaqMan® Copy Number analysis is based on quantitative real-time PCR (qPCR), comparing the 
signal from the test region against a reference locus and obtaining the ratio. Therefore TaqMan® 
Copy Number assays run simultaneously with a TaqMan® Copy Number Reference Assay in a 
duplex PCR. The Copy Number Assay detects the target gene or genomic sequence of interest, 
and the Reference Assay detects a sequence that is known to exist in two copies in the diploid 
genome (for example, the human RNase P H1 RNA gene). The number of copies of the target 
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sequence in each test sample is determined by relative quantization using the comparative CT 
(ΔΔCT) method. 
 
Figure 2.8  PCR and detection of target and reference gDNA sequences in a duplex reaction. A TaqMan® 
Copy Number Assay, a TaqMan® Copy Number Reference Assay, TaqMan® Genotyping Master Mix, and a gDNA 
sample are mixed together in a single well or tube (A). The gDNA template is denatured and each set of assay 
primers anneals to its specific target sequences. Each TaqMan® probe anneals specifically to its complementary 
sequence between forward and reverse primer binding sites (B). When each oligonucleotide probe is intact, the 
proximity of the quencher dye to the reporter dye causes the reporter dye signal to be quenched. During each round 
of PCR, the target and reference sequences are simultaneously amplified by AmpliTaq® Gold DNA Polymerase (C). 
This enzyme has a 5′ nuclease activity that cleaves probes that are hybridized to each amplicon sequence. When an 
oligonucleotide probe is cleaved by the AmpliTaq Gold DNA Polymerase 5′ nuclease activity, the quencher is 
separated from the reporter dye increasing the fluorescence of the reporter. Accumulation of PCRS products can be 
detected in real time by monitoring the increase in fluorescence of each reporter dye at each PCR cycle. (Printed from 
TaqMan Copy Number Assay Protocol (PN 4397425D)) 
This method measures the CT difference (ΔCT) between target and reference sequences, then 
compares the ΔCT values of test samples to a calibrator sample known to have two copies of the 
target sequence. In a copy number quantification reaction, genomic DNA is combined with:  
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1. The TaqMan® Copy Number Assay, containing two primers and a FAM™ dye-labeled                            
MGB probe to detect the genomic DNA target sequence. 
 2. The TaqMan® Copy Number Reference Assay, containing two primers and a VIC® dye-
labeled TAMRA™ probe to detect the genomic DNA reference sequence. 
 3. The TaqMan® Genotyping Master Mix, containing AmpliTaq Gold® DNA Polymerase, UP 
(Ultra Pure) and dNTPs required for the PCR reactions.  
Figure 2.8 shows the steps in a duplex PCR reaction containing copy number target and 
reference assays, both of which are 5′ nuclease assays. After amplification, data files containing 
the sample replicate CT values for each reporter dye can be exported from the real-time PCR 
instrument software and imported into a software analysis tool for post-PCR data analysis of 
copy number quantitation experiments. 
Preparing the reactions for dried gDNA on 384 well-plates 
For assessing the copy number of regions of interest, we used Pre-designed TaqMan® Copy 
Number Assays from Applied Biosystems. We used four technical replicates for each gDNA 
sample and applied the same sample name to the wells of each technical replicate group so that 
later CopyCaller® Software could combine data of replicate wells for calculating copy number.  
Amplification reactions (10 μL), which were performed in quadruplicate, consisted of: 
• 10 ng gDNA    • 1X TaqMan® Copy Number Assay     • 1X TaqMan® Copy Number Reference 
Assay, RNase P   • 1X TaqMan® Genotyping Master Mix 
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Running the plates 
PCR was performed with an Applied Biosystems 7900HT Fast Real-Time PCR System using the 
default, universal cycling conditions according to below settings:
 
Cycle threshold (CT) values were generated by the SDS v2.0 software with manual CT threshold 
set to 0.2 according to Applied Biosystem recommendations.   
2.8.2 Copy number data analysis of TaqMan® Assays 
CopyCaller® Software v1.0 was used for TaqMan® Copy Number Assay data analysis. After 
amplification, the experiment results table, containing CT values for the copy number and 
reference assay for each well, was exported from the Applied Biosystems real-time PCR system 
software and then imported into CopyCaller® Software for post-PCR data analysis. 
CopyCaller® Software performs a comparative CT (ΔΔCT) relative quantification analysis of the 
real-time data. The analysis determines the number of copies of the target sequence in each test 
genomic DNA sample. ΔΔCT method first calculates the difference (ΔCT) between the threshold 
cycles of the target and reference assay sequences. Then, the method compares the ΔCT values of 
the test samples to the calibrator sample that contains a known number of copies of the target 
sequence:  
(ΔΔCT) s,t =  μ(ΔCT) s,t  –  μ(ΔCT) calibrator , where: s = sample; t = target copy number assay. 
Then the relative quantity (RQ) for the associated sample is calculated as:  
RQ(s,t)  = 2 
–(ΔΔCT)s,t   , where: s = sample; t = target copy number assay. 
Finally the copy number for the associated sample is calculated by the relative quantitation to  
the calibrator sampel as:  
cn sample = RQ sample × cn calibrator  , where cn = copy number. 
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In CopyCaller® Software, for each selected copy number assay, a plot displays the calculated or 
predicted copy number of each sample, and bars that indicate the copy number range for the 
associated replicate group (see Figure 2.9). Within each bar, a red line (bar) represents the 
minimum and maximum copy number calculated for the sample replicate group. 
 
 
Figure 2.9 Copy Number Plot displayed in CopyCaller® Software.  NTC (No Template Controls) 
 
Breakpoint mapping 
 Based on the genomic resolution provided by custom aCGH for the deletion, five flanking 
primers at each end of the predicted deletion were designed. The subsequent PCR then only 
yielded amplicons, if a deletion was present (without deletion the fragment is longer than 15 kb, 
no long range PCR was performed). All possible primer combinations were tested and an 
amplified fragment of about 610 nucleotides was used for Sanger sequencing. (Forward Primer: 
5’-TCCTTCCAGCATATCCCATC; Reverse Primer: 3’- 
GAATACTGATAACCACAAACAGACAGA). The resulted sequence was then used for BLAT 
query with the human genome sequence hg18 reference. For the duplications, breakpoints were 
derived from the aCGH mapping experiment. 
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3 Results 
3.1 CNV identification in MZ twins 
We conducted a comprehensive genome-wide screen for CNVs in 6 monozygotic twin pairs. For 
each twin pair, two array-CGH experiments were performed. In one, genomic DNA from 
peripheral blood lymphocytes of the IBD individual was used as the test sample, while in the 
other the test sample was genomic DNA obtained from the biopsy of the IBD patient. In both 
arrays for each twin, the peripheral blood DNA of the non-IBD co-twin (referred to as healthy 
individual) was used as the reference sample. Therefore this study included 12 microarray 
experiments for genomic comparison of six IBD-discordant twin pairs. 
 
3.1.1 Primary array-CGH results 
Primary implementation of segmentation algorithm on normalized intensity ratios of arrays 
produces a set of segments but does not classify them into gains and losses. In 12 IBD twin 
arrays, the highest and lowest mean log2ratio for the segments were 0.57 and -0.6 respectively. 
We initially selected predicted segments which spanned at least 10 probes and set the log2ratio 
thresholds as -+0.25, below/above which a segment represent a potential loss/gain CNV 
candidate upon previous descriptions. Table 3.1 presents the predicted segments which were 
suggestive of potential copy number variants after applying these criteria for CNV prediction. 
 
3.1.2 Technical validation of the predicted CNVs 
The predefined segments were visualized through SignalMap software, and TaqMan assays with 
regard to array-predicted breakpoints for 57 promising CNV candidates were designed. None of 
these regions showed consistent copy number differences in the corresponding twin-DNA 
samples, analyzed by quantitative PCR. Only two predicted regions in DNA from the biopsy of 2 
IBD patients compared to the blood DNA of their healthy co-twins, showed slight sign of copy  
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Figure 3.1 Screenshot of two genomic regions suggestive of CNVs between IBD-discordant MZ twins.  104 kb 
predicted deletion (loss) in genomic DNA of biopsy from a male UC patient relative to blood DNA of the non-IBD co-twin (upper 
track of A).  85 kb predicted deletion in biopsy DNA from a female CD patient relative to blood of the healthy co-twin (upper track 
of B).The signal was not predicted in blood DNA from these patients compared to blood DNA of their co-twins (middle track in 
each A and B). Quantitative PCR assays of the predicted CNVs (C & D) 
Biopsy UC/ Blood Healthy  
Blood UC/ Blood Healthy  
Overlapping genes 
Biopsy CD/ Blood Healthy  
Blood CD/ Blood Healthy  
Overlapping genes 
Chr12 : 122,337 – 122,442 (kb), 104 kb 
SBNO1 
SETD8 
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number difference in quantitative PCR (figure 3.1). However these signals were not reproduced 
after repeating the real time PCR experiments with newer DNA from biopsies of the 
corresponding patients.  
In order to increase sensitivity for detection of probable CNVs between MZ twins, we set a 
second less stringent log2ratio threshold of -+0.15 (Figure 3.2). This was assuming that the 
probable post-zygotic CNVs might occur in only a proportion of cells and therefore are not 
reflected by Sharp aberrations in signal intensity ratios on CGH arrays. But applying a more 
permissive log2ratio threshold, to increase power for hunting probable hidden CNVs can lead to 
higher rates of false positive predictions. To somewhat compensate for this, we doubled the 
minimum number of the probes (to n=20) required to be spanned by a predicted segment, in 
order for the segment to be selected for further validations. 17 segments fulfilled these criteria 
and were next assayed by quantitative PCR. Copy number variations could not be verified in 
these regions. In total we assessed relative copy number status of six twin pair members in 74 
genomic regions suggested from array-CGH analysis and we did not find any reproducible 
variations between individuals of MZ twins. 
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3.1.3  Efficiency testing of the platform for twin CNV analysis 
  To have an empirical assessment of the ability of our experiment platform to efficiently detect 
CNVs, we tested the genomic DNA of the HapMap sample NA15510 against the blood DNA of 
a non-IBD member of a MZ twin pair on the same array platform used for twin pair comparisons 
(here referred to as NA15510/twin array). Copy number genomic variants of NA15510 have 
been characterized previously with high-throughput CNV detection methodologies of paired-end 
mapping (PEM) and massively parallel sequencing (Korbel et al., 2007; Kid et al., 2008) and are 
cataloged in the database of genomic variants (see also 1.2.1).  
 
 
Figure 3.2  Distribution comparison of mean log2ratio of signal intensities of predicted segments in 3 different array 
combinations in one twin pair after processing with segmentation algorithm. The predicted segments from 3 different 
array combinations in one twin pairs are showed with different colors. The absolute log2ratio 0.25 is the threshold 
above which a predicted segment potentially represent a CNV. The less conservative threshold 0.15 (upper right 
plot) was set to include segments that probably represent mosaic CNVs occurring in only a minority of cells. 
Segments with highly aberrant signal intensities (absolute log2ratio >=0.5) and covered by at least 10 probes were 
only seen in the NA15510/ blood healthy (germline inter individual CNVs). 
100 
200 
300 
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This gave us the opportunity to have an estimation of the reliability of our array-CGH CNV 
analysis approach. Figure 3.2 shows distribution comparisons of log2ratios of signal intensities 
for predicted segments in 3 different array combinations in this twin pair. 
In NA15510/twin array, from 191 autosomal predicted segments with the above described 
criteria (absolute log2ratio >= 0.25 and probe coverage >=10), 61 segments were overlapping 
more than 60% with a CNV region reported for NA15510 in DGV (see table 3.1) and hence 
could be confirmed as true positive predictions. In order to declare that two variants detected on 
different platforms correspond to the same event, at least 40% reciprocal overlap between them 
is required (Conrad et al., 2010). According to this threshold, the remaining predicted segments 
were not fined in DGV records for NA15510. The intensity ratios on array-CGH, however shows 
the relative copy number status of the test versus reference genome. Based on this, even 
assuming an ideally unbiased array experiment with high specificity for CNV detection, half of 
the predicted segments on NA15510/blood healthy array (i.e. 191/2) are derived from copy 
number variants in individual NA15510. Therefore beside 61 truly predicted CNV segments in 
the test experiment, at least 34 other predicted segments for this individual have not been 
confirmed and represented the minimum amount of false positive predictions for NA15510 in 
our test platform. Yet this comparative estimation of performance might be affected after 
correcting for regions, in which both the test and reference sample harbor copy number 
variations (Ju et al., 2010) and also for complications of comparison between different (PEM 
versus array-CGH) CNV detection methodologies (Alkan et al., 2011) 
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        No of Log2 DGV  
Chr Start End Size (bp) Probes   Ratio Entry 
1 110,025,939 110,056,866 30,927 20 -0.5 dgv276n100 
1 150,819,257 150,853,362 34,105 26 0.45 dgv417n100 
2 88,943,435 89,161,015 217,580 171 -0.32 dgv3930n100 
2 88,943,435 89,161,015 217,580 171 -0.32 dgv3930n100 
3 20,262,559 20,604,344 341,785 233 0.3 esv2422249 
3 163,996,948 164,009,807 12,859 12 -0.99 nsv460966 
3 164,028,400 164,109,371 80,971 58 -0.62 dgv4969n100 
4 9,827,621 9,842,922 15,301 15 -1.72 nsv461259 
5 150,184,939 150,203,537 18,598 15 -0.45 esv2421997 
6 31,464,011 31,558,278 94,267 64 -0.53 nsv470809 
6 32,560,897 32,686,692 125,795 92 -0.74 nsv462881 
7 38,354,952 38,374,705 19,753 18 0.35 nsv1016904 
7 151,556,420 151,621,542 65,122 48 -0.25 nsv1161668 
8 6,822,624 6,869,541 46,917 41 0.27 dgv11908n54 
8 51,115,286 51,200,865 85,579 61 -0.34 dgv1396e214 
10 124,321,737 124,347,792 26,055 23 0.3 nsv1159772 
11 4,920,866 4,933,642 12,776 12 -0.69 nsv521088 
11 5,741,594 5,763,341 21,747 18 -1.46 nsv1075273 
11 55,122,740 55,198,065 75,325 53 -1.16 nsv1053424 
11 60,724,304 60,776,689 52,385 40 0.76 dgv1212n100 
13 68,143,472 68,163,932 20,460 19 -0.88 esv3632562 
14 105,265,168 105,315,345 50,177 14 -0.42 nsv566093 
14 105,317,329 105,397,727 80,398 58 -1.44 nsv566139 
14 105,406,066 105,428,623 22,557 11 -1.98 nsv821194 
14 105,430,230 105,481,651 51,421 37 -0.7 nsv952276 
15 19,093,219 19,475,422 382,203 266 0.35 dgv418n67 
15 19,763,549 19,874,394 110,845 86 0.47 esv3415650 
15 19,885,079 20,199,292 314,213 142 0.42 dgv2170n100 
15 32,470,093 32,532,596 62,503 50 -0.4 nsv568863 
15 32,534,148 32,584,558 50,410 39 -0.59 dgv2539n100 
15 32,585,521 32,659,076 73,555 45 -0.29 esv3892660 
16 21,648,297 21,713,878 65,581 50 0.41 esv3638187 
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16 22,467,708 22,529,247 61,539 47 0.46 nsv433440 
16 83,208,964 83,228,402 19,438 16 -0.57 dgv3053n100 
17 9,194,999 9,210,169 15,170 13 0.38 nsv833356 
17 21,961,590 22,068,041 106,451 83 -0.27 esv3892986 
17 31,474,225 31,505,847 31,622 27 1.31 nsv457722 
17 31,538,950 31,568,700 29,750 27 0.61 nsv833418 
17 31,626,182 31,669,315 43,133 37 0.72 nsv2027 
19 46,052,476 46,082,217 29,741 23 -0.47 nsv520061 
19 56,827,143 56,839,988 12,845 13 -0.69 esv3644863 
19 59,422,687 59,440,139 17,452 15 -1.03 esv28703 
20 1,516,595 1,532,009 15,414 13 1.85 esv3644980 
20 14,721,773 14,882,268 160,495 130 -0.78 nsv433323 
20 14,884,055 14,896,209 12,154 11 0.32 esv29969 
20 14,896,722 14,951,317 54,595 42 0.62 esv29969 
21 9,997,428 10,202,297 204,869 84 -0.38 esv2723012 
22 21,485,112 21,568,623 83,511 69 -0.62 nsv588309 
22 22,613,623 22,682,174 68,551 54 -0.38 esv2507410 
22 37,689,119 37,718,726 29,607 22 -0.39 nsv471196 
Table 3.1   61 CNV segments predicted for HapMap individual NA15510 from our NA15510 / twin array.  
Only segments overlapping more than 60% (in size) with a corresponding CNV segment reported for NA15510 in 
DGV (Database of Genomic Variants) are listed. In NA15510/twin array the genomic DNA of the HapMap individual 
NA15510 were tested against the blood DNA of a non-IBD member of a MZ twin pair on the same array platform 
used for twin pair comparisons. Therefore segments with negative log2 ratios show deletions and positive log2 ratio 
segments indicate duplications in NA15510 in our test array. NA15510 was used since its CNVs have been mapped 
in previous studies (Korbel et al., 2007; Kid et al., 2008) and are catalogued in DGV (Build GRCh37: Feb. 2009, 
hg19). Variant regions are assigned an nsv (NCBI; dbVar) or esv (EBI; DGVa) or dgv (database of genomic variants). 
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3.2 CNV analysis in UC case-control samples 
3.2.1 Screening in German discovery panel 
Initially a total of 2891 SNP array 6.0 CEL files (1121 German UC patients / 1770 matched 
controls) were subjected to CNV calling, which left 2466 samples (902 cases / 1564 controls) 
after discarding outliers with respect to raw data quality, per sample call rate, ethnic origin and 
relatedness. The primary aim was to identify rare variants in UC patients, which were absent or 
were underrepresented in controls. Therefore, regions of interest were defined in the primary 
sample as genomic segments containing CNVs in at least three cases and in no controls. This 
selection criterion was based on the inspection of the raw data plots where too many false-
positives were among the singleton and doubleton predicted events. Furthermore deletions or 
duplications with one carrier among the controls were also included, when at least five cases 
contained the corresponding event. Those CNVs occurred in more than two controls were 
excluded. Upon this setting, the discovery sample yielded 151 CNV regions through screening 
with our data-mining tool CNVineta.  
 
Figure 3.3 Number of copy number segments per sample identified from affy6.0 dataset in UC discovery panel. 
 
 
at least 5 markers per segment and average marker distance <= 5 
kb 
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3.2.2 Visual inspection of initial CNV regions  
151 rare CNVs as well as 218 common CNV regions were then inspected manually and CNV 
regions were discarded when; predicted events had a complex breakpoint pattern; covered by 
less than 10 probe sets or spanned large genomic gaps (e.g. if a predicted CNV contained a gap 
which was larger than the part(s) covered by array probes). 24 rare candidates (14 deletions and 
10 duplications) remained after manual inspection of their Z-scores, Log R ratio and B-allele 
frequency traces (See table 3.2). 
    
German 
discovery WTCCC2 sample German discovery WTCCC2 sample 
    CNV counts CNV counts CNV freq in % CNV freq in % 
genomic position cytoband 
902 
cases 
1564 
controls 
2396 
cases 
4886 
controls cases controls cases controls 
chr1:1151109-1151109 1p36.33 3 0 2 0 0.33 0.00 0.08 0.00 
chr2:221794031-221797760 2q36.1 3 0 7 11 0.33 0.00 0.29 0.23 
chr2:228621916-228622575 2q36.3 23 0 0 0 2.55 0.00 0.00 0.00 
chr3:195056555-195066854 3q29 4 0 0 1 0.44 0.00 0.00 0.02 
chr3:36657809-36657809 3p22.2 3 0 0 2 0.33 0.00 0.00 0.04 
chr4:134431169-134509830 4q28.3 4 0 1 4 0.44 0.00 0.04 0.08 
chr4:35052424-35087926 4p15.1 6 1 11 16 0.67 0.06 0.46 0.33 
chr4:95967326-95990607 4q22.3 6 0 0 1 0.67 0.00 0.00 0.02 
chr5:101083525-101123064 5q21.1 3 0 1 5 0.33 0.00 0.04 0.10 
chr6:58882675-58882675 6p11.1 3 0 2 5 0.33 0.00 0.08 0.10 
chr7:107596648-107618181 7q31.1 3 0 0 2 0.33 0.00 0.00 0.04 
chr7:4584859-4587453 7p22.1 4 0 0 0 0.44 0.00 0.00 0.00 
chr7:5937448-5937448 7p22.1 3 0 3 0 0.33 0.00 0.13 0.00 
chr7:71459253-71473235 7q11.22 3 0 0 0 0.33 0.00 0.00 0.00 
chr8:140523022-40523022 8q24.3 4 0 5 2 0.44 0.00 0.21 0.04 
chr10:20830090-20855699 10p12.31 4 0 8 18 0.44 0.00 0.33 0.37 
chr11:104259645-104265284 11q22.3 6 0 5 4 0.67 0.00 0.21 0.08 
chr11:108369095-108369095 11q22.3 3 0 0 0 0.33 0.00 0.00 0.00 
chr13:23991650-23994304 13q12.12 3 0 2 1 0.33 0.00 0.08 0.02 
chr13:94784155-94797183 13q32.1 5 1 5 6 0.55 0.06 0.21 0.12 
chr14:21768464-22020331 14q11.2 17 1 42 28 1.88 0.06 1.75 0.57 
chr18:69281471-69311825 18q22.3 3 0 0 7 0.33 0.00 0.00 0.14 
chr19:19801585-19823239 19p12 11 3 6 4 1.22 0.19 0.25 0.08 
chr19:58031861-58045469 19q13.41 3 0 2 10 0.33 0.00 0.08 0.20 
          Table 3.2 Frequencies of the 24 identified rare CNVs in German discovery panel in comparison with the 
WTCCC2 replication panel. Duplications are marked in blue, deletions in red. The 2 duplications, overrepresented 
in cases (compared to controls) in both panels (German discovery & WTCCC2) as well as the deletion (significant 
only in German discovery panel) are marked in green. These 3 regions were followed in additional independent 
cohorts. 
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3.2.3 Relevant common CNV regions in German discovery panel  
 
Region : Chr 22_37,693,552 - 37,779,261 (APOBEC3)          
 
Chr  Start (kb) End (kb) size     Type  Frequency   Gene  
22 39,358 39,388 30 kb    Deletion  9 -11 % (European)  APOBEC3B 
 
Figure 3.4  Regional Plots for the common deletion overlapping APOBEC3B 
A) Predicted deletions in cases of German discovery panel (hg 18) 
B) Predicted deletions in controls of German discovery panel (hg 18)  
C) Genomic coordinates of APOBEC3 deletion region in DGV (hg 19) 
 
 
 
 
 
 
C 
A 
B 
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Region: Chr 7_142,148,564 - 142,171,261 (TRBC1, T Cell Receptor Beta Constanst 1) 
 
 
        
Figure 3. 5  Regional Plot  for the common deletion encompassing T Cell Receptor gene in German         
discovery panel.  
 
 
 
3.2.4  Following in independent replication panels 
The status of the 24 rare CNVs (table 3.2) and the APOBEC3 common deletion polymorphism 
were then evaluated in two independent cohorts; the WTCCC2 sample (form UK), with CNV 
genotypes called from Affy6.0 intensity data, and a German cohort (453 UC patients, 1377 
controls) genotyped for the selected CNVs by quantitative PCR through TaqMan CNV assays. In  
British cohort (2394 cases, 4886 controls), of the 24 rare CNVs evaluated, two duplication 
events (single copy gains) were the only variants that showed the same distribution trend as the 
discovery panel (See table 3.2), i.e. more represented in cases compared to controls; A 119 kb 
large duplicated region at 7p22.1 carried by 3 cases and no control (3/902 cases, 0/1564 controls 
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in discovery panel) and a 134 kb duplication at 8q24.3 with 0.21% occurrence in cases versus 
0.04% in controls, two-sided Fisher's exact P = 0.058 (P = 0.018 in discovery) (Table 3.3). These 
two duplications however, were not relevant in the German replication panel, as from the sum of 
1830 samples (cases + controls) genotyped for these two variants only one individual (UC case) 
carried the duplication (Dup8q24.3). Further, of the 24 CNVs followed-up in the German 
replication panel, a 15.8 kb deletion (single copy loss) at 13q32.1 (chr13:94,781,525-
94,797,285), reproduced the trend of association with nominal P-value of 0.005 (P = 0.027 in 
discovery). (Table 3.3). Del13q32.1 was not correlated with UC in the WTCCC2 sample.  
 
            
 
Figure 3.6  Regional plot of APOBEC3 deleted region in WTCCC2 data (A) and related statistics in German and UK Affy 
6.0 data sets (B). ctrls (controls)  
 
3.2.5 Evaluation of the relevant CNVs in in-silico controls 
The frequency of the three relevant rare CNVs (one deletion and two duplications) were also 
estimated through SNP array-based genotyping data sets of a total of 6724 individuals recruited 
German (cases) German (ctrls)   Pvalue Uk (cases) Uk (ctrls)   Pvalue 
   0.077      0.03  8.25 E-08    0.017     0.011  0.0209 
A 
B 
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in previous studies (see 2.4 and table 3.3). We observed that 5 of a total of 4501 individuals 
carried the Del13q32.1, while only 1 of 5788 individuals contained Dup7p22.1 and 3 of 6727 
individuals contained Dup8q24.3. Genotypes for these 3 CNVs in in silico controls were not 
considered, when the applied platform in the corresponding study did not covered the CNV 
region with at least 10 probes. Upon this, genotype calls for Del 13q32.1 from 6 sample sets 
(highlighted by red background in table 3.3) were not included (as the region was covered by 
less than 10 probes in the applied arrays of the corresponding studies), yielding 4501 controls for 
this deletion. For Dup 7p22.1, only two sample sets (red zone in table 3.3) did not fulfil this 
criterion and were therefore excluded, resulting in 5788 controls for this duplication. 
Samples Ethnicity Array PMID Description chr13:94781525-
94797285 
chr7:5786323-
5905210 
chr8:140390975-
140524875 
60 CEU Illumina 
1M Duo 
18776910 Hapmap 9 63 49 
445 Caucasian Illumina 
550K, v3 
17116639 NINDS ctrl set from 
Andy Singleton, II 
5 12 29 
283 Caucasian Ill. Human 
Hap300 
16516587 CAP subset of PARC 
(Caucasian only) 
4 5 16 
653 Caucasian Ill. Human 
Hap300 
11434828 PRINCE subset of 
PARC (Caucasian only) 
4 5 16 
231 Caucasian Illumina 
610quad 
16516587 additional CAP samples 5 34 28 
551 Caucasian Illumina 
610quad 
11434828 additional PRINCE 
samples 
5 34 28 
1320 various 
European 
Affymetrix 
6.0 
19592680 European unrelated from 
CHOP DB 
13 54 107 
3181 various 
European 
Affymetrix 
6.0 
18668038 Ctrls. from ISC paper on 
Schizophrenia 
13 54 107 
6724         4501 controls 5788 controls 6724 controls 
 
Table 3.3 Description of in silico controls. The three relevant CNVs were evaluated through the SNP array- 
based genotyping data sets of a total of 6724 individuals recruited in previous studies (see also 2.4). The number of 
controls taken from each study, the sample origin, the array type, the PubMed-id (PMID) and a short description of the 
publication are showed in the table. The three right columns show the number of array probes lying within the 
genomic region of the 3 relevant CNVs. The red highlighted background indicates the sample sets not used for each 
of three CNV loci (covered by less than 10 probes in the corresponding study). Last row shows the number of in silico 
controls we used for each CNV locus. 
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Figure 3. 7 Technical validations of the three relevant CNVs (one deletion and 2 duplications) in the German 
discovery panel 
The left-side plots of each part A-C show the results of TaqMan® CNV assays. While the majority of samples have 
copy number state two (blue bars), green bars show deletion or duplication carriers. The right-side picture of each A-
C illustration shows the Affymetrix Power Tools (APT) prediction of CNVs. For each region the predicted CNVs are 
shown for cases (upper track) and controls (lower track) with Duplications in blue and deletions in red. Involved 
RefSeq genes are annotated in purple, SNP probe sets in black and copy number probesets in blue. For all 3 CNV 
regions TaqMan® results show exact correlation with the predicted CNVs from array dataset, except for one sample 
(UCGER2_m_117134) with predicted Dup8q24.3, the duplication could not be confirmed with TaqMan® (shown in 
yellow in part C). 
 
A)  Del 13q32.1 
 
B)  Dup7p22.1 
 
C)  Dup 8q24.3 
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3.2.6 Technical validations of the relevant CNVs 
For deletion Del13q32.1 and the two aforementioned duplications, we did a validation step, in 
which the genotypes of all 13 individuals of the discovery panel, predicted to carry these 3 CNVs 
(6 with Del13q32.1, 3 with Dup7p22.1 and 4 with Dup8q24.3) were confirmed through TaqMan 
assays (see Figure 3.4). Furthermore we mapped the physical extent of these 3 CNVs more 
precisely and beyond the resolution of Affy6.0. Figure 3.6 shows the regional plot of these 3 
CNV events, with their breakpoints resolved through custom high density a-CGH. The status of 
these 3 CNVs was additionally assessed in one small Norwegian sample with affy6.0-based 
CNV calls as well as a Lithuanian sample (445 cases, 1140 controls) genotyped through 
corresponding TaqMan CNV assays. The combined study-wide Fisher’s exact test P-value for 
deletion at 13q32.1 was 1.2×10-3(OR = 2.64), the duplication at 7p22.1had a P-value of 2.7×10-
3(OR = 8.41) and the duplication at 8q24.3 had a P-value of 8.7×10-4 (OR = 4.62). Table 3.4 lists 
all panel-wise frequencies as well as combined P-values for the three relevant CNVs. 
For Del13q32.1, fine mapping through high density a-CGH followed by Sanger sequencing 
identified the sequence motif 5’-GATCAC-3’ at both breakpoints of the deleted segment. As the 
deletion is flanked by 16 highly identical Alu repeats, it is very likely that non-allelic homologous 
recombination (NAHR) is the underlying mechanism of the event (see also 1.2.3).  
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Figure 3.8  Rare CNV Analysis Workflow.  
Affymetrix 6.0 data sets for the German (discovery) sample as well as WTCCC2 (UK replication) sample were 
processed with Affymetrix power tools (APT). Sample cleaning was based on identity by state (IBS) and principal 
component analysis (PCA) to exclude non-Caucasian samples as well as relatives. The remaining data sets were 
converted into the CNVineta format. 151 CNVs overrepresented in cases were identified after screening for rare 
CNVs in the German discovery sample, of which 14 deletion and 10 duplications remained after manual inspection. 
These 24 CNVs were further evaluated in two independent replication samples, one German and one British 
(WTCCC2). Dup7p22.1 and Dup8q24.3 were relevant only in UK (Affy6.0) sample, while Del13q32.1was replicated 
only in the German (TaqMan) sample. Fine mapping for the deletion was done by Sanger sequencing, while custom 
array-CGH was used for the two duplications. The status of the 3 relevant CNVs was further evaluated in a 
Norwegian sample (Affy6.0), a Lithuanian sample (TaqMan) and a control sample of various European individuals 
from previous published studies.  
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Figure 3.9 Regional Plots for Del13q32.1 (A), Dup7p22.1 (B) and Dup8q24.3 (C) 
For each CNV, SNP array data, array CGH (aCGH) data and breakpoints determined by Sanger 
sequencing (for the deletion) or array CGH (for the duplications) are illustrated. The lower panel shows the 
log2 ratio of raw data from the SNP array together with gene annotation and CNV calling. The middle panel 
shows array CGH data (aCGH) and is zoomed, which can be seen at the x-axis captions as well as at the 
slanted dashed lines between the bottom and the middle panel. The top panel shows ENCODE data for 
transcription factor binding sites and histone marks (enhancer & promotor). There is a zoom between 
middle and top panel again. The SNP probe sets in the bottom panel are highlighted in black and non-
polymorphic probe sets in blue. The RefSeq genes are annotated below with orange genes in reverse 
orientation and purple in forward orientation. The red horizontal bar represents the prediction of the deleted 
segment while the blue colored horizontal bar is used for duplications. This prediction was derived from 
Affymetrix Power Tools. For the middle panel, the predicted copy number state was performed by 
Nimblegen®’s in-house algorithm and is illustrated by horizontal red bars(s) again. The dots in gray 
represent the corrected raw data ratio, with a smoothed spline in red. The genomic region with yellow 
background highlights the deleted region as defined by Sanger sequencing. The upper panel shows 
encode data for enhancer and promotor histone marks and transcription-factor binding sites. The colors of 
the illustrated elements and curves correspond with adjacent legend colors for the different cell types used 
by the ENCODE project. (A) The 15.8 kb deletion at chr13:94,781,525-94,797,285 upstream of ABCC4 and 
CLDN10. (B) The 119 kb duplication at chr7:5,786,323-5,905,210encompasses the entire length ofthe 
genes ZNF815 and OCM, and partially overlapsCCZ1 and RNF216. (C) The 134 kb large duplication at 
8q24.3 (chr8:140,390,975-140,524,875) located upstream of KCNK9. An incidence peak (at 140,450 kb) of 
cis-acting regulatory elements is annotated in the genomic region affected by Duplication. 
 
 
3.2.7 Expression analysis of ABCC4 and CLDN10  
For interrogating the probable effect of the deletion on the expression of the two nearby genes, 
we examined two intestinal biopsy samples of unrelated patients carrying the deletion. Compared 
with the CLDN10 expression level of the deletion-depleted UC patients in inflamed mucosa, the 
biopsy specimen from the patient with the deletion showed very low levels of expression (Figure 
3.10). Yet, this differential expression was not clear for ABCC4. Due to the sparsity of the 
deletion variation, no more biopsies from distinct patients harboring the deletion were available 
to further verify the effect of deletion on the expression of these two genes. 
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1 Del13q32.1 carrier, no inflammation 
2 Del13q32.1 carrier, acute inflammation  
3 Non-carrier, inflamed 
4 Non-carrier, not inflamed 
 
 
Figure 3.10 Expression analysis of ABCC4 and CLDN10 in intestinal biopsies of a UC patient panel  
Real-time PCR through pre-designed TaqMan expression assays was carried out for ABCC4 (A) and CLDN10 (B) 
genes. Biopsy samples included one deletion carrier with acute inflammation (1), one deletion carrier without acute 
inflammation (2), thirty UC patients with acute inflammation and wild-type genotype (3) and thirty cases without acute 
inflammation and wild-type genotype (4). TaqMan® pre-designed expression assays were Hs01075312_m1 for 
CLDN10 and Hs00988717_m1 for ABCC4. 
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Locus: Deletion 13q32.1 Duplication 7p22.1 Duplication 8q24.3 
Breakpoints: chr13:94,781,525-94,797,285 chr7:5,786,323-5,905,210 chr8:140,390,975-140,524,875 
Previously reported: DGV(Variation_49277) 
   
      
DGV(Variation_53516)                   
CNV size: 15.8 kb 119 kb 134 kb 
Covered or close genes: ABCC4, CLDN10 ZNF815, OCM, RNF216, RSPH10B KCNK9 
  cases 
        
controls P-value OR cases     controls P-value OR cases controls P-value OR 
  wt cc wt cc   (95% CI) wt cc wt cc   (95% CI) wt cc wt cc   (95% CI) 
Germany (discovery) 
Affy6.0 
897 5 1563 1 0.027 8.71 899 3 1564 0 0.043 Inf 898 4 1564 0 0.018 Inf 
          (0.97 - 411)           (0.72 - Inf) 
 
  
 
    (1.15-Inf) 
Germany (replication) 
TaqMan 
445 6 1272 2 0.005 8.56 453 0 1279 0 > 0.05  452 1 1377 0 > 0.05  
          (1.52-87.2)            
 
  
 
     
WTCCC2 (UK) 
Affy6.0 
 
2391 5 4880 6 > 0.05  2393 3 4886 0 0.061  2391 5 4884 2 0.058 3.40 
                      
 
  
 
    (0.66 - 21.9) 
Norwegian  
Affy6.0 
251 1 272 0 0.36  252 0 272 0 > 0.05  252 0 272 0 > 0.05 
                       
 
  
 
    
 
Lithuanian 
TaqMan 
442 2 1131 2 > 0.05  438 0 1139 1 > 0.05  445 0 1134 0 > 0.05  
                      
 
  
 
     
in silico controls 
 European-ancestry 
- - 4496 5 ----  - - 5787 1 -----  - - 6724 3 -----  
                          
 
     
Combined results 
 
4426 19 13619 16 1.2×10-3 2.64 4435 6 14928 2 2.7×10-3 8.41 4438 10 15955 5 8.7×10-4 4.62 
 0.43%   0.11%     (1.3-5.2) 0.13%   0.01%     (1.4-88) 0.22%   0.03%     (1.5-15) 
Bonferroni corrected         3.6×10-3         8.1×10-3         2.6×10-3 
MARV         4.3×10-3         6.2×10-3         2.8×10-3 
 
Table 3.4  Summary of association statistics for 3 relevant rare CNVs. Frequencies are presented panel-wise and combined for the 3 relevant CNVs. P-values were 
calculated by two-sided Fisher’s exact tests for CNV carriership. Odds ratios (OR) with 95% confidence intervals (95% CI; inf= infinite) are listed when P-values are smaller 
than 0.05. cc refers to CNV carrier individuals and wt (wild type) to non-carriers. To account for population structure and low frequencies, the M.A.R.V. analysis method 
(Rivas et al., 2011) was applied to the overall study sample. 
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4 Discussion 
As it was described in the introduction, population-based evidences such as increased disease 
risk among relatives of IBD patients as well as higher concordance rates for IBD among MZ 
twins, compared with DZ ones, have implicated the genetic contribution to IBD (see 1.1.1). It 
was also mentioned that the genetic contribution to IBD has been mainly interrogated through 
GWAS studies of mostly common single nucleotide polymorphisms represented on oligo-
nucleotide microarrays (SNP-array) in the last decade (see also 1.1.2). Subsequent meta 
analyses of these SNP-GWAS data have substantially increased the number of susceptibility 
loci (n > 160) for IBD, nevertheless the identified risk alleles are mostly of low to modest 
effects (odds ratio < 1.5) and explain less than 15% of the overall disease variance for IBD 
(see 1.1.2.2). It has been assumed that genomic structural variations, including CNVs are 
among the factors that could potentially account for the bulky missing genetic variance of 
complex disease phenotypes (Eichler et al., 2010). To examine whether genetic alterations in 
the form of CNVs contribute to IBD risk, we undertook two parallel studies in this thesis; first 
recruiting an existing SNP-GWAS data set of UC and 4 other independent UC cohorts, we 
performed a multi-step genome-wide case-control analysis to interrogate the presence of 
disease-relevant rare copy number variants. Second, 6 IBD-discordant monozygotic twins 
were compared genome-wide to explore whether somatic CNVs might have contributed to 
IBD discordance. Here, I first discuss the results already presented for each of these two 
studies and their relations to each other and then describe the methodological pitfalls 
encountered and finally I conclude with remarks and suggestions for future studies. 
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4.1 Rare CNVs overrepresented in UC cases 
Employing UC-GWAS data set of 1121 German UC patients and 1770 healthy controls for 
CNV calling, coupled with CNV data-mining tool we performed a genome-wide scan for rare 
CNVs associated with UC. Two main follow-up panels consisted of an independent German 
cohort of 451 cases and 1274 controls, in which CNVs were assayed through quantitative 
PCR, and a British cohort of 2396 cases versus 4886 controls with CNV genotypes based on 
array data. Twenty-four rare copy number variants (14 deletions and 10 duplications), 
overrepresented in UC patients were identified in the initial screening. Follow-up of these 
CNV regions in 4 independent case-control series as well as an additional public in silico 
control group (totaling 4,439 UC patients and 15,961 healthy controls) revealed 3 copy 
number variants, one deletion and two duplications as overrepresented (at a nominal 
significance) in UC patients compared to controls. Del13q32.1, as a 15.8 kb single copy loss 
at chr13:94,781,525-94,797,285 showed the trend of association in the discovery panel, which 
was reproduced in the so called TaqMan replication panel originated from Germany. 
However, correlation of Del13q32.1 with the disease phenotype was not observed in the 
WTCCC2-UC panel. The two duplications i.e. Dup7p22.1(chr7:5,786,323-5,905,210) and 
Dup8q24.3 (chr8:140,390,975-140,524,875) were overrepresented in UC patients of the 
discovery panel (compared to controls) and this trend was replicated in the WTCCC2 cohort, 
although no association was seen for these duplications in two independent replication panels 
with German and Lithuanian origins. The status of these three CNVs were further evaluated in 
an in silico data set comprising a total of 6727 unrelated control individuals of European 
ancestry. The scarce occurrence of the 3 variants (5 of 4505 for Del13q32.1, 1 of 5788 for 
Dup7p22.1 and 3 of 6727 for Dup8q24.3), observed in these samples was consistent with their 
low frequencies in our discovery and replication panels. It should be mentioned that CNV 
discovery platform used here (Affy6.0), although having a high probe density, has the limited 
resolution of detecting CNVs that are larger than ~15 kb. Therefore, possible smaller CNV 
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events (< 15 kb), most probably of disease relevance have not been examined in our study. On 
the other hand, in comparison to the small median size of common CNVs (~3 kb) in the 
human genome (McCarroll et al., 2010), the three rare CNVs identified here are intermediate to 
large genomic alterations, involving regions with multiple genes and can potentially result in 
functional (deleterious) consequences leading to disease pathogenesis. 
Dup7p21.1 indeed lies in a very gene rich region, encompassing either their entire lengths 
(ZNF815, OCM) or overlapping (RNF216, RSPH10B) partially. Dup8q24.3 is a 134 kb large 
duplication upstream of the gene KCNK9 (TASK3), which encodes a member of the subfamily 
K of the potassium channel proteins. The ever-increasing knowledge about the involvement of 
TASK3 (TWIK-related acid-sensitive potassium) channels in the pathogenesis of autoimmune 
inflammation (Bittner et al., 2010; Meuth et al., 2008) have converted them from "mere 
background" channels to key modulators in pathophysiological conditions. 
Del13q32.1 is located 33.7 kb upstream of the gene ABCC4 (ATP-binding cassette, sub-family 
C, member 4) also known as MRP4 (multidrug resistance-associated protein4), and 78.5 kb 
upstream of CLDN10 (claudin 10). ABCC4/MRP4 belongs to a large family of trans-membrane 
proteins that play an important role in regulating cAMP-dependent signaling pathways (Sassi 
et al., 2008) as well as human dendritic cell migration and thereby modulating immune response 
(van de Ven et al., 2008). Mapping of MRP protein expression among different regions of the 
human intestinal tract has showed that MRPs are higher expressed in the colon compared to 
the ileum (Zimmermann et al., 2005). Interestingly, one member of this protein family i.e. 
ABCC1/MRP1 has been previously associated with severe UC but not with CD (Onnie et al., 
2006). The other neighboring gene CLDN10, coding for a tight junction adhesion protein is 
also an intriguing candidate regarding the molecular pathogenesis of UC. Tight junctions 
contribute essentially to the intestinal epithelial integrity. Barrier disruptions are known to be 
one of the main hallmarks of both phenotypes (CD and UC) of IBD and various genes 
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involved in epithelial barrier maintenance have been associated with IBD (Khor et al., 2011). 
Moreover, changes in expression and distribution of Claudin 2, 5 and 8 have been shown to 
result in discontinuous tight junctions and barrier dysfunction in active CD (Zeissig et al., 
2007). For interrogating the probable effect of the deletion on the expression of the two 
nearby genes, we examined two intestinal biopsy samples of unrelated patients carrying the 
deletion. Compared with the CLDN10 expression level of the deletion-depleted UC patients in 
inflamed mucosa, the biopsy specimen from the patient with the deletion showed very low 
levels of expression. Yet, this differential expression was not clear for ABCC4. Due to the 
sparsity of the deletion variation, no more biopsies from distinct patients harboring the 
deletion were available to further verify the effect of deletion on the expression of these two 
genes. However, presence of cis-acting regulatory elements such as transcription factor 
binding sites, showed in ENCODE annotations of the deleted region might be an explanation 
of the distinct CLDN10 expression that we observed here.  
Overall we find that the rare CNV candidates of this study, verified by visual inspection of the 
underlying raw data, are true positive CNVs. All three relevant CNVs could technically be 
validated by independent methods and were followed-up in independent sample sets. In 
contrast to common variants, disease correlation of rare variants is difficult to be assessed 
through classical association statistics. Low frequency of these variants impedes to detect 
associations at the genome-wide level significance by modest or intermediate sample sizes. 
Power limitations may even increase when these variants do not have high penetrance. In this 
study, the trend of association with UC was present for each of the three mentioned copy 
number variants in the discovery sample as well as in at least one replication panel, 
nevertheless higher statistical power, provided by larger case control samples are needed to 
confidently evaluate the disease risk of these variants. 
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4.2 No confirmed CNVs in MZ twins discordant for IBD 
As described earlier, discordance with regard to IBD in MZ twins has been well documented 
(see 1.3.3). It was also mentioned that MZ twins, despite deriving from a single zygote might 
not actually be genetically identical and could vary in their genomes due to post-zygotic 
mutational events. CNVs, as one of the main forms of genetic alterations can potentially 
contribute to these genomic differences (see also 1.3.2). To explore probable IBD-relevant 
somatic CNVs, genomic DNA from peripheral blood as well as bowl biopsy specimens from 
6 IBD patients (3 UC and 3 CD) and their healthy MZ co-twins were screened for copy 
number differences by means of array-comparative genomic hybridization (array-CGH) 
followed by quantitative PCR. This survey however did not reveal any validated CNVs within 
the blood-derived genomic DNA of IBD-discordant MZ twins. Yet two probable confounding 
issues should be considered here; First, as blood tissue contains high levels of hematopoietic 
cell lineage, twin blood exchange could lead to lack of ability to detect probable genomic 
differences in blood-derived DNA of MZ twins (Erlich, 2011). This blood exchange is the 
result of shared blood circulation in monochorionic twins during embryogenesis (see also 
Figure 1.12). This instead results in mixed hematopoietic context, where stem cells from one 
twin are engrafted in the co-twin and vice versa (Greaves et al., 2003). About 70% of all MZ 
twin embryos are monochorionic and experience this blood exchange whereas the dichorionic 
ones do not (Machin et al., 2009). Unfortunately we didn´t have any records of mono- or di-
chorionic state of the twin pairs recruited in this study. Second issue is that any postzygotic 
genomic alteration is likely to be confined to specific tissues and certain cell lineages 
depending on the timing of the mutational event, resulting in tissue- and (or) organ-specific 
pathogenesis when mutations are deleterious. In order to somewhat address these two issues, 
we also analyzed genomic DNA derived from bowel biopsy of the IBD-affected twin 
individuals against blood DNA of their healthy co-twins through array-CGH, but no copy 
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number differences could be confirmed as well. It should also be noticed that genomic DNA 
obtained from bowel biopsies consists of a population of DNA molecules from different cell 
types and might not high proportionally represent the epithelial cells mainly involved in the 
pathophysiology of IBD. Therefore, further CNV profiling experiments, assisted with fine 
histo-pathological cell selection through laser-capture microdissection (Funke et al., 2011) of 
intestinal epithelial cells from inflamed mucosa specimens might provide more accurate 
insight in to the landscape of somatic genomics with relevance to IBD. Generally these 
aspects make identification of probable somatic (and likely disease-relevant) copy number 
alterations between siblings of MZ twins much more challenging than scoring inter-individual 
germline CNVs. The latter was performed in our twin study by genomic comparison of the 
sample NA15510 and one non-IBD individual of a twin pair, mainly for the assessment of our 
platform performance (see 3.1.3).  
The rate of de novo somatic CNV formations is not known well, essentially due to the 
complications of assaying this type of genomic alterations. For de novo germline CNVs, 
however, there are estimations of locus-specific mutation rates ranging from 1.6 × 10−6  to 1.2 
× 10−4  per locus per generation, which are 100 to 10,000 times greater than that for SNPs 
(Lupski, 2007; Itsara et al., 2010). These high mutation rates have been determined for genomic 
hot spot regions, which contain large blocks of repetitive sequences and are highly susceptible 
to structural rearrangements mediated by non-allelic homologous recombination (NAHR) (see 
also 1.1.2). There exist evidences that NAHR can also occur in mitosis, which results in mosaic 
populations of somatic cells carrying genomic rearrangements (Gu et al., 2008; Dumanski et al., 
2008).  Indeed it has been estimated that de novo CNVs may occur at a rate of 10% per 
twinning event (Bruder et al., 2008). Despite this, few studies examining copy number 
discordance in twins have been reported in disease phenotypes. Our study was an effort to see 
whether discordance for IBD in MZ twins could be explained, even partially, by copy number 
differences in their genomic DNA. In 2008 Dumanski and colleagues analyzed blood DNA of 
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nine pairs of selected MZ twins that were discordant for neurodegenerative phenotypes related 
to Parkinsonism (Bruder et al., 2008). They reported many loci that were suggestive of putative 
and mostly large (> 100 kb) CNVs. Their findings proposed that mosaic state with regard to 
copy number genomic rearrangements is a possible explanation for twin discordance. 
Noteworthy among their cases, one of the twin individuals had been diagnosed with chronic 
lymphocytic leukemia. Their finding of genomic CNVs in blood DNA at this case compared 
to its co-twin has been lacking novelty, since it is rather well recognized that many tumors 
especially in advanced stages are associated with high genomic instability, resulting in 
extensive somatic genomic rearrangements (Darai-Ramqvist et al., 2008; Stratton et al., 2009). In 
another study Baranzini and colleagues examined three pair of monozygotic twins discordant 
for multiple sclerosis (MS) as a common autoimmune and chronic inflammatory disorder, 
which has a concordance rate of approximately 30% among MZ twins (Willer et al., 2003). 
They reported no consistent difference in genomic DNA sequence and genomic DNA 
methylation in CD4+ lymphocytes between affected and unaffected twins (Baranzini et al., 
2010). Further it has failed to identify somatic CNVs as of etiological significance in twin 
pairs discordant for schizophrenia (Shinji et al., 2010; Lyu et al., 2016).  
It should also be emphasized that the applied array-CGH platform in our twin CNV analysis, 
despite having high probe density, yet provide the capability of detecting only imbalanced 
structural variations in the form of gain and loss of genomic DNA segments larger than 5 kb. 
Hence quantitatively balanced genomic alterations like inversions and translocations (see 
figure 1.8) as well as small CNVs beyond the resolution of our experimental approach have 
not been explored here and cannot be ruled out. 
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4.3 Methodological pitfalls  
4.3.1 The problem of wave artifacts in twin array-CGH analysis 
The results of array-based analysis are graphically represented as scatter plots, in which each 
spot represents a signal with regard to a genomic position. In the case of array-CGH, results 
are plotted as the log2 ratios of the test and reference sample hybridization signals along the 
genomic coordinates (see 1.2.1). In the absence of CNVs, ratio or signal values form a flat 
baseline. Deviations from the flat baseline indicate CNVs as genomic insertions (duplications) 
or deletions. However technical drawbacks, especially high rates of artificial segmentations in 
signal intensities interfere with the analysis and interpretation of array-based data and have 
been described by other groups (Marioni et al., 2007; Diskin SJ 2008; Conrad et al., 2010). In our 
twin CNV analysis, we also experienced an over-segmentation in the array-CGH signal 
intensity data especially in biopsy samples. This resulted in high rates of false positive CNVs 
that were not confirmed by the independent quantitative PCR used for validations of array-
predicted CNVs. These over-segmentation patterns in log2 ratio profiles of genomic DNA 
samples are called wave artifacts, as they appear as oscillating increases and decreases of the 
hybridization signals regardless of the presence or absence of CNVs. It has been reported that 
these wave artifacts are correlated with GC content of the targeted genome, so that regions 
with a low GC content corresponded roughly to peaks of the waves, while regions with high 
GC probe content corresponded to troughs (Marioni et al., 2007). Some CNV detection 
algorithms have been developed to correct for the effects of these waves based on the GC 
content of the probes (Komura et al., 2006;  Song et al., 2007) or the GC contents and sizes of 
genomic DNA fragments (Komura D 2006, Conrad et al., 2010) but none of them yield 
optimum results. Ylstra and colleagues presented a wave-smoothing method, which is 
independent from GC content and employs log ratios from samples known to have no CNVs, 
using multi-variable regression (van de Wiel et al., 2009). However, this method does not 
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account for the confounding effects from large segmental shifts. It has also been warned that 
available methods for removing wave artifacts can themselves introduce new artifacts due to 
skewed regression or even remove signals created by true CNVs due to blind smoothing 
(Lepretre et al., 2010). We considered this warning seriously and did not use any smoothing 
algorithm to ride of the wave artifacts, which we experienced in our twin CNV analysis. 
Instead we tried to detect false positives CNVs by verification through quantitative PCR. As 
false positive CNVs in our experiment were mainly predicted from biopsy samples and not 
the blood samples, we think that not the CG content but the poor quality (mainly high rate of 
fragmentation) of genomic DNA form biopsies has been the main source of artifacts in our 
twin CNV analysis. These difficulties in array-CGH data analysis make even more challenges 
when looking for somatic CNVs, as the post-zygotic genomic CNV events, if any, might 
occur in only a limited number of cells and are therefore not reflected by sharp aberrations in 
signal intensity ratios in array-CGH. We therefore recommend application of at least two 
replicates for each array design of this kind as suggested elsewhere (Conrad et al., 2010), 
followed by necessarily experimental validation of shared potential CNV signals. 
 
4.3.2 Deficient probe coverage and biases in Multiallelic CNV genotyping 
We used high resolution Affymetrix 6.0 SNP microarray in our UC case-control CNV 
analysis. Although this platform incorporate better SNP and non-polymorphic copy number 
probe selection criteria for complex regions of the genome, but still tends to have a paucity of 
probes in duplication-rich regions of the genome and therefore is unable to capture a large 
number of known CNPs (Kid et al., 2008; Alkan et al., 2011). It has been shown that around half 
of simple deletion variants are not well captured by even the highest-density SNP arrays and 
this deficiency increases when more complex multicopy variants within segmental 
duplication-rich regions are considered (Cooper 2008).  
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For CNPs with higher copy numbers often located in repeat-rich and duplicated regions, it is 
difficult or impossible to assign integer copy numbers from microarray hybridization data. 
The reason is that array-CGH and SNP platforms assume each location to be diploid in the 
reference genome but this is not valid for duplicated sequences. For example the signal for a 5 
to 4 copy ratio or other complex patterns will not fit the expected results for a diploid 
reference sequence and may drop below the assay’s sensitivity to discriminate signals (Alkan 
et al., 2011). Given the high frequency of CNPs in segmental duplications as mentioned 
previously (see 1.2.2), it will be important to test these variants for association to disease. One 
famous example of these complex regions with implications in inflammatory diseases is ß-
defensin locus. Beta-defensins are small secreted antimicrobial peptides, which are encoded by 
DEFB genes in three main gene clusters, two on chromosome 20 and one on 8p23.1(Ganz, 
2003). The beta-defensin genes on 8p23.1 are on a large repeat unit that is variable in copy 
number, for which individuals have between 2 and 12 copies per diploid genome (Hollox et 
al.,2003). However it is impossible or difficult to assign integer copy numbers from microarray 
hybridization data and this poses particular challenges for case–control association studies 
(McCarroll 2008). The influence of genotyping error for ß-defensin copy number on the 
outcome of different studies is evident in reports of discordant findings. In 2006 there was a 
report of an association between low beta-defensin copy number and CD of the colon 
(Fellermann et al., 2006). In contrast, a later study reported an association between CD and 
higher beta-defensin copy numbers, using real-time PCR measurement in 466 cases and 329 
controls (Bentley et al., 2010). Schalkwijk and colleagues genotyped beta-defensin copy number 
for two cohorts of psoriasis patients and controls from the Netherlands and Germany (Hollox 
et al., 2008). They used two different methods, namely multiplex amplifiable probe 
hybridization assay (MAPH) and Paralogue Ratio Test (PRT) on the same set of samples. 
Unlike CD, increasing copy number was shown to be associated with susceptibility to 
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psoriasis but the association signal was much stronger in MAPH (P = 1.65 x 10-6) than in PRT 
(P = 0.01). These inconsistencies reflect differential genotyping biases in assaying copy 
number of multi-allelic complex CNV regions. 
It should additionally be mentioned that SNP microarray and array-CGH platforms are 
designed relative to the reference human genome sequence (International Human Genome 
Sequencing Consortium, 2004). However, other de novo whole genome sequencing efforts 
have led to the identification of sequence insertions, which are not present in the reference 
genome assembly (Levy et al 2007; Wang J 2008, The 1000 Genomes Project Consortium, 
2012). In fact, many of these novel insertions are polymorphic in human populations and thus 
represent genetic variants that will be missed by using microarrays designed to the reference 
genome assembly. 
 
4.3.3 Low consistency of  CNV detection algorithms  
Different computer programs are available to detect CNVs, using the intensity of the 
hybridization of sample DNA to the array probes. The underlying detection algorithms are 
generally based on either Hidden Markov model (Korn et al., 2008) or circular binary 
segmentation (Olshen et al., 2004). PennCNV and QuantiSNP were first developed based on an 
HMM-based algorithm for an Illumina platform (Colella  et al., 2007; Wang et al., 2007) and then 
later were modified to be compatible with Affymetrix platforms as well. Birdseye, another 
HMM-based approach was developed to detect CNVs in SNP genotyping arrays specifically 
Affymetrix platforms (Korn et al., 2008). Many studies have found considerable variation 
among the outputs and false call rates for CNVs, comparing different CNV detection 
programs (Baross et al  2007; Winchester et al., 2009). Table 4.1 shows the different number of 
CNVs identified with distinct algorithms and platforms for a single HapMap sample 
(NA10861). The average number of CNVs, called per individual by different programs varies 
also with regard to the size of CNVs. Affy6.0 data in 1001 bipolar cases and 1033 controls of 
Discussion                                                                                                                                       97 
 
 
European ancestry have been used to assess CNV detection accuracy of currently used CNV 
detection softwares (Zhang et al., 2009). For CNVs larger than 100 kb, PennCNV called an 
average of 8, while HelixTree called an average of 27. The differences declined when the size 
of CNVs increased in the affy6.0 platform (Zhang et al., 2009).  
These evidences led us to the conclusion that without independent experimental genotyping, 
software-called CNVs based on array data are not reliable. Therefore we used quantitative 
PCR to independently verify all the CNVs predicted from array-CGH data in our twin CNV 
analysis as well as Affy6.0 data in the rare CNV analysis for UC. To further compensate for 
the poor consistency among different CNV programs, we used two distinct programs, namely 
quantiSNP and Affymetrix power tool for CNV detection. We then followed only those 
variants that were predicted by both programs (with at least 40% overlapping), as this 
approach has been suggested by others as well (Pinto et al., 2011). 
   
Algorithm Platform and  
array 
Number of   
CN events  
detected 
Birdsuite 1.5.5 (Canary & Birdseye) Affymetrix 6.0 137 
CNAT (Genome Console 3.0.2) Affymetrix 6.0 10 
CNVPartition 1.2.1 Illumina 1M Duo 16 
GADA (R 0.7-5) Affymetrix 6.0 613 
GADA (R 0.7-5) Illumina 1M Duo 87 
Nexus Biodiscovery 4.0.1 Affymetrix 6.0 111 
Nexus Biodiscovery 4.0.1 Illumina 1M Duo 8 
PennCNV (2009Jan06) Affymetrix 6.0 67 
PennCNV (2009Jan06) Illumina 1M Duo 43 
QuantiSNP v2.0 Affymetrix 6.0 193 
QuantiSNP v1.1 Illumina 1M Duo 60 
 
Table 4.1  Comparison of CNV numbers detected for a single HapMap sample (NA10861) with different SNP-arrays 
and algorithms.  According to Winchester et al.,2009 
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4.4 Probable sources of discordance in IBD MZ twins 
No finding of CNV differences in our examined twins might be in favor of the view that 
mainly non-genetic factors contribute to phenotypic discordance in MZ twins. Not high 
concordance rates in MZ twins of IBD (~34% for CD and only ~16% in UC) as well as more 
frequent IBD records in the first-born sibling of twin pairs have been described (Spehlmann et 
al., 2008) and attributed to pre- and post-natal environmental trigger factors. Here I describe 
the relevant non-genetic factors that could potentially contribute to MZ twin discordance and 
also point to evidences and proposed mechanisms of their involvement in IBD pathogenesis, 
where applicable. 
 
4.4.1 Epigenetic factors 
Epigenetics is generally referred to mitotically and/or meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence (Russo et al., 1996). The most 
typical examples of such changes are DNA methylation and histone modifications, both of 
which serve to regulate gene expression. More recently other components such as ATP-based 
chromatin remodeling complexes (Vignali et al., 2000), non-coding RNAs (Esteller., 2011) and 
prions (Halfmann et al., 2010) have been recognized and increased the complexity of epigenetic 
regulation mechanisms. Among these factors, genomic DNA methylation of cytosine bases 
(5-methylcytosine), especially in the context of CpG islands has been studied more 
extensively. CpG islands are cytosine-phosphate-guanine dinucleotide rich sequences (mostly 
around 1 kb) and are found in the transcription start sites and promoter regions of more than 
half of the genes in the human genome (Jones, 2012). Microarray- and sequencing-based 
approaches for genome-wide mapping of 5-methylcytosine (methylome) through bisulphate-
treated DNA have emphasized the correlation between methylation position and its effect on 
transcription (Lister et al., 2009; Heyn et al., 2012). Methylation at the 5' transcription start sites 
mostly blocks initiation of transcription, whereas methylation in the gene body does not block 
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transcription and might stimulate transcription elongation and even affect splicing (Jones, 
2012). It has been proposed that transcription down-regulation due to methylation is the result 
of either the inability of specific transcription factors to bind methylated CpGs or the 
recruitment of methyl-CpG-binding proteins (such as MeCP) with transcription repression 
activity (Nan et al., 1997; Castillo-Fernandez et al., 2014)   
The first comprehensive survey of epigenetic differences in MZ twins was carried out through 
comparing total content of methyl-cytosines and histone acetylation levels of peripheral 
lymphocytes (Fraga et al., 2005). In that study, discordances within MZ twin pairs were found 
for X-inactivation, DNA methylation and histone acetylation, which were correlated with the 
age of twins and the amount of time they lived together. This observation led to the expected 
conclusion that a bulk of epigenetic differences accumulate during the life time of MZ twins 
(Fraga et al., 2005). In 2009, Petronis and colleagues confirmed the presence of DNA 
methylation differences between co-twins across three different tissues, namely white blood 
cells, buccal epithelial cells and gut biopsies (Kaminsky et al. 2009). They observed greater 
similarity between DNA methylation profiles within MZ twins than within DZ ones. 
Furthermore, they suggested a functional stratification of the epigenome, based on the finding 
of fewer differences between co-twins in CpG islands and promoter regions than in all non-
CpG island loci. Extensive region-specific variability in DNA methylation between MZ twins 
was recognized from profiling of the major histocompatibility complex (MHC) in CD4+ 
lymphocytes of 49 Norwegian MZ twins (Gervin et al., 2011). In that study, CpG islands, 5' 
untranslated regions and conserved non-coding regions showed less variability than CpG-poor 
regions within twins. In contrast to the study of Fraga et al, which suggested that epigenetic 
divergence of MZ twins occur mainly within their life time, differences in neonatal 
epigenome were observed in a longitudinal study that profiled genome-wide DNA 
methylation of 10 MZ and 5 DZ twin pairs at birth and at 18 months (Martino et al., 2013). In 
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their study, epigenetic differences between MZ co-twins appeared to arise early in life (during 
embryonic development) and surprisingly tended to either diverge or converge in a twin-pair-
specific manner. 
  
4.4.2 Gut microbiota 
Microbiota of the gut describes the collection of more than 100 trillion microorganisms, 
mostly bacteria, which colonize the oral–gastrointestinal tract, with highest concentration 
(1011 or 1012 cells/g of luminal contents) in the colon (Dave et al., 2010). It is believed that 
millions of years of co-evolution between the host and these microorganisms have led to a 
symbiotic relationship, in which the microbiota contributes to many host physiological 
processes and the host, in turn, provides niches and nutrients for microbial survival (Hooper et 
al., 2010). Gut homeostasis is provided by the complex interplay between the host immune 
system and the microbiota as these resident microbes digest substrates inaccessible to host 
enzymes, educate the immune system and repress the growth of harmful microorganisms 
(O'Hara et al., 2006). Recent evidences suggest that human intestinal microbiota is seeded even 
before birth (Rodríguez et al., 2015). Maternal microbiota forms the first microbial profile and 
prenatal factors such as mode of delivery, diet, genetics and intestinal mucin glycosylation 
influence microbial colonization (Palmer et al., 2007; Funkhouser et al., 2013). After birth, the 
microbial diversity increases and shapes an adult-like microbial profile by the end of the first 
3–5 years of life (see figure 4.1). After that, the composition of the gut microbiota is relatively 
stable throughout the life, but may alter as a result of bacterial infections, antibiotic treatment, 
lifestyle, surgical interventions and long-term changes in diet (Marques et al., 2010; Claesson et 
al., 2011). A shift in the composition of the gut microbial community from a symbiotic 
commensal flora to a potential deleterious and pathogenic profile is called dysbiosis and has 
been correlated with the development of IBD (Kaur et al., 2011). The effect of host genetics 
versus environment in shaping the gut microbiota has been investigated by analysis of 
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individuals with varying degree of relatedness. A study with children under the age of 10 
indicated that the degree of similarity in bacterial community was higher in MZ twins 
compared with DZ ones and was lowest in the unrelated control group (Stewart et al., 2005). 
Recently more comprehensive profiling and functional dissection of the gut microbiota 
between individuals and between healthy and diseased states have become possible, thank to 
the high throughput metagenomic analysis using next-generation sequencing technologies 
(Qin et al., 2010; Human Microbiome Project Consortium, 2012). A metagenomic study using 
deep sequencing of samples from 31 monozygotic and 23 dizygotic twin pairs and their 
parents, however, did not identify significant differences in bacterial diversity between the  
 
 
Figure 4.1 Factors affecting the stability and complexity of the gut microbiome in health and disease 
Many factors are indicated to impact the microbiome including genetics, diet, medication, among others (marked in the grey 
boxes at the top of the figure). Some of these factors can introduce perturbations affecting the complexity and stability of the 
microbiome, leading to microbial dysbiosis. Features of an imbalanced microbiome include, for example, an increase in 
Gram-negative bacteria linked to an environment of oxidative stress and inflammation, and metabolite production. The first 3 
years of life represents the most critical period for dietary interventions aimed at microbiota modulation to improve child 
growth and development and positively affect health. Illustration from Kostic et al., 2014 
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two types of twins, although the members of the same family were found to share a higher 
numbers of bacterial phylotypes (Turnbaugh et al., 2010). Several studies have observed a 
decreased diversity in gut microbiota of UC patients, compared with healthy controls at both 
mucosal (Nishikawa et al., 2009; Ott et al., 2008) and fecal (Martinez et al., 2008) samples. This 
reduced diversity of the gut microbiome was also demonstrated in IBD patients within MZ 
twin pairs discordant for CD (Dicksved et al., 2008). Decreased microbial diversity has even 
been observed within the same patient in inflamed versus non-inflamed tissues, so that CD 
patients had lower overall bacterial loads at inflamed regions (Sepehri et al., 2007). In 2011 
Lepage and colleagues used 16S ribosomal DNA libraries to determine Microbiom profiles of 
sigmoid colon biopsies from 8 MZ twins discordant for UC, 11 healthy DZ twins as well as 7 
healthy MZ twins (Lepage et al., 2011). They found that Patients with UC had dysbiotic 
microbiota, characterized by less bacterial diversity and more Actinobacteria and 
Proteobacteria than that of their healthy siblings. Further they observed that healthy members 
from discordant twins had more bacteria from the Lachnospiraceae and Ruminococcaceae 
families, when compared to their diseased sibling but this was not the case within healthy 
twins (Lepage et al., 2011).  
 
4.4.3 Other environmental factors 
As described earlier, there exist epidemiological evidences of a putative environmental 
component in the risk of common idiopathic IBD and especially UC (see 1.1.2). As a result, it 
has been assumed that differentiated environmental exposures of twin individuals could also 
contribute to their discordance with regard to IBD. Although these environmental triggers are 
not fully characterized, however potential relevant influences span the spectrum of life, from 
mode of childbirth and early-life exposures (such as  breastfeeding and antibiotic exposure in 
infancy) to exposures later on in adulthood including smoking, major life stressors, diet and 
lifestyle (Ananthakrishnan, 2015). In 2012 Schreiber and colleagues profiled environmental 
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risk factors in a randomly selected population of 512 German MZ and DZ twins, in which at 
least one sibling had IBD (Spehlmann et al., 2012). In their study the most significant factors 
associated with CD or UC included high frequency of antibiotic use, high consumption of 
processed meat, recall of bacterial gastrointestinal infections and living abroad before the time 
of diagnosis. 
Here I briefly mention environmental risk factors, which have been implicated so far, as they 
could also contribute to IBD discordance in MZ twins.  
 
Diet 
An inverse association with dietary fiber, particularly fruits and vegetables has been observed 
in IBD (Amre et al., 2007). Pediatric patients with CD had markedly lower intake of fruits and 
vegetables than controls without IBD (Amre et al., 2007). Further, it has been shown that long-
term fiber intake reduces the risk of CD (Ananthakrishnan et al., 2013). A potential mechanism 
is that soluble fibre (from fruits and vegetables) is metabolized by the intestinal bacteria to 
short-chain fatty acids that inhibit transcription of pro-inflammatory cytokines (Galvez et al., 
2005). Dietary fat particularly saturated fats, Vitamin D, Zinc and iron might also have a role 
in pathogenesis and course of IBD (Ananthakrishnan, 2015).  
 
Smoking 
Increase in risk associated with smoking has been seen in CD, while in UC increased risk has 
been correlated with former smoking (and not current smoking), demonstrating an inverse 
association between UC and smoking (Harries et al., 1982; Mahid et al., 2006). Consistent with 
the direction of effect, smoking is associated with a more aggressive disease course in CD. 
Smokers are more likely to need immunosuppression and surgery and have greater probability 
of recurrence after ileocecal (section between small and large intestine) resection (Lakatos et al., 
2007). By contrast, in UC smoking cessation is frequently a trigger for disease flares within a 
year of cessation and current smokers have a milder disease state with less need for strong 
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immunosuppression or surgery interventions (Cosnes, 2004). It has been proposed that 
Smoking could alter smooth muscle tone and influence endothelial function through nitric 
oxide production (Hatoum et al., 2006), or affect the integrity of the gut mucous barrier 
(McGilligan et al., 2007) or result in less production against oxidative stress (Bergeron, et al., 
2012). Smoking cessation is associated with an early change in the microbiome, an effect that 
may underlie the influence of smoking cessation on UC (Biedermann et al., 2014). 
 
Hygiene 
The hygiene hypothesis was first proposed to explain the increase in the incidence of 
autoimmune diseases in the industrialized world (Strachan et al. 1989). Many studies supporting 
this hypothesis have shown that factors such as number of siblings, larger family size, 
drinking unpasteurized milk, living on a farm and exposures to pets particularly early in 
childhood are inversely associated with risk of IBD (Bernstein et al., 2006; Radon et al., 2007). 
These correlations are generally explained in the context of influence of such factors on the 
parallel development of gut microbiota and maturation of the immune system early on in life 
(see also 4.4.2) 
 
Lifestyle 
IBD has long been associated with psychosocial stressors as well as certain personality types 
including neuroticism, obsessive–compulsive behavior, dependency and perfectionism 
(Bernstein et al., 2010). Neuroticism is a personality trait characterized by anxiety, fear, 
moodiness, worry, envy, frustration, jealousy, and loneliness (Thompson, 2008). Obsessive–
compulsive behaviour is a mental characteristic, in which people feel the need to check things 
repeatedly, perform certain routines or have certain thoughts repeatedly (Fenske et al., 2009). 
Stress can influence intestinal inflammation via the hypothalamus–pituitary–adrenal axis and 
(or) the autonomic nervous system, resulting in increased production of proinflammatory 
cytokines, activation of macrophages and alteration of intestinal permeability and gut 
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microbiota composition (Bonaz et al., 2013). The association between physical activity and IBD 
was established, as sitting occupations like administration and office work were shown to 
increase risk of IBD, whereas heavy manual labour (including building and construction, 
cleaning and maintenance) associated with a low IBD risk (Sonnenberg et al., 1990). 
Supporting this hypothesis, a prospective cohort study demonstrated that rigorous physical 
activity reduced the risk of CD by 44% (Khalili et al. 2013). Finally disturbed sleep quality is 
common in society, but is more frequent in patients with IBD and is associated with active 
disease (Swanson et al., 2011) 
 
Infections and Antibiotics 
The influence of antibiotics has been shown to be more relevant during early childhood, when 
the gut microbiota is rather unstable and its perturbation could influence the gut immune 
response and thereby alter the susceptibility to IBD (Penders et al., 2006). In a nested case-
control analysis, 58% of pediatric patients with IBD had received an antibiotic in their first 
year of life, compared with only 39% of the controls (Shaw et al., 2010). The association of 
pediatric IBD with antibiotic use is greater for CD than UC and is stronger for exposure in the 
first year of life as well as multiple courses of antibiotic use (Kronman et al., 2012).  
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4.5 Missing genetic variance (heritability) and CNVs 
The main goal of the CNV analysis in MZ twins as well as case-control samples in this thesis 
was to explore whether CNVs, either somatic or germline (inherited), contribute to the risk of 
IBD. We hypothesized that potential findings of pathogenic CNVs could account, although 
partially, for the missing genetic variance assumed for IBD. The issue of missing variants for 
IBD and other common disease phenotypes has mainly arisen by the end of the last decade. 
During the past 15 years, genome-wide association studies (GWAs) have identified more than 
2,200 robust associations with more than 300 complex diseases and traits, which are 
catalogued in https://www.genome.gov/gwastudies. It has been however observed that most of 
the identified common associated variants have small effect sizes and confer relatively small 
increases (1.1-1.5 fold) in disease risk and therefore explain only a minority of the estimated 
heritability (Zuk et al., 2012). Heritability refers to the total phenotypic variation of a trait that 
can be attributed to genetic effects (Falconer et al., 1995). There are only few disease 
phenotypes such as age-related macular degeneration, in which identified associated loci exert 
large effects in disease risk and have explained more than 50% of the estimated heritability 
(Maller et al., 2006). This is however not the case in IBD and most other common diseases. In 
IBD the median odds ratio (OR) of more than 160 associated risk loci, identified so far, is ~ 
1.1 and these loci account for only 13.6% and 7.5% of the total disease variance for CD and 
UC respectively (see also 1.1.2.2).  
 
4.5.1 Inflated (Phantom) heritability for IBD? 
The proportion of heritability explained by a set of variants is the ratio of the heritability due 
to these variants (numerator), estimated directly from their observed effects, to the total 
heritability (denominator) inferred from population data (Visscher et al., 2008). As already 
mentioned, small odds ratio of the GWAs-indentified variants for IBD (and many other 
common diseases) has resulted to obtain small numbers for numerator (compared to 
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denominator). Generally the predominant view is that the compensation for missing 
heritability lies in the numerator, i.e., there are missing variants underlying the susceptibility 
of the disease, which remain to be discovered.  Accordingly many debates and efforts have 
been raised on how and where this hidden variability is to be hunted (Manolio et al., 2009; 
Eichler et al., 2010). In contrast, it has been argued that although many genetic risk variants 
remain to be found, but a significant fraction of the missing heritability is probably due to 
overestimation of disease heritability itself (denominator), an effect referred to as phantom 
(inflated) heritability (Zuk et al., 2012).    
There are different approaches to estimating the heritability of diseases, with each having their 
own potential source of biases in sampling strategies and analysis methods, leading to 
heterogeneous and even confounding results (Tenesa et al., 2013). This ambiguity is classically 
highlighted in the case of type 2 diabetes, in which heritability estimations using first-, 
second- and third-degree relatives have resulted in measures ranging from 0.19 to 1.02 (Smith 
et al., 1972). Two approaches have been mostly used for quantifying heritability in the case of 
IBD and many other diseases. First approach measures the correlation in liability between 
relatives, through scoring the disease incidence among the relatives of affected individuals 
against incidence in the general population (Falconer et al., 1995). Second method, compares 
the resemblance among MZ twins versus DZ ones (Boomsma et al., 2002). Familial aggregation 
studies have indicated that 2% to 14% of patients have a family history of CD (Halme et al., 
2006), while estimates of the sibling relative risk ratio (the ratio of disease risk among siblings 
of patients to the risk in the general population) ranged from 15 to 42 (Halme et al., 2006). The 
large variation in these estimations points to the challenges encountered in obtaining accurate 
heritability measures for IBD. Confounders also include inconsistent study design (e.g. only 
counting first degree relatives rather than all relatives), sample selection bias (e.g. using 
hospital cases that are likely to have a more severe form of the disease than the general IBD 
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population) and variation in disease prevalence rates, both between different populations and 
over time (Liu et al., 2014; Ananthakrishnan, 2015). Moreover, it has been almost impossible to 
distinguish the influence of shared environment from common inheritance in familial 
clustering of IBD, an ambiguity that could also lead to inflated heritability measures from 
population-based familial data.  
It should be further mentioned that estimations of total heritability classically assume that the 
disease involves no genetic interactions among loci (Visscher et al., 2008). Indeed, under the 
model that the disease arise from a strictly additive genetic architecture (no interaction 
assumed), the identified loci for CD explain only 15% of the estimated heritability (Jostins et 
al., 2012). However it is now appreciated that additive models for disease risk in IBD are not 
justified, as many interacting molecular and cellular pathways have been shown to contribute 
to its pathogenesis (see also 1.1.2.2). Under non-additive models (models counting for various 
interacting pathways), the total heritability may be much smaller (non-inflated) and thus the 
proportion of heritability explained much larger (Tenesa et al., 2013). It has been argued that 
phantom heritability might be around 60% for CD, so that of the current missing heritability, 
80% is estimated to be due to unaccounted genetic interactions among different pathways 
involved in IBD (Zuk et al., 2012).  
    
4.5.2  Where (how) to find the probable missing variants for IBD 
It has been emphasized that nearly all IBD-associated variants with frequency greater than 5% 
and OR greater than 1.2 in individuals of European ancestry have been already identified and 
the remaining genetic contribution will arise from a combination of common variants with 
smaller effect sizes and not common variants with large effects (Liu et al., 2014). However, all 
variants with large effects (OR > 3) and frequency greater than 1% (low frequency variants) 
have also been uncovered by GWAs and linkage studies (see also 1.1.2). Yet, genetic factors 
such as rare variants (frequency smaller than 1%), private mutations, CNVs especially small 
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insertions and deletions (indels) as well as interactions between genes have not been dissected 
well.  
Association studies of rare variants in common diseases mainly suffer from the lack of enough 
power to detect true associations, especially for those variants which are not highly penetrant. 
For instance, for an allele that doubles disease risk (OR = 2) and has a frequency of 0.1%, 
nearly 60,000 cases and a similar number of controls will be required for the variant to reach 
genome-wide significance (Liu et al., 2014). To increase power to detect association, rare 
variants are often aggregated based on characteristics such as their position within genes, 
functional features and allele frequencies (Bansal et al., 2010). Dozens of these burden tests 
have been proposed along with methods for meta-analysis and replication (Hu et al., 2013).  
Eventually it should be mentioned that the missing variability certainly comprise genetic and 
epigenetic components, which interact with environmental factors mainly microbiota of the 
gut (see 4.4.2) and likewise the full spectrum of genetic variance in IBD would not resolve 
completely, unless somatic and tissue-specific variations will be studied adequately.  
 
4.6 Concluding remarks 
This thesis was an effort to investigate the contribution of genomic CNVs, either somatic or 
germline to the risk of IBD.  
Somatic CNV events in the blood or bowel biopsies of IBD patients in comparison to their 
healthy MZ co-twins were not confirmed in 6 IBD twins, examined through comparative 
genomic hybridization. However elucidating probable genetic variations underlying 
discordance of MZ twins needs more comprehensive high resolution studies that analyze all 
types of genomic structural variations as well as single nucleotide variants. Ideally whole 
genome sequencing of a larger number of IBD-discordant twins, coupled with fine histo-
pathological cell targeting through laser-capture microdissection of intestinal epithelial cells 
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from inflamed mucosa might provide more accurate insights into the landscape of somatic and 
tissue-specific variations with relevance in IBD pathogenesis.      
On the other hand, genome-wide analysis of germline CNVs for UC case-control cohorts in 
this thesis was an effort of further mining of accumulated SNP-GWAS datasets, towards 
characterization of additional genetic loci underlying susceptibility to IBD. In contrast to 
common variants, disease correlation of rare variants is however difficult to be assessed 
through classical association statistics. Low frequency of these variants impedes to detect 
associations at the genome-wide level significance by modest or intermediate sample sizes. 
Power limitations may further increase when these variants do not have high penetrance and 
confer only small effect sizes to the disease risk. The association signals of the rare CNV loci 
implicated in this thesis were not strong enough with genome-wide level significance and 
therefore their contribution to UC needs to be confirmed by other independent case-control as 
well as functional studies. 
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6 Supplementary Material  
Sample Recruitment and Ethics 
German patients of the discovery and replication panels were recruited either at the Department 
of General Internal Medicine of the Christian-Albrechts-University Kiel, the Charité University 
Hospital Berlin, through local outpatient services, or nationwide with the support of the German 
Crohn’s and Colitis Foundation. Clinical, radiological, histological, and endoscopic (i.e. type and 
distribution of lesions) examinations were required to unequivocally confirm the diagnosis of 
ulcerative colitis (UC).1214 German healthy control individuals of discovery panel (1703 total) 
were obtained from the biobank PopGen (http://www.popgen.de).The remaining 489 German 
healthy controls in discovery panel were selected from the KORA F4survey, an independent 
population-based sample from the general population living in the region of Augsburg, Southern 
Germany[2].Written, informed consent was obtained from all study participants and all protocols 
were approved either by the ethical committee of the University-Hospital Schleswig-Holstein, 
Center Kiel or through the institutional committee of the “KompetenznetzDarmerkrankungen” 
(http://www.kompetenznetz-ced.de/) in Germany. 
The 274 clinically well-characterized Norwegian UC patients of replication panel were recruited 
through a population-based incidence study, the Inflammatory Bowel disease in South-Eastern 
Norway (IBSEN) study. An ethnically and sex-matched group of Norwegian healthy controls 
(n=282) was randomly selected from the Norwegian Bone Marrow Donor Registry (NBMDR). 
The strict criteria (including absence of any autoimmune disease) on inclusion in the NBMDR 
ensured correct classification of these controls as healthy. Norwegian sample recruitment was 
approved by the ethics committee of Oslo University Hospital, Rikshospitalet, Norway. 
The Lithuanian study population consisted of 443 UC patients recruited at 6 hospitals in 
Lithuania: Kaunas Medical University Hospital (Kaunas), Vilnius University Hospital 
Santariskiu Clinic(Vilnius), M. Marcinkevicius Hospital (Vilnius), Klaipeda Seamen’s Hospital 
(Klaipeda), Panevezys Regional Hospital (Panevezys), Siauliai Regional Hospital (Siauliai) and 
2 hospitals in Latvia: P. Stradin Clinical University Hospital (Riga) and Riga Eastern 
ClinicalUniversity Hospital,Clinic Linezers (Riga). The diagnosis of UC was based on standard 
clinical, endoscopic, radiological and histological criteria. The control group consisted of 
1157ethnically, age and sex-matched healthy blood donors. Written, informed consent was 
obtained from all study participants and all protocols were approved by the institutional ethical 
review committee of the Lithuanian University of Health Sciences, Kaunas, Lithuania. 
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SNP array genotyping 
The genotyping for the German discovery panel and Norwegian panel - which were both part of 
the German NGFN GWAS initiative (see press release 04-26-07 on 
http://www.ngfn.de/englisch/index_368.htm) funded by the NGFN – was performed by an 
Affymetrix® service facility (South San Francisco, CA, USA) using the Affymetrix® Genome- 
Wide Human SNP Array 6.0 (1000k) (Santa Clara, CA, USA). The array is based on an assay 
termed whole-genome sampling analysis (WGSA) developed for highly multiplexed SNP 
genotyping of complex DNA. This method reproducibly amplifies a subset of the human genome 
through a single primer amplification reaction using restriction enzyme digested, adapter-ligated 
human genomic DNA. In brief, 5 μl of genomic DNA samples at 50 ng/ul were aliquoted to the 
corresponding wells of two 96-well plates. The first run of samples was processed as an entire 
plate. In the lab, transfers were made with a 12-channel pipette, reducing the risk of sample 
tracking errors. One plate was digested with NspI and the other plate was digested with StyI. The 
reaction was incubated at 37 °C for 2 hours and at 65 °C for 20 minutes to deactivate the 
enzyme. The digested DNA was then ligated to their respective NspI adaptor and StyI adaptor. 
The ligated product was then PCR-amplified using a common primer. Both NspI PCR product 
and StyI PCR product were combined, and then purified by ethanol precipitation in combination 
with membrane filter plate. Purified PCR product was further fragmented with DNaseI then 
labeled with biotin. Labeled NA was combined with hybridization mix and then injected into 
array. Arrays were hybridized for 18 to 22 hours at 50°C. DNA samples were recovered from 
arrays and washed and stained by using Affymetrix® FS450 fluidic stations. Stained arrays were 
scanned using Affymetrix® GeneChip Scanner 3000 7G. 
WTCCC2 data processing 
First the dataset was cleaned based on genotype calling. Genotype calling was performed using 
the Birdseed v2 algorithm implemented in Affymetrix Power Tools version 1.12.0 [4]. 
Subsequently, genotypes with their corresponding intensity values were converted into the 
Beagle format by means of python scripts. Because we observed an excess of genotyping 
artifacts that would result in false positive associations, the software Beagle call v1.0.1 
(Browning and Yu 2009) was used to generate accurate genotype calls by using both allele signal 
intensities and inter-marker correlation. Beagle call’s built-in data quality filters excluded any 
marker with large deviation from the Hardy-Weinberg equilibrium (PHWE < 10-6) or with > 5% 
of samples having maximal genotype probability < 0.95. We also excluded individuals from each 
pair of unexpected duplicates or relatives, as well as individuals with outlier heterozygosities of 
Supplementary Material                                                                                                                 125 
 
 
± 5 s.d. away from the mean. The remaining GWAS samples were tested for population 
stratification using the principal components stratification method, as implemented in 
EIGENSTRAT [5], and population outliers were subsequently excluded. SNPs that had a minor 
allele frequency < 1% and exact Hardy-Weinberg equilibrium P controls< 10-4 were finally 
excluded. For the remaining samples a CNV calling was performed. CEL files were processed 
with the Affymetrix Power Tools (APT)apt-copynumber-workflow v 1.67. The values for 
contrastQC and MAPD were extracted and samples that failed default QC values were discarded 
(MAPD > 0.4 and/or contrastQC< 0.4). The apt-copynumber-workflow output was converted to 
CNVineta format [6]. A preliminary filtering was performed based on the number of called 
CNVs per samples. This was performed batch wise, as one batch consists of a sample collection 
which was prepared in the same process. Outlier were defined as samples which had more CNVs 
than the 75% quantile plus 1.5 fold of the interquantile range. 
  
Table 6.1 Twenty-four regions with rare CNVs overrepresented in UC cases of the German discovery panel. 
For each region the predicted CNVs are shown for cases (upper panel) and controls (lower panel) with Duplications in blue and 
deletions in red. Involved RefSeq genes are annotated. SNP probe sets in black and copy number probe sets in blue.
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Table 6.2  Independent Replication of Deletion 13q32.1with TaqMan®CNV assays. Each graph of the table 
shows the result of real time PCR for oneTaqMan® plate. Graphs with red frame are for case plates and blue frames 
from control plates. Deletion carriers are highlighted by red bars. Samples with green bars are calibrator samples, 
which are samples with confirmed deletion. These calibrator samples are used to identify the CNV carriers within 
the replication sample set. If there is a second bar next to a red bar with the same identifier, then it is just a technical 
replicate. This was sometimes done due to the noisy nature of the data. The two technical replicates of the fourth 
graph (id 4020) show both copy number state one. Nevertheless this sample was not counted as deletion carrier, 
because it shows copy number state one for every TaqMan® assay that ran on this plate. TaqMan®quality control 
was based on confidence greater or equal to 94%. 
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Table 6.3 Technical validations of Del13q32.1 for the German discovery panel. Results of TaqMan®CNV 
assay is showed as the top illustration. While the majority of samples have copy number state two (blue bars). Green bars show 
deletion or duplication carriers The TaqMan®results show exact correlation with the predicted CNVs and raw data quality of the 
SNP array data is pretty good. For all deletions a loss of signal intensity can be seen corresponding with a loss of heterozygosity. 
 Raw data visualization of intensities. In each picture LRR in the top pannel and B allele frequency (BAF) in the lower one. 
Non polymorphic probe sets are blue and SNP probesets black, a smoothed spline was added for all LRR plots. RefGene 
annotation is added with purple arrows. The red (deletion) or blue (duplication) horizontal bars visualize the redicted CNV. 
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Table 6.4  Independent Replication of Duplication 7p22.1 with TaqMan®CNV assays. Each graph shows the 
result of one real time PCR TaqMan® plate, with the samples at the x-axis and the intensities at the y-axis. Graphs 
with red frame are from case plates, blue frames from control plates and green frames from technical replicates. 
Duplication carriers are highlighted by dark blue bars. Samples with green bars are calibrator samples, which are 
samples with confirmed duplication. These calibrator samples are used to identify the CNV carrier within the 
replication sample set. If there is a second bar next to a dark blue bar with the same identifier, then it is just a 
technical replicate. This was sometimes done due to the noisy nature of the data. TaqMan®quality control was based 
on confidence greater or equal to 94%. 
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Table 6.5  In-silico replication of the 24 (13) rare CNV regions within the Norwegian data set.  
24 rare CNVs identified by initial CNV screening in German discovery panel were evaluated in the Norwegian in -
silico replication data set. Eleven of the 24 regions have no predicted CNVs within the Norwegian sample set (neither 
cases nor controls) and are not visualized here. Each picture consists of two main panels. The upper panel shows 
the case CNVs and the lower panel the control CNVs 
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Tble 6.6  Deletion 13q32.1 in WTCCC2 data set. Evaluation of Del13q32.1 within the UK-WTCCC2 data set is 
visualized here. The first graph of this figure shows an overview of the CNV prediction for that region (Affymetrix 
Power Tools copy-number-workflow). The pictures show the raw data visualization of LRR in the top part and B allele 
frequency (BAF) in the lower part. Non polymorphic probe sets are blue and SNP probesets black. RefGene 
annotation is added with purple arrows. The red bar between RefSeq annotation and raw data highlights the 
predicted deletion. 
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Table 6.7  Duplication 8q24.3 in WTCCC2 data set. In each figure, raw data visualization of LRR in the upper track 
and B allele frequency (BAF) in the lower track are shown.  Non polymorphic probe sets are blue and SNP probe 
sets black. RefSeq gene annotations are added with purple arrows. The blue bar between RefSeq annotation and 
raw data highlights the predicted duplication. 
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Table 6.8  Evaluation of the 24 rare CNVs within the UK (WTCCC2) data set. Each figure of the table consists of 
two main panels. The upper panel shows the predicted CNVs in cases and the lower panel the control CNVs. The 
RefSeq genes are annotated in purple. SNP probe sets in black and copy number probe sets in blue. 
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Table 6.9  CNV load in German screening panel and UK replication panel. Table shows the results of the 
CNV load analysis performed with CNVineta (Wittig et al. 2010). The columns from left to right are the sample set, 
the size of the sample set, median deletions per sample, median duplications per sample and median CNVs per 
sample. The next three columns are the calculated p-values based on the CNV counts per sample. P-values were 
obtained by Wilcoxon rank sum test.  
samples deletions
per sample
duplications
per sample
CNVs per
sample
pValue-Del pValue-Dup pValue-CNV
German 
cases
902 44 18 62
German 
Controls
1564 39 17 56
UK cases 2396 43 17 61
UK 
controls
4886 43 18 61
< 2.2×10
-16
< 2.2×10
-16
< 2.2×10
-16
9.5×10
-3 0.24 0.17
 
 
 
Table 6.10  Inheritance of Deletion 13q32.1 verified by TaqMan® CNV assays. For all confirmed deletion carriers 
of the initial screening, for which samples of family members were available, the samples were analyzed with TaqMan® copy 
number assays. Each graph below represents a family with a legend at the top left, the TaqMan® signal intensities at the 
bottom and the family tree at the right. For some families samples are missing. The results show that all complete family 
trees show Mendelian inheritance and that the incomplete family trees at least do not show any inconsistencies. 
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Table 6.11  Inheritance of Duplication 8q24.3 verified by TaqMan® CNV assays.  For all confirmed 
duplication carriers of the initial screening, for which samples of family members were available, the samples 
were analyzed with TaqMan® copy number assays. Each graph below represents a family with a legend at the top 
left, the TaqMan® signal intensities at the bottom and the family tree at the right. For some families samples are 
missing. The results show that all complete family trees show Mendelian inheritance and that the incomplete 
family trees at least do not show any inconsistencies.  
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7 Summary 
Background and aims 
Crohn's disease (CD) and ulcerative colitis (UC), the two main subtypes of inflammatory 
bowel disease (IBD) are chronic relapsing inflammatory disorders of the gastrointestinal tract, 
which are characterized by excessive immune responses to commensal gut microbial flora in 
genetically susceptible individuals. Genetic contribution to IBD has been mainly interrogated 
through genome-wide association studies (GWAs) of mostly common single nucleotide 
polymorphisms (SNPs). However, the identified risk loci confer only modest effects on 
disease susceptibility and it has been assumed that the majority of the genetic risk remains to 
be explained. Copy number variations (CNVs), as one major form of genetic variations, 
comprise insertions, deletions and duplications of genomic sequences and have been shown 
to be involved in the pathogenesis of some common disease phenotypes. To examine 
whether genomic CNVs contribute to IBD risk, two parallel studies were conducted in this 
thesis; first, by recruiting an existing SNP-GWAs data set of UC and 4 other independent UC 
cohorts, a multi-step genome-wide association analysis was performed to interrogate the 
presence of disease-relevant germline CNVs. Second, nine monozygotic (MZ) twin pairs, 
discordant for IBD, were compared genome-wide to explore whether somatic CNVs might 
have contributed to their IBD discordance. 
  
Results 
1121 German UC patients and 1770 healthy controls were initially screened for rare and 
common deletions and duplications employing SNP-array data. Quantitative PCR, high 
density custom array-CGH and sequencing were used for validation of identified CNVs as 
well as fine (break-point) mapping. Twenty-four copy number variants (14 deletions and 10 
duplications) overrepresented in UC patients were identified in the initial screening panel. 
Follow-up of these CNV regions in 4 independent case-control series as well as an additional 
public in silico control group (totaling 4,439 UC patients and 15,961 healthy controls) 
revealed three copy number variants enriched in UC patients; a 15.8 kb deletion (0.43% 
cases, 0.11% controls) upstream of ABCC4 and CLDN10 at 13q32.1, a 119 kb duplication 
(0.13% cases, 0.01% controls) at 7p22.1, overlapping RNF216, ZNF815, OCM and CCZ1 
and a 134 kb large duplication (0.22% carriers among cases, 0.03% carriers among controls) 
upstream of the KCNK9 gene at 8q24.3. Break-point mapping of the deleted region 
suggested non-allelic homologous recombination as the mechanism underlying its formation. 
Expression analysis of the two nearby genes of Del 13q32.1 in intestinal biopsies of a UC 
patient panel showed differential expression of CLDN10 correlated with the deletion.      
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Additionally, genomic DNA from peripheral blood as well as intestinal biopsies from nine 
monozygotic twin pairs discordant for IBD manifestations (4 CD, 5 UC) were recruited and 
compared for genome-wide CNVs by means of array-comparative genomic hybridization 
(array-CGH), followed by quantitative PCR and (or) sequencing. Initial CNV calls were also 
contrasted with expression data of the affected genes in the corresponding biopsy samples.   
No consistent copy number differences were however revealed in the genomic DNA of 
discordant twins. Post-zygotic genomic CNVs appear not to be the common cause of IBD-
discordance in MZ twins.  
 
Conclusion 
The pragmatic approach for effective CNV analysis in this thesis implicated the potential 
contribution of germline structural variants in the risk of UC. Nevertheless follow-up studies in 
larger disease cohorts as well as further functional experimental assays are needed to verify 
the disease relevance of the genetic loci presented here.  
No findings of somatic variations within twins examined in this thesis would lend a further 
support for the notion that environmental and (or) epigenetic factors are the key drivers of 
IBD discordance in MZ twins. 
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8 Zusammanfassung 
Morbus Crohn und Colitis Ulcerosa sind die beiden häufigsten chronisch-entzündlichen 
Darmerkrankungen (CED). Diese Erkrankungen treten in genetisch prädisponierten 
Individuen auf und werden vermutlich durch Überreaktionen des Immunsystems auf ein 
krankhaft verändertes Darmmikrobiom ausgelöst. Die genetische Veranlagung für CED 
wurde vor meinen Promotionsarbeiten überwiegend durch genomweite Assoziationsstudien 
(GWAS) anhand von Einzelnukleotid-Polymorphismen im menschlichen Genom („single 
nucleotide Polymorphisms“, SNPs) untersucht. Die bisherigen, durch SNP-GWAS 
identifizierten Risikovarianten besitzen meistens niedrige Risikoeffekte (mediane Effektstärke 
von 1,1) und erklären deshalb nur einen geringen Anteil (<20%) der kumulativen genetischen 
Varianz der CED bei Patienten europäischer Abstammung. Man nimm daher an, dass die 
Mehrheit der genetischen Risikofaktoren für CED noch nicht identifiziert sind. 
Kopienzahländerungen („Copy number variations“, CNVs) sind eine weitere wichtige Klasse 
von genetischen Varianten. Hierbei handelt es sich um Insertionen, Deletionen und 
Duplikationen von DNA-Sequenz-Abschnitten im Genom, die nach allgemeinem Konsensus 
eine Länge von mindestens 1000 Basenpaaren aufweisen. Für einige CNVs sind bereits vor 
meinen Arbeiten zum Thema signifikante Assoziationen mit komplexen Erkrankungen 
gefunden worden. Um die Frage zu beantworten, ob CNVs auch zum CED-Risiko beitragen, 
habe ich im Rahmen dieser Promotionsarbeit zwei Studien durchgeführt. In meiner ersten 
Studie habe ich den Datensatz einer SNP-basierten Colitis Ulcerosa GWAS-Studie 
untersucht, um krankheitsassoziierte CNVs mittels eines mehrstufigen, genomweiten Fall-
Kontroll-Analyseverfahrens zu identifizieren. In meiner zweiten Studie habe ich die 
genomische DNA von sechs CED-diskordanten eineiigen Zwillingen verglichen, um 
potentielle krankheitsrelevante somatische Mutationen (hier wiederum CNVs) zu detektieren. 
Ergebnisse 
Im ersten Schritt habe ich 1121 Colitis ulcerosa Patienten und 1770 Kontrollen mittels SNP-
Array-Daten auf Insertionen, Deletionen und Duplikationen untersucht. In diesem ersten 
Screening wurden 24 seltene CNVs (14 Deletionen und 10 Duplikationen) identifiziert, die in 
Colitis Ulcerosa Patienten überrepräsentiert sind. 
Zur Validierung und Feinkartierung der auf diese Weise identifizierten CNVs habe ich 
Replikationsanalysen an weiteren Kohorten mittels quantitativer PCR bzw. mittels Array-CGH 
mit hoher Sondendichte durchgeführt. Charakterisierung der initial gefundenen 24 CNV-
Regionen mittels Replikationskohorten und zusätzlichen in-silico-Kontrollgruppe (insgesamt 
4.439 Patienten und 15.961 Gesundheits-Kontrollen) ergab schließlich drei CNVs, die in 
Patienten häufiger auftraten, nämlich eine 15,8-kb große Deletion vorgelagert vor den Genen 
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ABCC4 und CLDN10 auf Chromosom 13q32.1 (0,43% der Fällen vs. 0,11% der Kontrollen), 
eine 119 kb große Duplikation auf Chromosom 7p22.1, die die Gene RNF216, ZNF815, OCM 
und CCZ1 im Ganzen bzw. zum Teil enthält (0,13% der Fälle vs. 0,01% der Kontrollen), und 
letztlich eine 134 kb große Duplikation vorgelagert vor dem Gen KCNK9 auf 8q24,3 (0,22% 
der Fälle vs. 0,03% der Kontrollen). Eine Bruchpunktkartierungsanalyse deutete darauf hin, 
dass die Deletion durch den Mechanismus der nicht-allelischen homologen Rekombination 
entstanden sein könnte.  
In der Zwillingsstudie habe ich CNVs in genomischer DNA aus den Blutproben sowie Darm-
Biopsie-Proben von sechs CED-Patienten (3 Morbus Crohn, 3 Colitis Ulcerosa) und ihren 
gesunden eineiigen Zwillingen untersucht und verglichen. Hierzu wurden vergleichende 
Genom-Hybridisierung (Array-CGH) und anschließend quantitative PCR verwendet. Es 
ließen sich allerdings keine Unterschiede bezüglich der Kopienzahlvarianten in den 
genomischen Kandidatenregionen der Zwillinge feststellen. Eine hohe Anzahl von CNVs 
wurde durch die Array-CGH-Analysesoftware ermittelt, die sich aber als falsch-positiv 
erwiesen. 
Schlussfolgerung 
In dieser Arbeit wurde ein pragmatischer Ansatz für ein effektives CNV-Screening entwickelt, 
der den potentiellen Beitrag von drei seltenen genomischen Strukturvarianten zum Risiko von 
Colitis Ulcerosa impliziert. Es sind weitere Nachuntersuchungen in größeren Kohorten sowie 
funktionelle Studien erforderlich, um die Assoziation der in dieser Arbeit vorgestellten CED-
assoziierten CNV-Loci ultimativ zu belegen. Der fehlende Nachweis von somatischen CNV-
Varianten zwischen diskordanten eineiigen Zwillingen in dieser Arbeit deutet darauf hin, dass 
eher andere genomische Varianten, epigenetischen Modifikationen, oder Umweltfaktoren die 
Hauptfaktoren der CED-Diskordanz bei eineiigen Zwillingen erklären könnten. 
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